I. Understanding the Architecture of Stigma

Stigma around psychoactive plant medicines operates through seven distinct pillars, each requiring a different strategic response.

The Seven Pillars

Pillar 1 — Pharmacological Stigma ("They fry your brain.") Counter: The Hinkle et al. 2024 meta-analysis (3,504 participants, 114 studies with analyzable adverse-event data) documented no deaths, no persistent psychosis, and no HPPD in contemporary research settings.¹¹ Classic psychedelics are not neurotoxic at therapeutic doses.¹⁷²

Pillar 2 — Psychiatric Stigma ("They cause psychosis.") Counter: Clinical screening excludes psychosis-vulnerable individuals. Serious adverse events in the Hinkle meta-analysis occurred only in participants with pre-existing neuropsychiatric conditions. Acknowledge this risk candidly.

Pillar 3 — Legal-Moral Stigma ("They are illegal, therefore wrong.") Counter: The Controlled Substances Act is not a scientific document. The Supreme Court held unanimously that Schedule I classification does not automatically satisfy RFRA's compelling interest test.³¹ Native American Church peyote use is federally protected.³³

Pillar 4 — Cultural Stigma ("This is drug culture.") Counter: Clinical protocols, indigenous ceremonies, and informed autonomous use are distinct contexts with different intentions, risk profiles, and support structures. Each merits accurate, context-specific communication rather than a hierarchy in which only clinical use is treated as legitimate. The culture of careful, informed engagement with these substances — across research hospitals, ceremonial traditions, and private settings — has produced the evidence base the field now relies on. Distinguishing clinical from non-clinical contexts is appropriate; treating non-clinical use as inherently irresponsible is a form of stigma, not a neutral observation.

Pillar 5 — Epistemic Stigma ("There is no real research.") Counter: Scheduling foreclosed research from 1970 to approximately 1992 — not any finding of harm. More than 1,000 clinical papers discussing 40,000 patients and six international conferences addressed therapeutic applications before prohibition.⁷⁰ The FDA published a psychedelic drug clinical trial guidance document in June 2023.⁶⁵

Pillar 6 — Historical Stigma Counter: The Nixon administration's "War on Drugs" was, by its architects' own account, at least partly motivated by political targeting of Black communities and antiwar activists, not pharmacological evidence.⁴⁸ Nixon's own Shafer Commission recommended federal decriminalization of marijuana for personal use in 1972; Nixon rejected the findings publicly before the report was released.¹⁰³ MK-Ultra (1953—1973) — the CIA's covert program administering LSD to unwitting subjects⁶⁹ — is categorically distinct from modern IRB-approved, consent-based clinical research.

Pillar 7 — Medicalization Stigma ("The only legitimate use is supervised and clinical.") Counter: Medicalization is one legitimate pathway among several — not the threshold for legitimacy itself. Indigenous and ceremonial traditions with documented histories spanning centuries are legitimate on their own terms, not because they can be mapped onto a clinical model. Autonomous adult use informed by accurate harm reduction information is a matter of cognitive liberty — the right to alter one's own consciousness.⁴⁷ Restricting destigmatization to the clinical frame re-stigmatizes indigenous practitioners, ceremonial facilitators, harm reduction communities, and adults making informed personal choices about their own minds. A destigmatization framework that requires medicalization as its entry condition is not a destigmatization framework — it is a rebranding of who gets to be the gatekeeper.⁹³ Pace and Devenot (2021) further warn that medicalization does not inoculate the field against reactionary political capture.⁹⁴ Langlitz (2025) documents this pattern in comparative analysis of medicalization frameworks in Switzerland and Australia.⁹⁵

Cognitive Liberty: The Foundational Principle

Running beneath every effective destigmatization argument is a principle that should be made explicit: cognitive liberty — the right to alter one's own consciousness in the absence of harm to others — is an aspect of bodily and mental self-determination that exists prior to and independent of any clinical approval process.

The doctrine was formally articulated by Wrye Sententia and Richard Glen Boire at the Center for Cognitive Liberty and Ethics, defining cognitive liberty as "the right of each individual to think independently and autonomously, to use the full power of his or her mind, and to engage in multiple modes of thought."⁸⁶ Jan Christoph Bublitz and Reinhard Merkel developed the human-rights grounding, arguing that freedom of thought must be recognized as encompassing the right to alter one's own mental states absent harm to others.⁸⁷ Ienca and Andorno proposed cognitive liberty as the foundational right encompassing mental privacy, mental integrity, and psychological continuity in the age of neurotechnology.⁸⁸ Nita Farahany's The Battle for Your Brain (2023) operationalized these principles as implementable through existing international human rights frameworks.⁴⁷ Most recently, Manríquez Roa and colleagues applied cognitive liberty directly to psychedelic policy, arguing that drug prohibition operates as "a war on consciousness itself."⁸⁹

The U.S. Supreme Court's recognition in Sell v. United States (2003) of a fundamental liberty interest in avoiding forced alteration of mental processes, building on Washington v. Harper (1990) and Riggins v. Nevada (1992), provides the closest U.S. constitutional anchor for the principle, though no court has yet recognized cognitive liberty as a free-standing right to use psychedelics.⁹⁰

Cognitive liberty is not a consolation prize for those who cannot access clinical trials. It is the foundational principle from which clinical access arguments, RFRA ceremonial protections, and harm reduction infrastructure all derive their deepest moral force. A destigmatization framework that treats it as a footnote has the architecture backwards.

Downstream Applications for Practitioners and Advocates. (1) Harm reduction as a constitutional obligation: If cognitive liberty grounds a right to alter consciousness, then state provision of accurate harm reduction information may be affirmatively required — not merely permitted. The doctrine is not settled, but the structure of the argument is available. (2) Constitutional cause of action for personal use: No U.S. court has recognized cognitive liberty as a free-standing defense to personal-use prosecution. Sell v. United States (2003) provides the closest analogy — a fundamental liberty interest in avoiding forced mental alteration — but it operates in the involuntary medication context, not the personal choice context. The gap between the constitutional anchor and the personal use case is the unresolved frontier. (3) Relationship to RFRA: RFRA is the strongest current legal pathway precisely because it operationalizes a version of cognitive liberty through the specific vehicle of religious exercise. RFRA's compelled-interest test does the work that a standalone cognitive liberty right would need to do in theory. Practitioners should treat RFRA as the instrument and cognitive liberty as the underlying theory that explains why RFRA applies with full force to psychedelic religious practice.

II. How Psychedelics Work: The Three-Tier Mechanism Model

Tier 1 — Receptor Level: 5-HT₂A Agonism

Classic psychedelics (psilocin, LSD, DMT, mescaline) are partial agonists at the serotonin 5-HT₂A receptor on cortical pyramidal neurons. González-Maeso et al. established that 5-HT₂A activation is necessary for hallucinogenic-like behavioral effects:³ animals lacking 5-HT₂A receptors show no head-twitch response to LSD.

Tier 2 — Intracellular: TrkB and BDNF

Moliner et al. (2023) demonstrated that LSD and psilocin "directly bind to TrkB with affinities 1,000-fold higher than those for other antidepressants" — language verified word-for-word from the PMC full text.¹ The binding is allosteric: psychedelics facilitate and potentiate endogenous BDNF signaling rather than directly activating TrkB. Critically, the head-twitch response depends on 5-HT₂A and is independent of TrkB binding.¹ This dissociation indicates that plasticity-promoting effects may be pharmacologically separable from hallucinogenic effects — the foundation for next-generation non-hallucinogenic neuroplastogens.⁶⁶

Vargas et al. (2023) further established that the plasticity-promoting effects specifically require intracellular 5-HT₂A receptor engagement,² explaining why serotonin itself does not produce comparable neuroplasticity.

Tier 3 — Network Level: Default Mode Network Disruption

Carhart-Harris et al. (2012) characterized psilocybin's reduction of connectivity within the Default Mode Network (DMN) — midline cortical regions associated with self-referential rumination, depression, and anxiety.⁴ Muthukumaraswamy et al. (2013) characterized the complementary phenomenon: psilocybin produces broadband cortical desynchronization across delta, theta, alpha, beta, and gamma frequency bands — a global departure from organized oscillatory brain states rather than a localized change.⁹⁸ DMN hyperactivation is a documented feature of treatment-resistant depression, PTSD, OCD, and addiction.^{194 190 195 218 219 220}

Critical nuance on the post-treatment effect: Carhart-Harris et al. (2017) measured fMRI brain activity before and after psilocybin treatment in 19 patients with treatment-resistant depression and found that after treatment, resting-state connectivity within the DMN increased — and this post-treatment increase correlated significantly with clinical improvement.⁹⁹ The mechanism is not simple "DMN suppression": the acute disruption appears to create conditions for network reorganization; the improved state reflects that reorganization. This nuance is important for clinical audiences who will otherwise overcorrect from "the DMN is suppressed" to a simpler story than the data support.

Integration: Why the Three Tiers Must Be Read Together

5-HT₂A activation initiates the acute subjective state (Tier 1). TrkB/BDNF signaling drives the neuroplastic window (Tier 2). DMN disruption provides the experiential substrate for therapeutic reappraisal (Tier 3). "Set and setting" in psychedelic pharmacology is the behavioral expression of activity-dependent plasticity: BDNF-TrkB signaling selectively strengthens active synapses, so the therapeutic session's content shapes which synaptic connections are potentiated.^{206 207}

III. Historical Foundation: The Research Timeline

Discovery Era (1938—1947)

Albert Hofmann synthesized LSD-25 at Sandoz Laboratories in Basel, Switzerland on November 16, 1938,⁶³ while searching for a circulatory and respiratory stimulant. Its psychoactive properties were discovered inadvertently on April 16, 1943. The intentional self-experiment and bicycle ride home occurred on April 19, 1943⁴⁹ — commemorated as "Bicycle Day." Sandoz distributed LSD under the trade name Delysid from approximately 1947 to 1966.

First Wave: Clinical Research (1950—1970)

Between 1950 and the mid-1960s, more than 1,000 clinical papers discussing 40,000 patients appeared in the psychiatric literature, alongside six international conferences on psychedelic drug therapy.⁷⁰ NIMH funded multiple grant streams. Key researchers included Humphry Osmond and Abram Hoffer (Saskatchewan, alcoholism), Stanislav Grof (Prague then Maryland Psychiatric Research Center), Sidney Cohen (Los Angeles), and Walter Pahnke (Good Friday Experiment, 1962). The term "psychedelic" was coined in 1956 in correspondence between Osmond and Aldous Huxley, first formally published in 1957.⁵⁰ The term "entheogen" was introduced by Ruck, Wasson, and colleagues in 1979.⁵¹

MK-Ultra and the Research Freeze (1953—1992)

The CIA's MKULTRA program (1953—1973) administered LSD and other substances to unwitting subjects.⁶⁹ The Controlled Substances Act of 1970 placed LSD, psilocybin, mescaline, and DMT in Schedule I, halting legitimate research for nearly two decades. Former Nixon aide John Ehrlichman later reportedly admitted the targeting was at least partly political,⁴⁸ not pharmacological.

Second Wave: Modern Research (1992—Present)

Between 1970 and 1992, federally approved research was frozen but knowledge was not lost. Underground therapists, harm-reduction practitioners, artists, and researchers who continued engaging with these substances outside any institutional framework preserved the experiential and phenomenological knowledge that clinical researchers later systematically formalized. Norman Zinberg's Drug, Set, and Setting (Yale University Press, 1984), drawing on extensive naturalistic observation, codified the three-variable model of drug effects — the substance, the user's mindset, and the social setting — that now underlies every contemporary clinical protocol.⁹² The concept of "set and setting" itself had been formalized by Leary, Metzner, and Alpert in 1964 from their own autonomous practice, adopted by Zinberg through systematic naturalistic research, and incorporated into clinical protocols without this lineage being commonly acknowledged.⁹¹

Rick Strassman's 1994 University of New Mexico DMT study was the first federally approved Schedule I psychedelic research in the U.S. after prohibition.⁵² Griffiths' first psilocybin trial at Johns Hopkins (2006) launched the modern resurgence, and a 2008 Hopkins follow-up established that psilocybin-occasioned mystical experiences predict lasting personal meaning at 14 months.⁵³ The 2016 Hopkins cancer-distress trial⁵ and the 2016 NYU cancer-distress trial⁶ established the therapeutic framework. The 2021 NEJM psilocybin vs. escitalopram comparison⁷ and 2022 NEJM Phase 2b COMP360 study⁸ brought psychedelic medicine into the world's most-cited journals. COMP005 (June 2025)⁹ and COMP006 (February 2026)¹⁰ are the first Phase 3 pivotal trials of a classic serotonin 2A agonist psychedelic to report efficacy data.

IV. Substance Profiles

A. Psilocybin and Psilocin

Identity and Pharmacology

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring tryptamine prodrug found in approximately 200 fungal species, predominantly Psilocybe spp. Dephosphorylated to psilocin (4-hydroxy-DMT) on ingestion. Psilocin is a partial 5-HT₂A, 5-HT₂C, and 5-HT₁A agonist. Onset: 20—40 min. Peak: 60—90 min. Duration: 4—6 hrs. Metabolism: hepatic via MAO and UGT; renal excretion. Schedule I under the CSA.^{209 210 208 172}

Clinical Evidence (Through May 2026)

Cancer-related existential distress — Hopkins (2016): Randomized double-blind crossover trial (n=51). At 6-month follow-up, the overall rate of clinical response was 78% for depression and 83% for anxiety⁵ — language verified word-for-word from the PMC full text. Remission rates: 65% depression, 57% anxiety. 67.4% rated the high-dose experience among the five most personally meaningful of their lives.

Cancer-related existential distress — NYU (2016): Randomized controlled crossover trial (n=29). At 6.5-month follow-up, "approximately 60—80% of participants continued with clinically significant reductions in depression or anxiety"⁶ — language verified word-for-word from the published abstract. 87% reported increased life satisfaction.

NYU cancer-distress 4.5-year follow-up (2020): Agin-Liebes et al. (2020) conducted a long-term within-subjects follow-up of the NYU Ross 2016 cohort at mean 3.2 and 4.5 years post-treatment (15 of 16 surviving participants). At the 4.5-year follow-up, 60—80% continued to meet criteria for clinically significant antidepressant or anxiolytic responses. 71—100% attributed positive life changes to the psilocybin-assisted therapy and rated it among the most personally meaningful and spiritually significant experiences of their lives.⁹⁶ This is among the most powerful durability statistics in the clinical literature for any psychiatric intervention from a single session.

Psilocybin vs. escitalopram (2021): Phase 2 randomized trial (n=59). Primary outcome (QIDS-SR-16): psilocybin numerically superior (p=0.17 — not statistically significant). Multiple secondary remission and response outcomes significantly favored psilocybin but without correction for multiple comparisons.⁷ Proper framing: "comparable performance on the primary endpoint; secondary outcomes generally favoring psilocybin." Do not state this trial proved psilocybin superior — it did not meet statistical significance on its primary endpoint.

COMP005 Phase 3 (June 2025): Randomized double-blind placebo-controlled trial (n=258 dosed, 32 U.S. sites). MADRS mean treatment difference: −3.6 points (95% CI −5.7 to −1.5; p<0.001) at Week 6; 25% of 25 mg participants achieved clinically meaningful ≥25% MADRS reduction at Week 6. Durability through Week 26 for responders; in Part B, over 40% of Week-6 non-remitters achieved full remission after a second dose. First Phase 3 trial of a classic (serotonin 2A agonist) psychedelic to report efficacy data.⁹

COMP006 Phase 3 (February 17, 2026): Randomized double-blind trial; n=568 dosed participants; comparing two 25 mg doses, two 10 mg doses, or two 1 mg doses (3 weeks apart). Primary endpoint: 25 mg vs 1 mg. Note: the 10 mg arm data was not included in the February 2026 topline readout; those results are pending. MADRS mean treatment difference: −3.8 points (p<0.001) at Week 6. 39% of patients achieved clinically meaningful ≥25% MADRS reduction.¹⁰ Across both Phase 3 trials, more than 800 patients treated in 25 mg arms.

COMP360 Rolling NDA strategy and PTSD expansion (2026). Compass has guided to rolling NDA submission completion in Q4 2026, with COMP006 Part B 26-week durability data expected early Q3 2026 as the final required dataset.¹⁶¹ Across COMP005, COMP006, and the prior Phase 2b program, Compass has data on over 1,000 participants and has met its primary endpoint "three for three" with high statistical significance. Analyst caution (Psychedelic Alpha): COMP006's -3.8 MADRS delta and 39% responder rate are at the modest end of field expectations; the 1 mg active comparator — rather than inert placebo — means the effect size appears smaller than COMP005's head-to-head vs. placebo design. Practitioners should not represent the two trials as uniformly strong or interchangeable. PTSD indication: FDA accepted Compass's IND for COMP360 in PTSD on January 7, 2026, opening a second indication pathway independent of TRD; a separate Phase 3 PTSD program will be required.¹⁶²

HLP003 Phase 2b (Helus Pharma/formerly Cybin; formerly CYB003): 75% remission at 4 months and 71% at 12 months after two 16 mg doses in the highest-dose arm.^{64 133} FDA Breakthrough Therapy designation for MDD. Phase 3 trials (PARADIGM/APPROACH (topline Q4 2026)) enrolling internationally.

Tobacco cessation (2014 pilot): Open-label pilot (n=15). 80% 7-day point prevalence abstinence at 6 months.¹³ Long-term follow-up at a mean of 30 months (range 16—57 months): 60% confirmed abstinent.¹⁴ First randomized comparison against an approved treatment (pilot, open-label, unblinded, 2026, n=82): 40.5% psilocybin vs 10.0% nicotine patch sustained abstinence at 6 months (OR=6.12; 95% CI 1.99—23.26; p=.003).¹⁵

Alcohol use disorder (2022): Randomized trial (n=93 dosed). Percentage of heavy drinking days: 9.7% psilocybin vs 23.6% diphenhydramine active control; mean difference 13.9% (95% CI 3.0—24.7; p=.01; Hedges' g=0.52). No serious adverse events in psilocybin group.¹⁶ A second Swiss randomized trial (Rieser et al. 2025) found no significant difference on its primary endpoint — abstinence duration (p=0.55) or mean alcohol use (p=0.51) — demonstrating that psilocybin efficacy in AUD is not yet established across studies.¹⁷

Anorexia nervosa (2023, Phase 1): Open-label feasibility study (n=10 adult females, mean BMI 19.7 — largely weight-restored or in partial remission). No serious adverse events. The authors’ conclusion is that psilocybin therapy is safe, tolerable and acceptable in this population; the study was not powered for efficacy and the safety finding does not extend to severely malnourished patients.⁵⁵

Obsessive-compulsive disorder (2025): Ching et al. (2025, Yale; NCT03356483) conducted the first double-blind, active-placebo-controlled (niacin 250 mg) RCT of single-dose psilocybin for treatment-refractory OCD. Results: clinically significant reductions in OCD symptoms in the psilocybin group vs. placebo at the 48-hour primary endpoint.¹¹⁹ OCD has a ~40% failure rate on standard treatment; no FDA-approved pharmacotherapy for refractory OCD exists. Quantitative primary results paper forthcoming.

Cancer-related depression, community oncology group model (2024): Phase 2 open-label (n=30; community oncology practice; both curable and non-curable cancer patients; single 25 mg psilocybin administered in cohorts of 3—4). MADRS reduction 19.1 points (p<.0001) at week 8; 80% sustained response; 50% full remission at week 1 sustained through week 8; no serious adverse events; no suicidality.¹⁰⁹ Demonstrates a scalable group-delivery, community cancer center model.

Migraine (2021): Randomized crossover trial. Low-dose psilocybin significantly suppressed migraine frequency.⁵⁶

Cluster headache blinded extension (2024): Schindler et al. (2024, Yale/VA Connecticut; n=10) reported pulsed psilocybin reduced cluster headache attacks from 18.4 to 9.8 per week (p=0.013; Cohen d-prime=0.97) — approximately 50% reduction regardless of prior response; well tolerated.¹²⁰ Cluster headache is sometimes called the "suicide headache" due to its severity and treatment resistance; this is the strongest evidence to date for a neurological indication independent of psychiatric comorbidity.

Population-Level and Naturalistic Evidence

The clinical trial literature captures outcomes in screened, prepared, and supported participants under laboratory conditions. A parallel and comparably large evidence base documents outcomes in the much larger population of people who use psilocybin and other classic psychedelics in naturalistic settings. This evidence does not establish causation — all major population studies use cross-sectional designs with selection effects — but it constitutes the most representative available data on what actually happens when these substances are used outside clinical settings.

NSDUH population analyses (United States, 2008—2019): Hendricks et al. (2015) pooled five years of National Survey on Drug Use and Health data (n > 190,000 adults) and found lifetime classic psychedelic use significantly associated with reduced odds of past-month psychological distress (OR=0.81), past-year suicidal thinking (OR=0.86), planning (OR=0.71), and attempt (OR=0.64); lifetime illicit use of other drugs was associated with increased odds of these outcomes.¹⁹ Johansen and Krebs (2015) independently analyzed 135,095 NSDUH adults (19,299 psychedelic users) and found no significant associations between lifetime classic psychedelic use and any mental health problem or suicidal behavior after adjustment: "Psychedelics are not known to harm the brain or other body organs or to cause addiction or compulsive use; serious adverse events involving psychedelics are extremely rare."⁷⁵ Sexton, Nichols, and Hendricks (2020) extended the analysis through 2017 (weighted N=260,964,827) and confirmed that classic tryptamine use was associated with reduced psychological distress (aOR=0.76) and suicidal thinking (aOR=0.79), while cautioning against novel phenethylamines.⁷⁶ Jones and Nock (2022) found that race and ethnicity significantly moderate these protective associations — they are robust for White participants but substantially attenuated for racial and ethnic minorities — a finding that underscores both the equity gaps in psychedelic research and the importance of culturally specific harm reduction.⁸⁰

Challenging experiences in naturalistic settings: Carbonaro et al. (2016, Johns Hopkins; n=1,993) surveyed people about their single worst psilocybin experience. Thirty-nine percent rated it among the five most challenging experiences of their lifetime; 11% put self or others at risk of physical harm; 2.7% sought medical help; 7.6% sought treatment for enduring psychological symptoms more than one year later. Despite this, 84% endorsed benefiting from the experience.⁷⁷ The authors explicitly note that harm reduction support — physical comfort, social support, preparation — was associated with reduced risk, and that laboratory-setting rates are dramatically lower. This paper simultaneously establishes that naturalistic adverse event rates are low in absolute terms and identifies the marginal benefit of harm reduction infrastructure.

Prospective naturalistic cohorts: Healy et al. (2025; n=85 adults with childhood maltreatment histories; settings: organized ceremonies and raves) found significant improvements from baseline to two-month follow-up in PTSD symptoms, complex PTSD symptoms, trait shame, social connectedness, and general connectedness (ds=0.73—1.12); acute subjective experience dimensions significantly predicted longitudinal outcomes.⁷⁹ This is the first prospective longitudinal study of psychedelic use at both ceremonial and rave/electronic dance music settings and documents therapeutic benefit in both.

Global naturalistic ayahuasca survey: Perkins et al. (2024; n=7,576; 50+ countries) found dose-response associations between naturalistic ayahuasca use and improved current mental health and psychological wellbeing; associations held for participants with and without mental illness history and were independent of community effects.⁷⁸

Gap between naturalistic use and medical infrastructure: Glynos et al. (2023; n=2,384 Canadians) found that 33.7% of naturalistic psychedelic users used these substances specifically to self-treat a health condition, while 81.2% never discussed this use with their primary health care provider, and only 4.4% used psychedelics with a therapist.⁸¹ The people most likely to benefit from accurate information are the least connected to clinical infrastructure. Harm reduction services fill this gap.

VA Healthcare System pilot (2025): Ellis et al. (2025, VA Palo Alto/Stanford; n=15 veterans with severe TRD; 73% comorbid PTSD): first psilocybin study within the VA system. 60% response and 53% remission at Week 3; 47% and 40% maintained at 12 weeks. Comorbid PTSD did not moderate outcomes. The psychedelic experience score (5D-ASC) did NOT correlate with response.¹¹⁷ That last finding is important for the "experience-is-essential" debate.

COMP360 Phase 2 for PTSD (2025): McGowan et al. (2025, King's College London / Mount Sinai / Sunstone; n=22 PTSD; NCT05312151): single 25 mg COMP360. CAPS-5 reduction of 29.9 points at Week 4 and 29.5 points at Week 12 (from baseline 47.5). No serious adverse events. Compass finalizing Phase 3 PTSD designs.¹¹⁸

Usona Institute uAspire Phase 3 (NCT06308653/PSIL301; MDD; pending results). Usona is a 501(c)(3) nonprofit whose psilocybin BTD (2019) covers the broader indication of MDD — not limited to TRD. The uAspire Phase 3 randomizes ~240 adults with MDD to 25 mg vs 5 mg vs placebo; 6-week double-blind + 12-month follow-up. Status as of May 2026: active, not recruiting; estimated completion April 2026; topline results not yet reported. Note: the estimated completion date has now passed (May 14, 2026); Usona has not announced topline data as of the document verification date. The topline is either imminent, delayed, or will be announced without advance notice given Usona's nonprofit operating model.¹³⁵ The preceding Phase 2 (PSIL201, n=104, JAMA August 2023): rapid, large, sustained antidepressant effect vs active placebo at Day 43. NDA submission targeted 2026 upon Phase 3 completion. Usona is the only nonprofit with a Phase 3 psilocybin trial; if approved, it would not be commercially licensed, representing a distinct access model from Compass.

MEQ vs. 5D-ASC: resolving the measure-of-mechanism tension. Two validated measures of the psychedelic experience give different answers about whether subjective experience predicts therapeutic outcome. Griffiths et al. 2011 (Note 97) found that depth of mystical experience measured by the Mystical Experience Questionnaire (MEQ) predicted response, and this has replicated across multiple cancer-distress and depression trials. Ellis et al. 2025 (VA Palo Alto; Note 117) found that the 5-Dimensional Altered States of Consciousness scale (5D-ASC) did NOT correlate with response. The resolution is pharmacological, not contradictory: the MEQ measures specifically mystical-type qualities — unity, noetic quality, sacredness, sense of transcendence — while the 5D-ASC measures altered states broadly, including anxiety, derealization, and visual disturbance. It is consistent that mystical experience quality predicts outcome while total altered-state intensity does not. This means the therapeutic mechanism may be linked specifically to mystical phenomenology rather than to psychedelic intoxication generally. That distinction matters enormously for the "it's all placebo" debate: if the predictive mechanism is mystical quality rather than drug effect magnitude, the subjective experience is the treatment — not merely an epiphenomenon of the pharmacology. COMP005 and COMP006 collected MEQ data; those Phase 3 analyses will constitute the first large-sample test of the MEQ-as-mechanism hypothesis under rigorous trial conditions.

The mystical experience as therapeutic mechanism: Across multiple trials, the depth of the mystical experience on session day — measured using the validated Mystical Experience Questionnaire (MEQ) — predicts therapeutic outcome more reliably than any other measured variable. In the 2011 Griffiths et al. dose-effect study (n=18; 0/5/10/20/30 mg/70 kg; 14-month follow-up): 72% at the highest doses had a complete mystical-type experience; 94% endorsed increased well-being or life satisfaction; 83% rated the experience among the five most spiritually significant of their lives; ratings were undiminished at 14-month follow-up.⁹⁷ This pattern — which has replicated across cancer patients, healthy volunteers, smoking cessation, and depression trials — is the foundation of the entheogenic argument: the subjective quality of the experience, not merely the pharmacological intervention, appears to be the mechanism of durable benefit. That mechanism does not require a clinical setting to be active. Steve Jobs stated that his LSD experiences were "one of the most important things" he had done, crediting them with expanding his sense of design possibility (per his authorized biographer).¹⁰⁴

Hinkle et al. 2024 meta-analysis (214 studies; 114 with analyzable adverse-event data; 3,504 participants): serious adverse events in no healthy participants; approximately 4% of those with pre-existing neuropsychiatric conditions. No deaths by suicide, no persistent psychosis, no HPPD in contemporary research settings.¹¹ Nutt et al. 2010: psilocybin mushrooms received an overall harm score of 5 — the lowest of all 20 substances assessed — followed by buprenorphine (6) and LSD (7). Alcohol scored 72, heroin 55, cannabis 20.¹² All harm scores verified word-for-word from the Imperial College London official press release, as the Lancet paper is paywalled.

Documented acute adverse effects: transient blood pressure and heart rate elevation; nausea in 15% of participants at high dose in the Hopkins cancer trial;⁵ psychological discomfort in 32% of high-dose sessions; anxiety in 26%. Absolute contraindications: personal or first-degree family history of schizophrenia-spectrum or primary psychotic disorder; uncontrolled hypertension; recent cardiac events; pregnancy; severe hepatic impairment. SSRIs and SNRIs attenuate psilocybin effects and require supervised taper.²⁰ Lithium co-administration carries seizure risk (47% seizure rate in 62 documented cases).⁵⁴

Legal Status (May 2026)

• Federal: Schedule I. BTDs: Compass COMP360 (TRD), Usona psilocybin (MDD), Helus Pharma HLP003 (formerly CYB003; MDD). Active rescheduling proceedings (2025): DEA forwarded psilocybin rescheduling petition (Schedule I to Schedule II) to HHS for medical-scientific review on August 11, 2025. DEA raised the aggregate production quota for psilocybin from 30,000g (2025) to 50,000g (2026) — a 67% increase; the psilocin APQ was separately raised to 80,000g for 2026.¹¹⁴

Schedule II vs. Schedule III: The Prescribing Framework Problem. The current rescheduling petition targets Schedule II — the same schedule as morphine, oxycodone, fentanyl, and cocaine. Schedule II prescribing carries binding requirements that are structurally incompatible with psilocybin-assisted therapy: DEA Form 222 required for every order, no refills permitted, in-person prescriber visit required at each refill, no phone-in or telepharmacy prescriptions. A schedule-II psilocybin session model would require the prescribing physician to be physically present at each 6-8 hour dosing session. By contrast, Schedule III (ketamine, buprenorphine, anabolic steroids) permits refills, telemedicine prescribing, and more flexible treatment models. The cannabis Schedule III rescheduling — accomplished via the same 21 U.S.C. § 811(d)(1) treaty mechanism — establishes the precedent for FDA-approved substances. The correct advocacy position for psilocybin is Schedule III, not Schedule II. Practitioners and policymakers who support the current DEA petition without understanding this distinction may be advocating for a regulatory outcome that makes clinical implementation structurally unworkable.

• Oregon: Regulated adult services operational since July 2023 (Measure 109). HB 2387 (signed and effective May 22, 2025; emergency clause) permits dual-licensed healthcare providers to provide psilocybin services without professional board discipline.³⁹
• Colorado: Prop 122 (2022) legalized adult personal use of psilocybin, DMT, ibogaine, and mescaline excluding peyote; licensed healing centers operating.
• New Mexico: S.B. 219 (Medical Psilocybin Act) signed by Governor Michelle Lujan Grisham in April 2025. First state to enact medical psilocybin through the legislature rather than a ballot initiative. Effective June 20, 2025; program operational deadline December 31, 2027. Qualifying conditions: treatment-resistant MDD, PTSD, substance use disorders, end-of-life care. Program administered by NM Dept. of Health.¹⁶⁰
• Australia: Schedule 8, authorized prescriber, effective July 1, 2023.⁴⁵
• Czech Republic: Medical access framework (35 mg/dose max; 75 mg/month), effective January 1, 2026.⁴⁴
• Germany: First EU compassionate-use program at CIMH Mannheim and OVID Clinic Berlin, operational July 11, 2025, administering Filament Health's PEX010 botanical psilocybin formulation.⁴³
• Switzerland: Federal OFSP/BAG extraordinary-treatment exception pathway since 2014, documented in Liechti et al. 2025.⁴⁶

B. LSD and DT120 ODT (Lysergide D-Tartrate) / Definium Therapeutics (formerly MindMed / MM120)

Identity and Pharmacology

Lysergic acid diethylamide (LSD): semi-synthetic ergoline alkaloid, first synthesized by Hofmann November 16, 1938. DT120 ODT (lysergide D-tartrate orally disintegrating tablet) is Definium Therapeutics' pharmaceutical formulation, developed under the name MM120 and renamed at the company's January 2026 corporate rebrand (MindMed → Definium Therapeutics, Nasdaq: DFTX). Partial 5-HT₂A, 5-HT₂C, and 5-HT₁A agonist. Onset 30—90 min. Duration 8—12 hours — the longest of the classical psychedelics.¹⁸⁶

Clinical Evidence

DT120 ODT / MM120 for generalized anxiety disorder (2025): Note on naming: the JAMA paper cited here uses MM120 because it was published in September 2025 — four months before MindMed rebranded to Definium Therapeutics and renamed the drug DT120 ODT. The citation is correct as published; the drug and company are now Definium's DT120 ODT and DFTX. Phase 2b RCT (n=198, 22 U.S. sites; published in JAMA, 334 JAMA 1358, September 2025 — the first Phase 2b of LSD in a peer-reviewed top-tier journal). MCP-Mod dose-response significant for 100 µg (HAM-A LS mean difference −5.0 points; 95% CI −9.6 to −0.4) and 200 µg (−6.0 points; 95% CI −9.8 to −2.0) vs placebo at Week 4; 25 µg and 50 µg not significant. Clinical response rate at 12 weeks (100 µg arm): 65%; remission rate: 48%. MADRS secondary endpoint (antidepressant signal): -5.7 at Week 4 (p≤0.05), -6.4 at Week 12. FDA Breakthrough Therapy designation for GAD; Phase 2b data per Robison et al. 2025.²¹

LSD for anxiety in life-threatening illness (2014): Randomized double-blind active placebo-controlled crossover trial (n=12). Sustained reductions in anxiety at 12-month follow-up.²²

LSD microdosing for ADHD — null result (2025): First placebo-controlled RCT of LSD microdosing (n=53; 20 µg twice weekly, 6 weeks). LSD AISRS improvement: −7.1 points. Placebo improvement: −8.9 points. No between-group difference (p=.80 one-sided). Authors conclude microdosing benefits in open-label settings are likely driven by expectancy.¹⁸ Do not cite microdosing observational data without citing this null result.

Drug harm ranking: Nutt et al. 2010: LSD harm score = 7. This is the third-lowest of 20 substances (after psilocybin mushrooms at 5 and buprenorphine at 6). Claiming LSD is "second least harmful" is factually incorrect.¹²

Legal Status

Federal Schedule I. DT120 ODT (formerly MM120) FDA Breakthrough Therapy designation for GAD (granted March 2024; originally held by MindMed; carried to Definium as legal successor). Switzerland: OFSP/BAG extraordinary-treatment exception since 2014. IP: Definium Therapeutics holds exclusive rights to the Catalent Zydis® ODT fast-dissolve platform for all salt and polymorphic forms of lysergide for pharmaceutical use in the US, UK, EU, Switzerland, Israel, and Canada through 2041 (USPN 12,036,220, issued July 2024; originally granted to MindMed; held by Definium as corporate successor). No external licensing conflict: Definium IS MindMed's successor and holds its own IP.¹⁴²

DT120 Phase 3 program (Definium Therapeutics / formerly MindMed MM120 program, as of May 2026). Three pivotal trials are underway.¹⁴² (1) Voyage — Phase 3, GAD, ~200 participants, U.S. only, HAM-A primary endpoint at 12 weeks; topline Part A anticipated early Q3 2026 (timing slipped from initial 1H 2026 guidance; not yet reported as of May 2026). (2) Panorama — Phase 3, GAD, ~200 participants (sample size re-estimated April 2026; down from initial ~250), U.S.+Europe; topline Part A anticipated late Q3 2026. (3) Emerge — Phase 3, MDD, ~140 participants, U.S., MADRS at Week 6; topline late Q2 2026 (n=149 fully enrolled per April 2026 Definium investor day). Additionally: Ascend (MDD, n=175, first patient dosed May 12, 2026; topline anticipated 2027); Haven (PTSD Phase 3 planned 2027). DT402 (autism spectrum disorder): early-stage oral lysergide program; Phase 2a data expected 2026.¹⁷¹ Nasdaq: DFTX. Note: there is ONE company and ONE LSD-class BTD program — Definium Therapeutics, Inc. (formerly MindMed). DT120 ODT is MM120 ODT renamed; the trial names (Voyage, Panorama, Emerge) are Definium's programs, formerly MindMed's programs. Do not reference these as two separate competing programs.

DT120 ODT formulation details. DT120 ODT (lysergide D-tartrate orally disintegrating tablet) uses Catalent Zydis® fast-dissolve technology designed for faster absorption, faster onset, improved bioavailability, and lower GI side effects vs a standard oral tablet. Ergoline derivative; partial 5-HT2A agonist. Pharmacology is identical to MM120/LSD: the rebrand affected the corporate and brand name, not the molecule. Phase 2b GAD: single 100 μg dose produced HAM-A -21.9 points at Week 12; 48% remission; well tolerated. IP: Definium holds exclusive Zydis rights for lysergide (USPN 12,036,220, through 2041) as MindMed's legal successor — no third-party licensing required; no IP conflict.¹³⁴

C. DMT and Ayahuasca

Identity and Pharmacology

N,N-Dimethyltryptamine (DMT) is an endogenous tryptamine found in numerous plant species and in trace amounts in human tissues. Inhaled or IV: onset seconds, duration 20—40 minutes. Ayahuasca combines DMT-containing ¹⁷⁷Psychotria viridis (chakruna) with β-carboline-containing Banisteriopsis caapi vine; β-carbolines inhibit MAO, making DMT orally bioavailable. Onset 30—60 min. Duration 4—6 hours.¹⁷⁸

Clinical Evidence

Palhano-Fontes et al. (2019): first randomized placebo-controlled trial of ayahuasca for treatment-resistant depression (n=29, Brazil). Day 7 response rate: 50% vs 9% placebo.²³ Strassman's 1994 University of New Mexico IV DMT study was the first federally approved Schedule I psychedelic research after prohibition.⁵²

Pharmaceutical DMT formulation research (2024). Mueller et al. (2024, University of Zurich; n=31 healthy male volunteers; Phase 1 RCT) tested a novel standardized pharmaceutical formulation of DMT and harmine designed to address ayahuasca's variable pharmacokinetics, nausea/vomiting risks, and lack of dose standardization.¹⁵⁴ A repeated-intermittent dosing scheme (10mg DMT intranasal every 15 minutes) produced Cmax values of 22.1 ng/mL with psychological effects resembling ayahuasca and a duration of 2—3 hours. Buccal harmine (100mg) produced sustained-release pharmacokinetics without distinguishable subjective effects. All conditions were safe and well tolerated. This study establishes the clinical feasibility of a standardized, patient-oriented pharmaceutical formulation for the DMT/harmine combination — potentially addressing the dose standardization and tolerability barriers that have limited ayahuasca's pharmaceutical development path.¹⁵⁴

DMT and harmine in meditation retreat (2024). Meling et al. (2024, University of Zurich/Freiburg; n=40 experienced meditators; double-blind placebo-controlled RCT; NCT05780216; published J. Psychopharmacol. 38:897). Participants received DMT-harmine or placebo during a 3-day mindfulness group retreat. Compared to meditation with placebo, DMT-harmine produced significantly greater mystical-type experiences, non-dual awareness, and emotional breakthrough during acute effects, and greater psychological insight at 1-day follow-up. At 1-month follow-up, the DMT-harmine group rated their experience as significantly more personally meaningful, spiritually significant, and well-being-enhancing. Mindfulness and compassion measures were not significantly different between groups. This study documents the synergy between meditation context and psychedelic pharmacology — the first placebo-controlled RCT of psychedelics specifically in a meditation retreat setting.

Ayahuasca and DMT: safety profile. White et al. (2024, systematic thematic review of 78 articles; Monash University / University of Melbourne; published Int. J. Toxicol. 43:327) reviewed adverse events and toxicity of traditional ayahuasca preparations and isolated alkaloids (DMT, harmine, harmaline, tetrahydroharmine). Overall conclusion: ayahuasca and DMT are generally safe; serious adverse effects are rarely reported in healthy populations in controlled settings. Animal studies at higher doses showed abortifacient and teratogenic effects of isolated harmala alkaloids — these may not extrapolate to human therapeutic doses of plant-based extracts. Harmaline showed the most preclinical safety signals. The review concludes that the traditional use of ayahuasca and DMT in controlled settings carries an acceptable safety profile, while calling for larger RCTs with longer duration. The clinical implications: nausea and vomiting are the most commonly reported adverse effects in human use; drug-drug interactions with serotonergic medications (SSRI, lithium, tramadol) require careful management due to the harmala alkaloids' MAO-inhibiting activity.

Ayahuasca for addiction: the emerging evidence base. Observational and pilot trial evidence documents ayahuasca's potential in addiction treatment. Retrospective survey studies with participants from ayahuasca ceremonies have documented reductions in problematic alcohol, cannabis, cocaine, and tobacco use following ceremonial participation. While no Phase 2 or Phase 3 RCTs of ayahuasca for addiction have been published as of May 2026, this body of evidence has generated sufficient interest that several North American clinical trial groups have registered IND-authorized studies. The key pharmacological mechanism under investigation: the ayahuasca experience combined with MAOI-potentiated serotonergic activation may produce the same neuroplasticity-mediated disruption of addictive behavioral patterns documented for psilocybin in tobacco cessation and alcohol use disorder trials. Methodologically: the naturalistic ceremonial setting, variable brew composition, and cultural context make controlled trial design challenging — the pharmaceutical DMT/harmine formulation (Note 154) may ultimately enable better-controlled clinical investigation.^{188 216 221 222}

β-Carboline mechanism: why ayahuasca is pharmacologically unique. The β-carboline alkaloids in Banisteriopsis caapi vine — harmine, harmaline, and tetrahydroharmine — are reversible MAO-A inhibitors that prevent the gastrointestinal and hepatic breakdown of DMT, making it orally bioavailable. Without MAO inhibition, DMT is inactive orally (it is rapidly deaminated). Tetrahydroharmine is additionally a weak serotonin reuptake inhibitor. The result is a multi-mechanism brew: DMT's 5-HT2A agonism and TrkB engagement, harmine/harmaline's MAO-A inhibition and direct 5-HT2A activity, and tetrahydroharmine's serotonin reuptake inhibition — operating simultaneously. This multi-component pharmacology is why ayahuasca's safety considerations differ materially from smoked or inhaled DMT: the MAOI activity creates significant drug-drug interaction risk (contraindicated: SSRIs, SNRIs, lithium, tramadol, decongestants, tyramine-rich foods) that does not apply to short-duration inhaled or vaporized DMT without a harmala co-administration.

Legal and Religious Context

The Supreme Court held unanimously in Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal (2006) that RFRA requires the government to demonstrate a compelling interest applied through the least restrictive means before suppressing sacramental ayahuasca use.³¹ The Ninth Circuit extended analysis to the Church of the Holy Light of the Queen's Santo Daime congregation, upholding a RFRA exemption.³² The Road to Eleusis (Wasson, Hofmann, and Ruck, 1978) hypothesized that the kykeon drink of the Eleusinian Mysteries contained ergot-derived psychoactive compounds.⁶⁸ DMT is Schedule I; ayahuasca preparations are Schedule I when intended for human consumption.

D. 5-MeO-DMT

Identity and Pharmacology

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT): primary activity at 5-HT₁A receptors (full agonist), secondary 5-HT₂A activity. Found in the Sonoran Desert toad (Incilius alvarius) and numerous plants. Inhaled/vaporized: onset seconds, peak 5—15 min, duration 20—40 min. ^{189 198}Conservation note: Toad-derived 5-MeO-DMT vaporization does NOT have documented ancient ceremonial tradition — this practice appears to date to the late 20th century. Clinical and ceremonial use now predominantly uses synthetic material.¹⁹¹

Clinical Evidence

GH001 Phase 2b results (February 2025). GH Research's GH001 (inhaled mebufotenin) met its Phase 2b primary endpoint: MADRS -15.5 vs placebo at Day 8 (p<0.0001); 57.5% remission at Day 8; 73% remission at 6 months; psychoactive duration ~11 minutes (median); well tolerated; no SAEs.¹³⁶ FDA clinical hold lifted January 5, 2026; Phase 3 initiation targeted 2026. GH001 does NOT hold a BTD as of May 2026.

BPL-003 (AtaiBeckley, BTD October 2025) for TRD. Intranasal mebufotenin (5-MeO-DMT) benzoate nasal spray; BTD granted October 16, 2025.¹³⁷ Phase 2b (NCT05870540, n=193 TRD, 38 sites/6 countries): 12 mg vs 0.3 mg comparator — MADRS -11.1 vs -5.8 at Day 29 (p=0.0038); 8 mg arm: MADRS -12.1 (p=0.0025); 8 mg selected for Phase 3 (equivalent efficacy, lower dose). Rapid onset from Day 2; effects through Day 57. Open-label extension (8 mg arm): MADRS -22.3 at Day 57 in OLE (Week 16 of program); 81% responder rate; 67% remission. For context: this 81% responder rate from a single dose at ~16 weeks is among the strongest single-dose durability signals in the field (compare: COMP005 25% responder at Week 6 from one dose; GH001 73% remission at 6 months from repeated dosing). OLE data supports Phase 3 durability thesis. FDA End-of-Phase 2 alignment complete; Phase 3 initiation Q2 2026 in two trials (~650 total patients; primary efficacy at Week 4; 12-week blinded; long-term extension; final data projected early 2029); well tolerated; ~100 min post-dose discharge readiness. Peer-reviewed publication: 12-week durability data from Phase 2a Cohort 1 published in J. Psychopharmacology (March 2026), providing first peer-reviewed BPL-003 durability data.¹⁶⁹ Corporate: AtaiBeckley (Nasdaq: ATAI) was added to the S&P Total Market and CRSP U.S. benchmark indices effective March 23, 2026, and to the Nasdaq Biotechnology Index December 2025 — representing institutional index-fund investment eligibility.^{168 140}

Prior GH001 Phase 1/2 evidence (Reckweg 2023, predates Phase 2b):

Reckweg et al. (2023): Phase 1/2 trial of GH001 — vaporized synthetic 5-MeO-DMT (GH Research). A personalized same-day dose-escalation protocol (6→12→18 mg) in 16 patients with treatment-resistant depression achieved 87.5% remission at Day 7 in the personalized arm.²⁴ GH Research has advanced to additional Phase 2 trials.

Legal Status

Federal Schedule I (since 2011). Not scheduled in all international jurisdictions. GH001: No BTD as of May 2026; Phase 2b positive; Phase 3 planned 2026 (Note 136). BPL-003 (AtaiBeckley): BTD for TRD, October 16, 2025 (Note 137).

E. Mescaline, Peyote, and San Pedro / Huachuma

Identity and Pharmacology

Mescaline (3,4,5-trimethoxyphenethylamine): the only major classical psychedelic from the phenethylamine rather than tryptamine chemical class. Partial 5-HT₂A and 5-HT₂C agonist. Principal sources: peyote (Lophophora williamsii, slow-growing, vulnerable status in Mexico) and San Pedro/huachuma (Echinopsis pachanoi and E. peruviana, fast-growing, widely available, not protected). Onset 45—90 min. Duration 8—12 hrs.¹⁹⁶

Ethnobotanical and Indigenous Context

Peyote: multi-millennia documented ceremonial use among Wixáritari/Huichol, Rarámuri/Tarahumara, and other northern Mexican peoples. The use is not merely claimed — it is physically verified: El-Seedi et al. (2005) conducted radiocarbon dating and alkaloid analysis (HPLC-MS) on archaeological peyote buttons from Shumla Cave No. 5, Rio Grande, Texas, confirming mescaline alkaloid content and dating to approximately 3,780—3,660 BCE.¹⁰¹ Bruhn et al. (2002) reported the same archaeological specimens confirming 5,700 years of documented use.¹⁰² This is biochemical evidence, not legend. San Pedro/huachuma: documented Andean ceremonial use to at least 1000 BCE based on Chavín archaeological evidence.⁷³ The Native American Church peyote exemption protects enrolled members of federally recognized tribes in bona fide ceremonies.³³ It does not extend to non-Native practitioners.

Conservation and equity note: Peyote populations have declined significantly due to illegal harvesting and habitat loss. Many indigenous leaders and plant medicine advocates urge non-Native practitioners to use San Pedro — which has comparable mescaline content and is far more sustainable — rather than peyote.¹⁹³

Clinical and Legal Status

Modern randomized trials of mescaline specifically are limited. Mescaline is Schedule I under the CSA; the peyote exemption (42 U.S.C. § 1996a) applies to peyote for tribal members.³³ Colorado Prop 122 (2022) legalized adult personal use of mescaline (excluding peyote) along with psilocybin, DMT, and ibogaine.

F. MDMA (3,4-Methylenedioxymethamphetamine)

Identity and Pharmacology

Substituted amphetamine. Acts primarily by releasing serotonin, norepinephrine, and dopamine from presynaptic terminals. Secondary 5-HT₂A activity. Categorically distinct from classic psychedelics: documented neurotoxicity risk with heavy or chronic use; abuse liability. Onset 30—60 min. Duration 3—6 hrs.¹⁸⁷

Clinical Evidence

MAPP1 Phase 3 (2021): Randomized double-blind placebo-controlled (n=90; MDMA n=46, placebo n=44). CAPS-5 mean change: −24.4 (MDMA) vs −13.9 (placebo); p<0.0001; Cohen's d=0.91. SDS: p=0.0116; d=0.43.²⁵

MAPP2 Phase 3 (2023): Confirmatory randomized trial (n=104; MDMA n=53, placebo n=51). CAPS-5 LS mean: −23.7 (MDMA) vs −14.8 (placebo); p<0.001; d=0.7. SDS: p=0.03; d=0.4. More diverse sample: 26.9% Hispanic/Latino, 33.7% non-White.²⁶

FDA CRL (August 2024) and Public Release (September 4, 2025): FDA declined to approve Lykos Therapeutics' NDA (NDA 215455) on August 8, 2024. The FDA advisory committee vote was decisive: 2 FOR, 9 AGAINST effectiveness; 1 FOR, 10 AGAINST benefit-risk balance.²⁷ On September 4, 2025, FDA publicly released the complete response letter as part of a batch of 89 previously confidential CRLs — a new agency transparency initiative.¹⁶³ The CRL's specific findings: (1) unreported adverse events at two trial sites — FDA found that Lykos training materials instructed sites not to report "positive" adverse events such as euphoria, despite the protocol requiring it; (2) lack of durability data — FDA found no evidence of efficacy past the 18-week end-of-study assessment; (3) high prior MDMA use among participants and prescreening failures undermining the randomization; (4) FDA requests a new Phase 3 trial with a low-dose active comparator to address functional unblinding. MAPS response: "FDA moved the goalposts" after agreeing to the Phase 3 design in 2017 via Special Protocol Assessment. Doblin characterizes the CRL as "not yet," not a final rejection. Phase 3 efficacy data remains striking: 67% (MAPP1) and 71% (MAPP2) of MDMA recipients no longer met PTSD diagnostic criteria vs. 32% and 48% placebo. Breakthrough Therapy Designation remains active. No Phase 3 resubmission timeline has been announced.¹⁶³

MDMA for social anxiety in autistic adults (2018): Randomized double-blind placebo-controlled crossover pilot (n=12). Statistically significant improvements in social anxiety sustained at follow-up.²⁸

Safety note on SSRIs: SSRIs substantially attenuate MDMA's subjective effects.⁶¹ Supervised taper required. MAOIs are contraindicated (serotonin syndrome risk).

Legal Status

Federal Schedule I. Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) holds the Breakthrough Therapy Designation for MDMA-AT for PTSD, which remains active despite the August 2024 CRL. Lykos rebranded to Resilient Pharmaceuticals in August 2025 after a $50M Series B recapitalization led by Antonio Gracias and Sir Christopher Hohn; new CEO Mike Burke and CMO Javier Muniz appointed; no Phase 3 resubmission timeline disclosed as of May 2026.¹⁶³ Australia authorized prescribing effective July 1, 2023.⁴⁵

Harm Reduction Note: Adulteration Is the Primary Hazard

In unregulated markets, the primary safety hazard for people who use MDMA is not the substance itself at known doses — it is adulteration. Palamar et al. (2021) documented widespread adulteration of ecstasy with cathinones (including N-ethylpentylone), 4-fluoroamphetamine (4-FA), para-methoxyamphetamine/para-methoxymethamphetamine (PMA/PMMA), and methamphetamine — all of which carry substantially greater toxicity and mortality risk than MDMA itself.⁸⁴ Fitzgerald and Palamar (2024) documented that drug-checking-kit use among New York City electronic dance music event attendees who use ecstasy nearly doubled from 23.1% to 43.1% between 2017 and 2022; at the same time, among those who tested their supply, suspected adulteration fell 69.1% (p<0.001) and suspected methamphetamine adulteration fell 83.6%.⁸² Measham (2019) found that on-site drug checking at UK festivals led approximately 1 in 5 users to dispose of their drugs upon learning the contents.⁸³ These findings have direct implications for policy: harm reduction infrastructure — drug checking services, reagent testing kits, education — addresses MDMA-related mortality risk at its actual source.

TSND-201 (methylone) for PTSD (2025-2026): Transcend Therapeutics' TSND-201 is methylone — a structural MDMA analog but with distinct pharmacology: acts at monoamine transporters with NO 5-HT2A activity (non-hallucinogenic). IMPACT-1 Phase 2 (n=65 severe PTSD; 4 weekly oral doses): primary endpoint met; well tolerated; rapid and durable improvement.¹³⁰ FDA BTD July 2025; FDA National Priority Voucher April 27, 2026 — the third voucher under the Trump EO. Why methylone got the voucher over MDMA/Resilient: no data integrity issues from Lykos trial record; non-hallucinogenic profile minimizes functional unblinding; oral repeated-dosing model fits standard psychiatric practice. Phase 3 initiated: Transcend began patient recruitment for the Phase 3 trial following FDA discussions; as of March 2026, enrollment is underway (acquisition by Otsuka expected Q2 2026 pending customary closing conditions).

G. Ketamine and Esketamine

Identity and Pharmacology

Arylcyclohexylamine. Acts primarily as NMDA receptor antagonist. Esketamine (S-enantiomer) is approximately 2—4× more potent. Administration routes: IV, IM, SC, intranasal, sublingual. Duration dose-dependent, typically 45—90 min IV. Rapid antidepressant effects appear within hours.¹⁷³

Legal Status and Regulatory Precedent

Ketamine: Schedule III (CSA). Esketamine (Spravato) received FDA approval March 2019 for treatment-resistant depression, and on January 21, 2025 received an expanded approval for use as a monotherapy for TRD — previously requiring co-administration with an oral antidepressant.³⁰ Annual worldwide sales grew to approximately $1.7 billion in 2025, crossing the $1 billion blockbuster threshold for the first time in 2024. This is the most powerful regulatory precedent argument for the field: an NMDA-antagonist psychedelic-adjacent compound is already FDA-approved, now with monotherapy approval, REMS-managed, and in routine clinical practice. Racemic ketamine IV infusion is used off-label for depression and is NOT itself FDA-approved for this indication.

Safety Warning: Unique Concerns Not Present with Classic Psychedelics

CRITICAL: Ketamine is the one substance in this toolkit with documented abuse liability, dependence risk, and severe urinary tract toxicity. Chronic heavy use causes ketamine-induced uropathy ("ketamine bladder") — a potentially irreversible condition. The 2023 death of actor Matthew Perry from acute ketamine toxicity (LA County Medical Examiner: acute effects of ketamine; discovered in jacuzzi, October 28, 2023) led to federal charges against five defendants (August 2024); all five pleaded guilty and were sentenced between October 2024 and May 2026: Jasveen Sangha ("Ketamine Queen") sentenced to 15 years (April 8, 2026); Dr. Salvador Plasencia 30 months (December 2025); Kenneth Iwamasa 41 months (May 2026); Eric Fleming 24 months (April 2026); Dr. Mark Chavez 3 years probation (October 2024). Core failure: ketamine administered by an untrained personal assistant without medical supervision, monitoring, or informed consent.^{192 176}

Off-label IV ketamine: the unregulated industry. Racemic ketamine IV infusion for depression is NOT FDA-approved for psychiatric use — Spravato (esketamine) is the only FDA-approved option. Despite this, hundreds of ketamine infusion clinics operate legally across the U.S., administering IV ketamine off-label (typically 0.5 mg/kg over 40 minutes). The off-label use is legal but carries no REMS requirement, no standardized screening mandate, no mandatory monitoring standard, and no billing infrastructure — cash-pay only at $400-$800/infusion, $2,400-$6,000 for a typical 6-infusion series. This is structurally analogous to pre-approval psychedelic therapy: legal to prescribe, highly variable practice standards, no federal oversight floor.

Ketamine-assisted psychotherapy (KAP) vs. ketamine-only. KAP integrates psychotherapy with ketamine infusions, using the altered state as a therapeutic window; ketamine-only protocols administer the infusion in a clinical setting without structured psychotherapy. Grabski et al. (2022, Univ. Exeter/UCL; Phase 2 RCT; n=96 severe AUD, four arms) found the ketamine+therapy group had 15.9 percentage points more days abstinent at 6-month follow-up than saline+education (95% CI 3.8-28.1); ketamine alone vs. placebo: +10.1 percentage points (95% CI 1.1-19.0), the first adequately powered RCT evidence of ketamine benefit in AUD.¹⁵⁵ The mechanistic note: ketamine's antidepressant mechanism operates primarily through NMDA antagonism and downstream glutamate signaling, independent of the subjective dissociative experience — confirming the drug-only regulatory model that the Spravato approval already established.

The Matthew Perry death and the home ketamine risk vector. The 2023 death of actor Matthew Perry from acute ketamine toxicity resulted in 2024 federal indictments for negligent unsupervised administration by multiple providers. The key failure: ketamine administered without adequate monitoring, documentation, or consent. For practitioners advising ketamine clinic operators and clients: (a) clinician must be present and monitoring for the full infusion and recovery period; (b) documented medical screening including cardiac history and contraindicated medications; (c) no at-home administration without physician present; (d) written informed consent covering ketamine-specific risks. The Perry indictments confirm that negligent unsupervised ketamine administration is not simply a civil liability issue — it is criminal exposure.

H. Ibogaine and Iboga

Identity and Pharmacology

Indole alkaloid derived from root bark of Tabernanthe iboga (Central Africa). Complex polypharmacology: NMDA antagonism, κ-opioid agonism, σ-2 binding, serotonin transporter inhibition. Critical cardiac risk: ibogaine binds the hERG potassium channel, prolonging QTc interval, which can precipitate ventricular arrhythmia or death. Active metabolite noribogaine (t½ 24—48 hrs) contributes to prolonged effects. Single dose produces an experience lasting 12—36 hours.¹⁷⁴

Clinical Evidence

Cherian et al. (2024, Nature Medicine): prospective observational study (n=30 male Special Operations veterans with predominantly mild TBI; MISTIC protocol with ibogaine plus intravenous magnesium sulfate for cardiac protection; treatment at a clinic in Mexico). Statistically significant improvements at 1-month follow-up in functioning (d=2.20), PTSD (d=2.54), depression (d=2.80), and anxiety (d=2.13).²⁹ Critical limitations: no placebo arm; small n; non-U.S. administration site; observational design. These results do not establish efficacy.

Ibogaine neural mechanism (2025): Lissemore et al. (2025, Nature Mental Health; Williams senior author; n=30, same cohort) analyzed EEG and MRI data. Single magnesium-ibogaine treatment increased theta/alpha oscillations, reduced beta/gamma power and cortical complexity. Veterans who improved in executive function showed increased theta rhythms; those with reduced PTSD showed reduced cortical complexity. Baseline EEG patterns predicted likely responders before treatment.¹¹⁰

Baseline EEG as a predictive biomarker (2025 implication). Lissemore et al. (2025, Note 110) found that baseline EEG patterns predicted which veterans would most benefit from ibogaine treatment before any drug was administered. This has several downstream implications: (1) Precision prescribing: patient selection could be optimized using pre-treatment biomarkers, potentially enabling personalized treatment allocation; (2) Insurance risk stratification: payers may eventually require biomarker evidence before authorizing treatment, making pre-treatment EEG part of the prior authorization process; (3) Reduction of the functional unblinding critique: if responders can be predicted before dosing, the "expectancy equals effect" argument is partially undermined — predicted responders benefit regardless of their expectancy.¹¹⁰

OUD observational evidence: the legislative driver. No published Phase 2 or Phase 3 RCT of ibogaine for opioid use disorder exists as of May 2026. The evidence base driving state and federal investment is observational: multiple open-label and retrospective cohort studies — most prominently the Mash et al. Bahamas cohort (n>400 across papers 2000-2018 from a licensed clinic) — document that ibogaine rapidly interrupts opioid withdrawal symptoms in the majority of patients and reduces cravings at follow-up. Critical limitations: no control arm, high self-selection bias, variable follow-up, no standardized outcome measures. DemeRx NB's noribogaine Phase 1 IND (Note 38) is the first FDA-authorized controlled investigation of an ibogaine analog for AUD — not OUD; the OUD RCT pathway remains undeveloped. The legislative advocacy is ahead of the evidence base. This must be disclosed in policy contexts.¹⁷⁹

Mexico clinic landscape: the access reality for U.S. patients. Ibogaine is not scheduled under Mexican federal law, making Mexico the primary destination for U.S. patients seeking ibogaine for opioid use disorder, trauma, and TBI. Fifteen or more ibogaine treatment centers operate in Baja California Norte (border region adjacent to San Diego/Arizona). Cardiac monitoring quality varies dramatically. Deaths that have occurred in ibogaine treatment settings have primarily involved inadequate cardiac monitoring — undetected QTc prolongation leading to fatal arrhythmia — or failure to identify contraindicated medications at intake. For practitioners advising clients: verify the clinic requires (a) baseline 12-lead ECG; (b) IV magnesium sulfate as cardiac prophylaxis; (c) continuous telemetry for the full 12-36 hour acute period; (d) cardiologist or emergency medicine physician on-site or immediately available; (e) complete contraindicated medication screening. These are not optional — they are the protocol elements that distinguish safe from dangerous ibogaine administration.

Noribogaine: the extended risk window. Ibogaine is rapidly metabolized to noribogaine, the primary active metabolite, with a half-life of 24-48 hours. Noribogaine maintains hERG channel blockade and QTc prolongation for up to 48 hours post-dose — meaning a patient who has completed the acute ibogaine experience and feels subjectively well may still carry significant cardiac risk. Clinical protocol: cardiac monitoring should continue for at least 24 hours post-dose. Discharging a patient the morning after an ibogaine session based on subjective improvement is a documented risk factor for post-discharge fatal arrhythmia.

Cardiac monitoring is the binding constraint. Ibogaine-associated deaths have been documented in uncontrolled settings. Current clinical protocols require: baseline ECG, continuous cardiac monitoring, IV magnesium sulfate, and cardiology back-up. A non-hallucinogenic ibogaine analogue (tabernanthalog, TBG), developed by Cameron and Olson et al. (2020), shows antidepressant-like and anti-addiction effects in rodents without QTc prolongation,⁶⁶ confirmed by Aarrestad et al. (2025, Nature Neuroscience) who demonstrated that structural neuroplasticity directly underlies these effects by experimental spine ablation.¹¹¹

Federal Policy 2025—2026

Former Texas Governor and U.S. Energy Secretary Rick Perry has been a leading ibogaine advocate since 2024, following personal treatment in Mexico. Perry co-founded Americans for Ibogaine, published a Washington Post opinion column, appeared on Joe Rogan's podcast twice (January 2025 and April 1, 2026) alongside Americans for Ibogaine CEO W. Bryan Hubbard, and lobbied at ALEC's State & Nation Policy Summit. Retired Navy SEAL Marcus Luttrell, whose ibogaine experience helped inspire Perry's advocacy, also attended the April 18, 2026 EO signing ceremony. Perry's advocacy is credited with helping build the bipartisan coalition that produced Texas SB 2308 and the Trump EO.⁷²

Texas SB 2308 (signed Governor Abbott June 11, 2025) allocated $50 million for the IMPACT ibogaine research consortium⁴² led by UTHealth Houston. Trump Executive Order No. 14,401 (April 18, 2026) directed FDA and DEA to establish Right-to-Try ibogaine access pathways and allocated $50 million ARPA-H matching funds.³⁷ FDA cleared DemeRx NB to begin the first U.S. Phase 1 trial of noribogaine for alcohol use disorder.³⁸

Ceremonial Context

Ibogaine for opioid use disorder (the legislative driver). Kentucky SB 77 and Mississippi HB 314 (Notes 106, 123) appropriated funds specifically for ibogaine research for opioid use disorder — distinct from the TBI/veteran evidence base. The OUD evidence consists primarily of observational and open-label studies showing ibogaine interrupts withdrawal and reduces cravings; no published Phase 2 or Phase 3 OUD RCTs exist. DemeRx NB's noribogaine Phase 1 IND (Note 38) is the first FDA-authorized controlled investigation. The OUD legislative advocacy is therefore ahead of the evidence base — this limitation should be acknowledged in policy contexts.

Iboga is central to the Bwiti spiritual tradition of Gabon, Cameroon, and the Congo basin. High-dose Bwiti initiation rites are among the most thoroughly documented sacred plant ceremonies in sub-Saharan Africa and are categorically distinct from Western medical use.²⁰⁴

I. Cannabis and Cannabinoids

Identity and Pharmacology

Cannabis (Cannabis sativa L.) contains over 100 cannabinoids. Δ9-THC is a partial CB1/CB2 agonist producing psychoactive effects. CBD is non-psychoactive with multi-target activity. FDA-approved products: dronabinol (Marinol, Schedule III), nabilone (Cesamet, Schedule II), and Epidiolex (CBD, Schedule V per DEA placement September 2018; approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis-associated seizures; moved to Schedule III under April 2026 Final Order as an FDA-approved cannabis product).²¹⁷

Therapeutic Evidence: FDA-Approved and Established Indications

Unlike other substances in this toolkit, cannabis has FDA-approved pharmaceutical products with established Phase 3 trial evidence. The clinical evidence below is for FDA-approved or well-established formulations and indications — not for unregulated cannabis products generally.

Epidiolex (CBD) for treatment-resistant epilepsy. Devinsky et al. (2017, NEJM 376:2011) conducted the pivotal Phase 3 RCT of pharmaceutical-grade CBD (Epidiolex, 20 mg/kg/day) for Dravet syndrome (n=120): median convulsive seizure frequency reduced significantly in the CBD group vs placebo (adjusted median difference −22.8 percentage points; 95% CI −41.1 to −5.4; p=0.01).¹⁵² Devinsky et al. for Lennox-Gastaut syndrome (GWPCARE4, Lancet 2018, n=225): total seizure reduction 41.9% CBD vs 21.8% placebo (p=0.0047); drop seizure reduction 43.9% vs 21.8% (p=0.0135).¹⁵³ Both trials supported FDA approval of Epidiolex in June 2018. Additional approved indication: tuberous sclerosis complex (TSC). These are the strongest-evidence pharmaceutical cannabis trials in the literature: blinded, placebo-controlled, powered for primary endpoints, in populations with multiple prior treatment failures.

THC for chemotherapy-induced nausea and vomiting (CINV). Two FDA-approved cannabinoid pharmaceuticals address CINV: dronabinol (Marinol, Schedule III) — synthetic THC approved for CINV refractory to conventional antiemetics and for anorexia/weight loss in AIDS patients — and nabilone (Cesamet, Schedule II) — synthetic cannabinoid approved for CINV in patients who have not responded to conventional antiemetic treatment. Both have been approved since the 1980s and are covered by Medicare and commercial insurance for their approved indications. The evidence base: multiple RCTs and systematic reviews from the 1980s—2000s established cannabinoids' superiority to placebo and comparability to available antiemetics for CINV; modern comparative trials against ondansetron/serotonin antagonists have mixed results. The clinical utility is primarily for refractory CINV and for patients with appetite/weight loss complications.

Chronic pain: the most contested evidence. Chronic pain is the most common reason patients report using medical cannabis in U.S. states with medical programs. The evidence is substantial but heterogeneous. A 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) comprehensive review found conclusive evidence that cannabis/cannabinoids are effective for treatment of chronic pain in adults (the evidence base: RCTs showing modest but statistically significant reduction in pain scores). However: most RCTs are small (n<100); duration is short (weeks, not months); standardization of cannabis products is absent in naturalistic studies; and the size of the effect is modest. The most clinically defensible statement: cannabinoids produce statistically significant pain reduction vs placebo in RCTs of chronic pain; whether this effect is clinically meaningful for individual patients depends on baseline severity and alternatives available. Note: neither THC nor CBD in unregulated cannabis products is approved for chronic pain as of May 2026.²⁰²

Adolescent and psychiatric risk: the non-negotiable caveats. Cannabis is not pharmacologically harmless. Three risk categories require honest statement: (1) Adolescent psychosis risk: heavy cannabis use during adolescence — particularly high-THC products — is associated with increased risk of psychosis-spectrum disorders in predisposed individuals. The association is robust across multiple epidemiological studies; causation vs selection remains contested but the signal is consistent. (2) Cannabis use disorder: DSM-5 criteria; approximately 9% of lifetime cannabis users develop cannabis use disorder; 17% of those who begin in adolescence. This is a documented addiction liability that differentiates cannabis from classic psychedelics. (3) Cognitive effects: Meier et al. (2012, PNAS) longitudinal Dunedin cohort study (n=1,037 born 1972-1973, followed to age 38) documented that persistent cannabis use beginning in adolescence was associated with an 8-point IQ decline; those who began in adulthood showed no significant IQ change. These findings remain contested in the literature but are the strongest longitudinal data available. When discussing cannabis destigmatization: acknowledge these risks candidly, substance-specifically, and age-specifically. The destigmatization of responsible adult use is consistent with honest communication about adolescent risk.^{201 200 197}

Cannabis and opioids: the substitution evidence. Multiple ecological and observational studies have found associations between medical cannabis legalization and reductions in opioid prescribing rates and opioid overdose mortality. These findings have been contested: more recent analyses with better controls have weakened or reversed some of the earliest associations. The current scientific position: the substitution effect is biologically plausible (cannabinoids and opioids both act on pain pathways), supported by some patient self-report data and some ecological analyses, but not established as causal by the available evidence. Do not claim that cannabis reduces opioid overdose deaths as an established fact; state it as a plausible association under active investigation.²⁰³

Cannabis: the 280E practitioner note. State-licensed medical cannabis operators are now outside 26 U.S.C. § 280E effective April 28, 2026; adult-use recreational cannabis operators remain subject to 280E pending the June 29, 2026 DEA hearing. For cannabis-adjacent clients (e.g., hemp/CBD businesses, cannabis technology companies, service providers to cannabis operators), 280E analysis must be client-specific: the disallowance applies to the cannabis trafficking activity, not necessarily to ancillary businesses. Consult a tax attorney before assuming any business is or is not subject to 280E. The cannabis Schedule III rescheduling does NOT extend to psilocybin or any other psychedelic substance.

Federal Rescheduling: April 2026

On April 23, 2026, Acting Attorney General Todd Blanche issued a Final Order under 21 U.S.C. § 811(d)(1) moving two categories of cannabis from Schedule I to Schedule III: (1) FDA-approved drug products containing marijuana; and (2) marijuana subject to a state medical marijuana license. Effective date: April 28, 2026 (91 Fed. Reg. 22,716).³⁶

Section 280E relief: 26 U.S.C. § 280E prohibited state cannabis businesses from deducting ordinary business expenses. Effective April 28, 2026, this prohibition is removed for state-licensed medical cannabis operators.⁵⁸ The effective tax burden under 280E has historically been estimated by cannabis tax practitioners at 60—80% of gross profit for many operators, as ordinary business deductions are disallowed. Adult-use (recreational) cannabis operators remain subject to Section 280E pending the DEA administrative hearing beginning June 29, 2026 (deadline July 15, 2026).³⁶

Pending issues: Interstate commerce remains federally prohibited. Banking barriers persist; the SAFE Banking Act has not passed as of May 2026. Legal challenges under the APA are anticipated.⁶⁷

V. Legal and Regulatory Landscape

A. U.S. Federal Scheduling (May 2026)

The Controlled Substances Act (21 U.S.C. § 812) assigns substances to five schedules. Schedule I requires: no currently accepted medical use AND high potential for abuse.

• Psilocybin/psilocin: Schedule I. BTDs: Compass COMP360 (TRD), Usona (MDD), Helus Pharma HLP003 (formerly CYB003; MDD).
• LSD: Schedule I. BTD: Definium Therapeutics DT120 ODT (lysergide d-tartrate ODT, GAD; formerly MM120 under MindMed brand; rebrand effective January 2026 — one company, one program).¹⁴²
• DMT/ayahuasca: Schedule I. RFRA exemption for UDV sacramental use established by the Supreme Court in O Centro (2006).³¹
• Santo Daime (ayahuasca): RFRA exemption for the Church of the Holy Light of the Queen established by the Ninth Circuit.³²
• 5-MeO-DMT: Schedule I. GH001 (GH Research): No BTD as of May 2026; Phase 2b positive; Phase 3 planned 2026.¹³⁶ BPL-003 (AtaiBeckley): BTD for TRD granted October 16, 2025.¹³⁷
• Mescaline/peyote: Schedule I. Peyote exemption for NAC tribal members.³³
• MDMA: Schedule I. BTD: Resilient Pharmaceuticals (PTSD) active.
• Ketamine: Schedule III. Esketamine (Spravato) FDA-approved (March 2019).³⁰
• - TSND-201 (methylone): Schedule I. Note: BTD July 2025 and Priority Voucher April 2026 do not affect scheduling. Otsuka acquisition of Transcend pending as of May 2026.¹³⁰
• Ibogaine: Schedule I. Right-to-Try pathway per April 2026 EO No. 14,401.³⁷ DemeRx noribogaine Phase 1 cleared.³⁸
• Cannabis: Schedule III (state medical + FDA-approved products), effective April 28, 2026. Recreational remains Schedule I pending June 29 DEA hearing.³⁶

B. State Landscape

• Oregon: Measure 109 (2020). Regulated psilocybin services operational July 2023. HB 2387 (signed and effective May 22, 2025 (emergency clause; effective immediately upon signing)) expands healthcare provider access.³⁹
• Colorado: Prop 122 (2022) legalized adult personal use of psilocybin, DMT, ibogaine, and mescaline (excluding peyote). Licensed healing centers operating.
• New Mexico: S.B. 219 (Medical Psilocybin Act) signed by Governor Michelle Lujan Grisham in April 2025. First state to enact medical psilocybin through the legislature rather than a ballot initiative. Effective June 20, 2025; program operational deadline December 31, 2027. Qualifying conditions: treatment-resistant MDD, PTSD, substance use disorders, end-of-life care. Program administered by NM Dept. of Health.¹⁶⁰
• Texas: $50M IMPACT ibogaine consortium funded, SB 2308 (2025).⁴²
• Kentucky (2026): S.B. 77 enacted April 14, 2026 via legislative veto override (Governor Beshear vetoed April 13; both chambers overrode April 14); $21 million appropriated from opioid abatement trust fund for ibogaine research for opioid use disorder and trauma.¹⁰⁶
• Virginia (2026): H.B. 1347 and S.B. 379 signed by Governor Youngkin April 7, 2026; trigger law requiring automatic psilocybin rescheduling at state level upon FDA approval and federal rescheduling.¹⁰⁷
• Mississippi (2026): H.B. 314 signed by Governor Reeves March 26, 2026; effective July 1, 2026; medical ibogaine research program.¹²³
• South Dakota (2026): H.B. 1099 signed by Governor Rhoden March 10, 2026 (House 58—7, February 9; Senate 21—12, March 2); psilocybin trigger law.¹²⁴
• West Virginia (2026): S.B. 906 enacted as trigger law, effective April 1, 2026 (veto window expired without signature); H.B. 4626 vetoed April 1, 2026 by Governor Morrissey.¹²⁵
• Georgia (2026): H.B. 382 signed by Governor Brian Kemp into law (40-day window closed May 12, 2026; passed House 167—0 March 6 and Senate 38—10 March 31): psilocybin trigger law creating exception for FDA-approved crystalline polymorph psilocybin, to be rescheduled per federal DEA schedule upon FDA approval.¹²⁶
• Georgia HB 717 (companion bill, also signed by Kemp): Amends the Medical Practice Act; requires Georgia Composite Medical Board to establish rules by December 31, 2026 for psychedelic-assisted treatment and therapy clinics (defined broadly to include ketamine, dissociatives, and related substances); clinic licensing required by July 1, 2027; administration restricted to physicians with advanced airway management training, CRNAs under physician direction, and qualified NPs and PAs with defined qualifications and experience. Primarily addresses the existing off-label ketamine clinic market, but the regulatory framework will govern any future FDA-approved psychedelic therapy administered in Georgia clinics.¹⁵⁹
• Municipal decriminalization: Lowest-enforcement-priority policies: Oakland, Santa Cruz, Denver, Seattle, Detroit, Ann Arbor, Washington D.C., and others.

Trigger Law Cascade — Crystalline Polymorph Specificity Issue. Compass has lobbied for trigger laws in Virginia and Colorado that reference "crystalline polymorph psilocybin" — the specific formulation of COMP360 — rather than psilocybin broadly. If enacted as written, these laws may fire exclusively for COMP360's approved formulation, NOT for natural psilocybin used in Oregon and Colorado service centers, Usona's psilocybin formulation, or any other psilocybin product not meeting the crystalline polymorph specification. Legal professionals advising service center operators or policy advocates should verify whether enacted trigger laws in each state contain this formulation-specific language before assuming FDA approval of COMP360 expands state access to all psilocybin services. The Usona wildcard: if Usona files first (broader MDD label, nonprofit model), trigger laws referencing "FDA-approved psilocybin" broadly — rather than a specific formulation — would fire for Usona too. The specific language of each enacted trigger law governs.

What each trigger law actually requires post-firing. FDA approval does not make treatment available day-one in trigger states. Each state's trigger law has different operational requirements: (a) Automatic rescheduling only — no additional action required from the legislature or governor; treatment available subject to existing licensing requirements. (b) Rulemaking required — the state agency must promulgate implementation rules before treatment is available, which may take 6-18 months post-approval. (c) Governor action required — some trigger laws require a gubernatorial finding or proclamation before the rescheduling takes effect. None of the enacted trigger laws make psychedelic therapy immediately available at an existing service on the day of FDA approval — there is always an implementation gap. Georgia's H.B. 382: signed by Governor Kemp into law; 40-day window closed May 12, 2026. Trigger fires upon FDA approval of FDA-approved crystalline polymorph psilocybin.

Trigger Law Cascade. Compass plans NDA filing year-end 2026; priority review voucher target 1-2 months suggests Q1 2027 FDA decision. FDA approval of COMP360 for TRD auto-activates Virginia (Note 107), South Dakota (Note 124), West Virginia (Note 125), and Georgia (Note 126; signed by Governor Kemp; 40-day window closed May 12, 2026) trigger laws simultaneously — no further legislative action required for enacted states.

• Rohrabacher-Joyce-Merkley rider: Annual appropriations language prohibiting DOJ from using funds to prevent states from implementing their own state medical marijuana laws.

C. International Landscape

• Australia: Psilocybin and MDMA reclassified to Schedule 8 (authorized prescriber), effective July 1, 2023.⁴⁵
• Czech Republic: Medical psilocybin access (35 mg/dose; 75 mg/month), effective January 1, 2026.⁴⁴
• Germany: EU's first psilocybin compassionate-use program at CIMH Mannheim and OVID Clinic Berlin, operational July 11, 2025, using Filament Health's PEX010 botanical psilocybin formulation.⁴³
• Switzerland: Federal OFSP/BAG extraordinary-treatment exception pathway for psilocybin, LSD, and MDMA since 2014, documented in Liechti et al. 2025.⁴⁶

EU regulatory horizon: EMA multi-stakeholder workshop (2025). The European Medicines Agency held a planned multi-stakeholder workshop on psychedelics in 2025, examining EU regulatory frameworks for trial design, approval pathways, and health technology assessment. No formal EU framework change has been proposed as of May 2026. The workshop signals EMA willingness to develop guidance — the first such signal at the EU level. A future EU pathway would most likely require centralized EMA marketing authorization rather than country-by-country approvals. Germany's compassionate-use program (July 2025) and Czech Republic's medical framework (January 2026) operate under national exceptional-use authorities that could coexist with a future centralized pathway.

International treaty constraints and the domestic rescheduling mechanism. The UN Convention on Psychotropic Substances (1971) schedules psilocybin, LSD, DMT, MDMA, and mescaline. This creates a floor of international control that member states generally cannot go below without treaty violation. Three important nuances: (1) Treaty scheduling does not prevent authorized research — countries may permit medical research under Schedule I. Australia's rescheduling to Schedule 8 (prescribable) was implemented as authorized medical access within a prescription system, which the treaty permits for therapeutically recognized substances. (2) The U.S. 21 U.S.C. § 811(d)(1) mechanism — used for cannabis Schedule III rescheduling — authorizes rescheduling "to the extent permitted" by treaty. FDA approval of psilocybin would establish "accepted medical use" and shift the treaty analysis to permit Schedule III.¹⁸⁵ (3) A small number of UN member states have acceded with conditions recognizing indigenous traditional use — relevant to Bolivia and Peru on ayahuasca and peyote.

Australia real-world data (through September 2025). TGA FOI data: 87 MDMA-AT/PTSD patients; 47 psilocybin/TRD patients; zero SAEs; >50% of MDMA-PTSD patients reported significant relief. Implementation barriers: 12-13 authorized prescribers; high costs; geographic centralization. ANU collecting real-world outcomes. See Dutton et al. 2026 (Aust. & N.Z. J. Psychiatry).¹³⁹

• Netherlands: Psilocybin truffles unscheduled and legally sold; retreat industry operational.
• Canada: Special Access Program covers psilocybin and MDMA; individual patient exemptions issued.
• Israel: Ministry of Health exceptional access program for psilocybin reported to be operational since 2023 (secondary sources; primary MoH documentation not independently verified as of May 2026).
• Brazil: Ayahuasca religious use legal since 1987; ibogaine treatment clinics operate legally.
• Jamaica: Psilocybin mushrooms not scheduled; commercial retreat industry operates legally.
• United Kingdom: No approved regulatory pathway for psychedelic medical access as of May 2026. Multiple active research programs at Imperial College London, King's College London, and Oxford. The Parliamentary Office of Science and Technology (POST) — Parliament's independent scientific analysis body — has published rapid-response briefings on psychedelic-assisted therapy for depression, PTSD, anxiety, and eating disorders, directly informing parliamentary debate. Home Office Schedule 1 research licenses required; application timelines are a documented barrier. Psychedelic reform has moved from fringe to mainstream UK policy consideration.
• New Zealand: Medsafe has granted individual compassionate access authorizations for psilocybin in specific cases; no general framework as of May 2026. Follows Australia's developments closely. If Australia's authorized prescriber model succeeds, New Zealand is the most likely next adopter.
• Portugal (harm reduction model): In 2001, Portugal decriminalized personal possession of all drugs up to a ten-day personal supply threshold. Possession is handled by Dissuasion Commissions (social workers, lawyers, medical professionals) — not criminal prosecution. Drug trafficking remains criminal. Population-level drug use has not increased; HIV transmission among people who inject drugs has dramatically decreased; drug-related incarceration has fallen. The Portuguese model is the most documented real-world rebuttal to the claim that decriminalization inevitably increases drug use. Psychedelic access follows the same decriminalization framework — possession is administrative, not criminal; no therapeutic or ceremonial framework exists.¹⁷⁵

D. RFRA and Religious Liberty Case Law

RFRA (42 U.S.C. §§ 2000bb—2000bb-4) prohibits the federal government from substantially burdening religious exercise absent a compelling governmental interest pursued through the least restrictive means.³⁴ In Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal (2006, unanimous), the Court held Schedule I classification does not automatically satisfy the compelling interest test.³¹ The Ninth Circuit extended favorable analysis to the Santo Daime Church of the Holy Light of the Queen.³² A 2025 Ninth Circuit ruling declined to extend Right-to-Try access for psilocybin outside the federal Right-to-Try Act framework (specific case name not independently verified as of May 2026; reported in legal commentary). Cognitive liberty doctrine — grounding a constitutional right to alter one's own consciousness — is gaining traction in legal scholarship.⁴⁷

Right-to-Try: The Manufacturer Consent Constraint. Executive Order No. 14,401 directed FDA and DEA to establish Right-to-Try pathways for investigational psychedelics. However, 21 U.S.C. § 360bbb-0a requires manufacturer consent — FDA cannot compel any company to supply product under the RTT pathway. Compass could decline to supply COMP360 under RTT during NDA review. For counsel advising terminally ill clients seeking RTT access to psilocybin: the pathway may legally exist and practically be inaccessible simultaneously. Document the consent issue in any RTT guidance. This is the operative constraint that the EO does not resolve.

For counsel advising clients on RFRA claims: document sincerity meticulously, define the specific sacramental practice precisely, and limit the scope to avoid broad decriminalization framing. The Right-to-Try Act (21 U.S.C. § 360bbb-0a) may provide an alternative access pathway for terminally ill patients when Phase 1 trial data exists.³⁵

2024-2025 RFRA Developments. The RFRA landscape for psychedelic churches has shifted substantially since 2023.

Church of Gaia: first non-litigated DEA exemption (May 16, 2025). On May 16, 2025, the DEA granted the Church of Gaia (Spokane, WA; 65 members; ayahuasca sacrament) the first-ever CSA religious exemption through the administrative petition process without litigation.¹⁶⁴ Attorneys Pat Donahue and Taylor Loyden (Terrapin Legal) built the strategy around three elements: (1) the church voluntarily suspended ayahuasca use during the entire pendency of the petition — a multi-year process; (2) counsel pursued cooperation, not confrontation, educating DEA agents on the spiritual components; (3) the church accepted security protocols and tracking requirements while refusing to agree to destruction of unused sacrament. DEA conducted a site visit; initial exemption grant communicated October 8, 2024; MOA finalized May 16, 2025. This is significant because the 2009 DEA petition pathway had produced zero exemptions across 24 petitions through January 2024. The Church of Gaia is the first to use this path successfully.¹⁶⁴

GAO 2024 critique and reform recommendations. The U.S. Government Accountability Office reported in 2024 that over an eight-year period (FY 2016 — January 2024), DEA received 24 petitions for religious CSA exemptions, granted zero, and had petitions pending for almost five and almost eight years without determination. GAO recommended DEA reform the petition process to provide timelines, transparency, and clearer criteria.¹⁶⁵ Church of Gaia's May 2025 exemption postdates this report; it is unclear whether the GAO recommendations or political dynamics under the Trump administration prompted DEA's new receptivity to the petition pathway.

Singularism v. City of Provo (D. Utah, February 2025). Judge Jill N. Parrish granted a temporary restraining order and preliminary injunction ordering Provo police to return seized psilocybin to Singularism, a Utah-based religious community. This is a new district-court precedent — the first reported federal court ordering return of seized psilocybin to a religious organization on RFRA grounds.¹⁶⁶ The case is ongoing; final merits judgment has not been issued. Sincerity and commercial-motive questions will be central to the final disposition. Note: Singularism pursued litigation, not the petition pathway; the Church of Gaia and Singularism represent two distinct strategic tracks.

Church of the Eagle and the Condor settlement (April 2024). Arizona-based indigenous-led church settled with DEA in April 2024, receiving RFRA exemption for sacramental ayahuasca use. This followed litigation. Joined by Church of the Celestial Heart (California, settlement May 5, 2025). The pipeline of recognized ayahuasca churches now includes: Union do Vegetal (SCOTUS 2006); Santo Daime/CHLQ (9th Circuit); Church of the Eagle and the Condor (April 2024); Church of the Celestial Heart (May 2025); Church of Gaia (May 2025, non-litigated).¹⁶⁷

Aggarwal petition: psilocybin rescheduling from Schedule I to II (August 11, 2025). Following the 9th Circuit's ruling in Aggarwal v. DEA (2023), DEA formally transmitted the AIMS/Aggarwal petition to reschedule psilocybin from Schedule I to Schedule II to HHS for scientific and medical evaluation under the 21 U.S.C. § 811 eight-factor analysis on August 11, 2025.¹⁷⁰ HHS has not publicly responded and no timeline has been disclosed as of May 2026. This substance-level rescheduling pathway is separate from and parallel to the product-specific rescheduling that will occur upon FDA approval of COMP360 or another psilocybin product. A Schedule II move would materially change the Right-to-Try calculus for practitioners.

RFRA Operational Framework for Practitioners. Based on O Centro and its Ninth Circuit progeny, a viable RFRA claim requires: (1) sincere religious belief — document it through written declarations, ceremony histories, community participation records, and clergy or community endorsements; (2) substantial burden — demonstrate that the government action meaningfully pressures the claimant to modify their religious practice; (3) compelling interest analysis — the government must show, as applied to this claimant, a compelling interest that Schedule I application serves; and (4) least restrictive means — the government must demonstrate no less restrictive alternative achieves the same interest. Favorable circuits for RFRA claims: Ninth Circuit (extended O Centro to Santo Daime), Tenth Circuit (O Centro itself); less developed in other circuits. Structural best practices: avoid broad decriminalization framing in pleadings; limit claims to the specific ceremony, preparation, and congregation; document the specific sacramental function of the substance in the tradition; secure expert declarations from recognized scholars of the relevant tradition. Avoid the error of treating O Centro as blanket authorization — it is a case-by-case, least-restrictive-means analysis that the government can still win with the right evidence.

E. Cannabis Rescheduling: April 2026

On April 23, 2026, Acting AG Todd Blanche issued a Final Order under § 811(d)(1) moving state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III. Effective April 28, 2026 upon Federal Register publication (91 Fed. Reg. 22,716).³⁶ A new DEA administrative hearing commences June 29, 2026 to address broader rescheduling of all cannabis. Legal challenges under the APA are anticipated.⁶⁷

VI. Real-World Implementation Data

A. Oregon Measure 109

Oregon's regulated psilocybin services framework is the first of its kind in the United States, operational since July 2023. Yu et al. (2026, Frontiers in Psychiatry) published the inaugural full-year report.⁴⁰

• Q1 2025: 1,509 clients served January—April 2025; six adverse reactions (0.4% adverse event rate — all minor; none required hospitalization; characterized as manageable psychological discomfort per OHA reporting categories). Cumulative clients served since program inception in July 2023 exceeded 10,000 by early 2025.⁴¹
• No hospitalizations, no deaths, and no product recalls reported through May 2026.
• HB 2387 (signed and effective May 22, 2025 (emergency clause; effective immediately upon signing)) permits dual-licensed healthcare providers to deliver psilocybin services.³⁹

A prospective naturalistic study (Gow et al., medRxiv preprint, 2026; peer review pending; n=91 Oregon program participants) found significant improvements in depression, anxiety, and well-being at 30-day post-session (p<0.001 on all measures). As an unreviewed preprint, these findings should be cited with that qualification.

C. Federal-State Conflict: Practitioner Risk Landscape

Oregon and Colorado operate legal psilocybin service programs under state law while psilocybin remains Schedule I federally. This creates specific, named legal risks that practitioners, facilitators, and patients should understand:

Banking. No federally insured bank is obligated to serve Schedule I businesses. Oregon service centers operate primarily through credit unions and payment processors that accept state-licensed cannabis clients; this remains at-will and legally precarious. Practitioners should maintain written records of their financial arrangements and understand that account closure without notice is legally possible at any time.

Federal prosecution exposure. The Department of Justice has maintained a policy of not prosecuting state-compliant cannabis operators since the Cole Memo era; no equivalent formal policy governs psychedelics. Federal prosecution of Oregon- or Colorado-licensed psilocybin service providers is currently legally available but politically improbable under the Trump administration given Executive Order No. 14,401. That calculus changes with every administration. Practitioners operating in state-legal frameworks carry ongoing federal Schedule I exposure.

Professional licensing. Licensed healthcare professionals (physicians, NPs, PAs, psychologists, LCSWs) in Oregon who also provide psilocybin services under dual-licensure (HB 2387) may face professional licensing consequences in other states or at the federal level. DEA registration, required for controlled substance prescribing, could theoretically be suspended or revoked for conduct involving Schedule I substances even if state-compliant.

Informed consent documentation. Practitioners should document that clients have been informed of the federal Schedule I status, the absence of federal legal protection, and the fact that state-legal operation does not create federal immunity. This documentation does not eliminate legal exposure but provides evidence of good-faith disclosure.

D. Colorado Proposition 122

Colorado's framework (2022) legalized adult personal use of psilocybin, psilocin, DMT, ibogaine, and mescaline (expressly excluding peyote). Licensed healing centers are operational. The Colorado model differs from Oregon's in two important ways: it includes personal possession protections in addition to the licensed services track, and it covers multiple substances beyond psilocybin.

E. Texas Ibogaine Initiative (IMPACT)

Texas SB 2308 (Governor Abbott, June 11, 2025) allocated $50 million for the IMPACT program⁴² led by UTHealth Houston with partners including UT Medical Branch Galveston, Dell Medical School at UT Austin, Baylor College of Medicine, Texas Tech, Texas A&M, and the University of North Texas. The Trump April 2026 EO allocated $50 million ARPA-H matching funds.³⁷

VII. Federal Policy 2025–2026

A. Executive Order No. 14,401 (April 18, 2026)

President Trump signed Executive Order No. 14,401 on April 18, 2026. Published in the Federal Register at Vol. 91, No. 77, page 21,709 (April 22, 2026). Full text read at the Federal Register official URL.³⁷ Key operative provisions:

B. FDA Priority Review Vouchers (April 24, 2026)

Six days after the EO, FDA Commissioner Makary announced three priority vouchers and cleared the first U.S. ibogaine derivative trial:³⁸

Competitive NDA Race: First-Mover Implications. Three priority vouchers were issued simultaneously, but FDA review is sequential. The first to file an NDA gets the first review under its voucher. Compass plans NDA filing year-end 2026 for TRD. Usona's Phase 3 completion was estimated April 2026 — if topline data are positive, Usona could file before Compass and potentially receive the first psilocybin FDA approval, with an indication for MDD broadly rather than TRD. Transcend has initiated Phase 3 for TSND-201 (patient recruitment underway as of March 2026; acquisition by Otsuka Pharmaceutical expected Q2 2026). If Usona files first: (a) the first psilocybin approval would come from a nonprofit (not a commercial company); (b) a broader MDD label (not TRD-limited) would expand the eligible population immediately; (c) access barriers differ because Usona's nonprofit model does not involve commercial licensing. If TSND-201 receives approval first — before any hallucinogenic compound — it establishes that the monoamine-transport mechanism without hallucinogenic effect is approvable in this therapeutic space, confirming the drug-only regulatory strategy and removing the "you need the experience" argument as a clinical or regulatory requirement. The sequence of approvals may matter as much as the approvals themselves. LSD-class NDA: Definium Therapeutics (formerly MindMed) holds the sole active lysergide BTD for GAD and the only LSD Phase 3 program. DT120 ODT (formerly MM120 ODT) Voyage topline expected early Q3 2026 (timing slipped from initial 1H 2026 guidance; not yet reported as of May 14, 2026); a positive readout would constitute the first Phase 3 confirmation of any psychedelic compound for an anxiety disorder. Definium holds the Catalent Zydis® ODT IP (USPN 12,036,220) as MindMed's legal successor — there is no competing LSD licensee. First approval sets the reference listed drug standard governing future generic entry.

GH001 and BPL-003: Inhalable/Intranasal Format Regulatory Implications. If either receives FDA approval: (a) first inhalable (GH001) or intranasal nasal spray (BPL-003) psychedelic-class drug approved in the U.S.; (b) REMS requirements would differ from oral tablet; (c) ~11-min and ~100-min discharge windows are compatible with standard outpatient psychiatric visits — changing the coverage argument from full-day infrastructure to standard office visit. The short-duration format is the factor most likely to accelerate commercial insurance coverage decisions. For clinic operators: GH001 administration requires an inhalation device protocol distinct from oral capsule administration; BPL-003 is nasal spray in a standard prescribing-clinician model. Spravato (esketamine) comparison: esketamine requires ~40 minutes post-administration monitoring under REMS; GH001's ~11-minute psychoactive window could result in materially shorter clinic visits. BPL-003's intranasal administration model closely mirrors Spravato's REMS framework, potentially enabling a faster path to analogous coverage and clinic certification. If either compound is approved, the competitive field of fast-acting antidepressants grows from one (Spravato) to three — with the psychedelic-class entrants offering no addiction liability, no documented uropathy, and potentially greater single-dose durability.

VIII. Economic Arguments

Cost-Benefit and QALY Analysis

Mental illness affects 23.4% of U.S. adults — approximately 61.5 million people — yet approximately 49.4% of those with any mental illness received no treatment in 2022.¹¹² In 2023, 105,007 Americans died from drug overdoses — declining to approximately 79,384 in 2024 but still dramatically elevated; alcohol kills more than 140,000 per year.^{182 113} The conventional public health approach has neither reduced use nor resolved the overdose crisis. Harm reduction infrastructure addresses the actual hazards; psychedelic medicine addresses the underlying conditions that drive harmful use.

Access and Coverage Economics. A 2024 Emory University analysis estimated 5+ million Americans would be clinically eligible for psilocybin-assisted therapy upon FDA approval, including approximately 17 million Medicaid beneficiaries. Insurance coverage requires either federal Schedule III rescheduling (enabling standard pharmaceutical coverage pathways) or explicit state legislation mandating coverage — neither has occurred. Oregon's licensed psilocybin services cost $1,000—$3,500 per session, cash-pay only. Without coverage, the people most economically excluded are those with the highest burden of treatment-resistant illness. The policy ask is not just regulatory approval — it is insurance mandates and Medicaid inclusion.¹²⁹ Payer timing implication: commercial health plans will almost certainly require durability data from BOTH Phase 3 pivotal trials before making coverage decisions. COMP006 Part B durability data are expected Q3 2026; following NDA filing (year-end 2026) and FDA priority review, the earliest plausible commercial insurance coverage date for COMP360 is 2028. Medicaid coverage follows commercial coverage and is structurally slower. This means the 5.1-5.6 million eligible patients face a multi-year access gap post-approval during which the only options are (a) Oregon/Colorado state-licensed services (cash-pay, $1,000-$3,500/session) or (b) off-label clinical approaches without an approved indication. That gap is the access equity problem. Exception: if Usona's nonprofit psilocybin is approved first, the cost floor could be substantially lower than Oregon cash-pay pricing, because Usona distributes at cost without commercial licensing — potentially changing the access equity calculus. The access gap analysis assumes a Compass commercial-distribution model.¹²⁹

Treatment-resistant depression — defined as failure to respond adequately to at least two adequate antidepressant trials — affects approximately 30% of people with major depressive disorder,⁵⁷ a commonly cited estimate derived from analyses including the STAR*D trial. Avanceña, Vuong, Kahn and Marseille (2025) modeled psilocybin-assisted therapy for treatment-resistant depression and found an incremental cost-effectiveness ratio of approximately $117,500 per QALY gained over a 12-month horizon vs. treatment-as-usual, assuming a $5,000 course cost. That sits near the top of the $50,000—$150,000 range commonly used as a U.S. cost-effectiveness threshold: the therapy had a 75% probability of being cost-effective at $150,000 per QALY, and cost is the decisive variable — at a $3,000 course cost the probability rises to 95%, at $10,000 it falls to 1%. Do not describe psilocybin therapy as comfortably cost-effective; describe it as cost-effective at the upper threshold and highly sensitive to delivery cost.^{180 57} The economic argument hinges on durability: if a single course (1—2 sessions) produces lasting remission, it substitutes for years of daily pharmacotherapy plus recurring clinical contacts.

Cost of Inaction: The Policy Ask

The economic arguments above establish the cost. The specific policy asks are:

(1) Schedule III rescheduling. FDA-approval of psilocybin for one indication would trigger rescheduling. Schedule III status enables standard pharmaceutical coverage pathways, removes the DEA Form 222 prescribing constraints of Schedule II, and opens Medicaid and Medicare reimbursement.

(2) Insurance coverage mandates. State legislatures can require insurers to cover FDA-approved psychedelic-assisted therapy as a mental health benefit, analogous to mental health parity requirements. Oregon and Colorado state legislative advocacy should target this specifically.

(3) Medicaid inclusion. Approximately 17 million Medicaid beneficiaries would be clinically eligible upon FDA approval per Emory 2024 analysis. Section 1115 Medicaid waiver authority provides a pathway for state demonstration projects covering approved psychedelic therapy before federal coverage is established.

(4) Harm reduction funding. Drug checking services, reagent testing access, and psychedelic crisis support at events reduce adverse outcomes in the 31 million current users (Rockhill 2025) independent of any approval timeline. SAMHSA grant programs that currently fund opioid harm reduction can be expanded to include psychedelic harm reduction under existing statutory authority.¹⁰⁸

Section 280E Relief for Cannabis

Removal of Section 280E for state-licensed medical operators effective April 28, 2026⁵⁸ eliminates an effective tax burden that cannabis tax practitioners have historically estimated at 60—80% of gross profit for many cannabis businesses, as ordinary business deductions are disallowed under the prior Schedule I/II status. Industry associations project substantial economic activity and job creation from this change, though independent peer-reviewed economic analyses are pending. Note for practitioners: Oregon and Colorado psilocybin service businesses are NOT covered by this 280E relief — the Final Order applies to state-licensed medical cannabis operators and FDA-approved cannabis products only. Psilocybin service centers remain subject to Schedule I federal tax treatment; do not assume any 280E benefit applies to psilocybin businesses.

Commercial Investment as Credibility Signal

Compass Pathways (Nasdaq: CMPS), Definium Therapeutics (Nasdaq: DFTX, formerly MindMed/MNMD, rebrand January 2026), Helus Pharma (formerly Cybin; Nasdaq: HELP), GH Research, AtaiBeckley Inc. (merged atai Life Sciences + Beckley Psytech, June 2025), and Transcend Therapeutics are publicly traded or venture-backed companies deploying institutional capital. AbbVie and Gilgamesh Pharmaceuticals entered a collaboration and option-to-license agreement in May 2024 ($65 million upfront) to research novel neuroplastogens; in August 2025, AbbVie exercised its option and acquired bretisilocin (GM-2505) for up to $1.2 billion.⁷⁴ Bretisilocin: 5-HT2A agonist and 5-HT releaser; ~90 min psychoactive duration vs 4-6 hrs psilocybin; Phase 2a MDD MADRS -21.6 vs -12.1 for 1 mg comparator at Day 14 (p=0.003).¹³¹ The ~90-minute psychoactive duration is not merely shorter — it is compatible with a standard 2-3 hour outpatient psychiatric appointment. Psilocybin at 4-6 hours requires full-day clinic infrastructure. The AbbVie acquisition price is the market's valuation of that operational difference: a psychedelic-type therapy that can fit inside a standard psychiatry appointment.¹³¹ J&J's Spravato (esketamine) generated approximately $1.7 billion in worldwide annual sales in 2025 — the drug's second blockbuster year (first crossed $1 billion threshold in 2024)³⁰ — demonstrating commercial viability of the psychedelic-adjacent mechanism.

IX. Comprehensive Safety Profile

Classic Psychedelics (Psilocybin, LSD, DMT, Mescaline, 5-MeO-DMT)

The Hinkle et al. 2024 systematic review and meta-analysis is the definitive evidence summary: 214 studies, 114 (53.3%) with analyzable adverse-event data, 3,504 participants. Serious adverse events in no healthy participants and approximately 4% of pre-existing neuropsychiatric condition participants. No deaths by suicide, no persistent psychosis, and no HPPD in contemporary research settings.¹¹

National poison center data (Leonard et al. 2018, n=5,883 psilocybin mushroom-specific exposures over 16 years) show psilocybin mushrooms associated with lower rates of emergency medical attention than most other substances.⁶² Nutt et al. 2010: psilocybin mushrooms scored 5 (lowest of 20 substances); LSD scored 7 (third lowest, after buprenorphine at 6).¹²

Adverse Event Rates in Naturalistic Settings

The clinical trial adverse event data (Hinkle 2024) reflects screened, prepared, and supported participants in laboratory settings. Naturalistic adverse event rates are somewhat higher but remain low in absolute terms, and harm reduction support substantially reduces them.

• Worst psilocybin experience survey (Carbonaro et al. 2016; n=1,993): Among people reporting their single worst psilocybin experience, 2.7% sought medical help and 7.6% sought treatment for enduring psychological symptoms. 84% still endorsed benefiting from the experience. Risk was associated with dose, duration, and absence of physical comfort and social support — the exact variables that harm reduction infrastructure provides.⁷⁷
• HPPD in clinical settings (Zhou et al. 2025, PNAS Nexus): Zero cases of HPPD meeting DSM-5 criteria — requiring clinically significant functional distress — in contemporary clinical trials. Approximately 32% of naturalistic users report some visual phenomena; only 1—4% find them distressing. Clinical HPPD prevalence substantially less than 1% of users.¹¹⁵ Additionally, Simonsson et al. 2025 (Psychopharmacology) found that 1.3% of lifetime psychedelic users reported a doctor diagnosis of HPPD in a population survey, with no association between lifetime use and past 2-week psychotic symptoms.¹³²
• Festival/ceremonial crisis support (Kosmicare, Boom Festival, Portugal): Carvalho et al. (2014) documented that structured psychedelic peer support significantly reduced psychiatric hospitalization rates among festival attendees in psychedelic crisis. Kosmicare's 2018 drug-checking program analyzed 671 samples with real-time alerts, addressing adulteration risk directly.⁸⁵
• Global Drug Survey (grey literature): Winstock et al.'s annual surveys (Global Drug Survey, 2017—2024) consistently report that psilocybin mushrooms have the lowest emergency medical treatment rate of any recreational drug surveyed, at approximately 0.2% of past-year users. Note: the Global Drug Survey uses self-selected online samples rather than representative population sampling; figures are indicative rather than epidemiologically representative. Adulteration is the primary identifiable risk factor; pure substance at known doses is rarely the hazard. Primary GDS reports available at globaldrugsurvey.com.

For context on COMP005/COMP006 effect sizes: Cipriani et al. 2018 (522 trials; N=116,477; 21 antidepressants) found between-drug ORs of 1.15 to 1.55 for efficacy.¹²² The COMP360 Phase 3 MADRS differences of -3.6 and -3.8 are contextually comparable in magnitude to the modest differences among approved antidepressants in this benchmark analysis. Conventional antidepressants are approved despite similar effect size ranges. For clinical audiences who raise effect size concerns, this context is essential.

The composite picture: naturalistic classic psychedelic use has a favorable safety profile even outside clinical settings; harm reduction support reduces the adverse event rate further; and the primary hazard in unregulated markets is adulteration, which drug checking directly addresses.

Absolute Contraindications (Classic Psychedelics)

• Personal or first-degree family history of schizophrenia, schizoaffective disorder, or other primary psychotic illness.
• Active mania (bipolar I with active manic phase).
• Uncontrolled hypertension or recent acute cardiac events.
• Pregnancy or breastfeeding.
• Severe hepatic impairment.
• Current MAOI use without appropriate washout (particularly critical for ayahuasca/DMT, which contains β-carboline MAO inhibitors).

Interactions Requiring Careful Management

• SSRIs/SNRIs: Attenuate psilocybin effects substantially.²⁰ Supervised medical taper required; typically 2—4 weeks washout per clinical trial protocols. However, Goodwin et al. (2023, Compass; n=19 TRD patients on concomitant SSRI) found 42.1% response and 42.1% remission at Week 3 with MADRS reduction of 14.9 points, without tapering.¹²¹ Helus Pharma's HLP003 Phase 3 (APPROACH) explicitly eliminates the washout requirement on this basis. Additionally, BPL-003 (AtaiBeckley, intranasal 5-MeO-DMT) demonstrated efficacy in SSRI-maintained patients in Phase 2a: 66.7% Day 2 response maintained through Week 12 in patients who remained on baseline SSRI therapy.¹⁴⁰ This is consistent with 5-MeO-DMT's primary mechanism at 5-HT1A receptors (rather than 5-HT2A), which may not be significantly attenuated by SSRIs. Practical implication: unlike psilocybin (attenuated) and MDMA (blocked), BPL-003 appears compatible with concurrent SSRI use — potentially the broadest SSRI-concurrent access profile of any psychedelic-class compound in development. Clinical implication: a much larger population of TRD patients who cannot safely taper antidepressants may still benefit. Regulatory implication: if APPROACH succeeds with no washout requirement, it establishes the precedent that psilocybin-analog therapy is approvable in SSRI-maintained patients — changing the default from "washout required" to "washout optional", expanding the eligible population, and potentially requiring Compass to seek a broader label amendment for COMP360. Field-level synthesis: three compounds across three mechanisms — HLP003 (psilocybin analog, SSRI washout-free Phase 3), TSND-201 (methylone, non-hallucinogenic, no washout issue), and BPL-003 (5-MeO-DMT, SSRI-compatible) — are simultaneously developing SSRI-washout-free protocols. This convergent pattern signals that mandatory SSRI washout is becoming an avoidable barrier rather than a pharmacological requirement, with implications for the cost-effectiveness model: washout-free treatments eliminate 2-4 weeks of supervised taper and associated clinical costs.
• Lithium: 47% seizure rate in 62 documented lithium-plus-psychedelic exposures (vs 0% in 34 lamotrigine exposures).⁵⁴
• MAO inhibitors: Contraindicated with MDMA (life-threatening serotonin syndrome). Intentionally combined in ayahuasca but must be approached cautiously with any other serotonergic agents.
• Cancer medications: Drug-drug interactions with oncology regimens are understudied. Consult with treating oncologist before psilocybin administration.

Suicidality: Accurate Framing

Hendricks et al. (2015) found that lifetime classic psychedelic use was associated with reduced odds of past-year suicidal ideation and attempt.¹⁹ Zeifman et al. (2022) pooled individual patient data across seven classic psychedelic clinical trials and found decreases in suicidality following psychedelic therapy, with no signal of increased risk in supervised trial contexts; Wong et al. (2025) meta-analysed nine psilocybin trials (N=593) and found a small but significant reduction in suicidal ideation (SMD −0.24). Note the limit of that evidence: no trial in the Wong review reported suicide attempts or deaths, so those outcomes are not evidenced in either direction.⁶⁰ These findings must be qualified: the Hinkle 2024 meta-analysis does document suicidal behavior as a serious adverse event in the pre-existing neuropsychiatric disorder population.¹¹

Racial and Demographic Equity Gaps

Doss et al. (2024, systematic review) documented substantial underrepresentation of non-white participants in psychedelic clinical trials.⁵⁹ The Hopkins cancer trial (Griffiths 2016, n=51) was 94% white.⁵ The NYU cancer trial (Ross 2016, n=29) was 90% white.⁶ The Bogenschutz 2022 AUD trial (n=93) was 78.9% non-Hispanic white.¹⁶ MAPP2 was more diverse (26.9% Hispanic/Latino, 33.7% non-White).²⁶ Any claim that findings generalize to diverse populations must explicitly acknowledge this limitation.

X. Evidence Hierarchy and Study Quality

Five-Tier Hierarchy

Key Methodological Limitations

Functional unblinding: Participants typically know whether they received an active dose. Mueller et al. 2025 found 80% correctly guessed their allocation even at the microdose level.¹⁸ Modern trials address this with active comparators and clinician-rated outcomes.

Publication bias: Proactively cite null results. Mueller 2025¹⁸ and Rieser 2025¹⁷ are critical counterexamples.

Modest effect sizes in Phase 3: COMP005 MADRS difference of −3.6 points⁹ and COMP006's −3.8 points¹⁰ are statistically significant but at the lower bound of clinical meaningfulness. Conventional antidepressants show similar MADRS effect sizes in large trials.

Population selection: Screened populations exclude those at highest risk. Efficacy and safety in excluded populations cannot be inferred from trial data.

XI. Credibility Anchors

A. Active Research Institutions (Selected)

• United States: Johns Hopkins Center for Psychedelic and Consciousness Research; NYU Langone Center for Psychedelic Medicine; UCSF Translational Psychedelic Research Program; Yale Psychedelic Science Group; Mount Sinai Center for Psychedelic Psychotherapy; MGH Center for the Neuroscience of Psychedelics; Stanford Psychedelic Science Group; UT Austin Dell Medical School/McGill Center; UC San Diego (eating disorders); UC Davis (Olson lab, non-hallucinogenic neuroplastogens).
• International: Imperial College London Centre for Psychedelic Research; King's College London; University of Basel (Liechti lab); Maastricht University; Charles University Prague/NUDZ; CIMH Mannheim; Karolinska Institute; University of Toronto; University of British Columbia; University of Sydney; McGill University.

B. FDA Breakthrough Therapy Designations (Verified as of May 2026)

• Compass Pathways COMP360 — treatment-resistant depression.
• Usona Institute psilocybin — major depressive disorder.
• Helus Pharma HLP003 (formerly CYB003; deuterated psilocin analog; NOT psilocybin) — major depressive disorder.⁶⁴
• Definium Therapeutics DT120 ODT (formerly MindMed MM120²¹; LSD d-tartrate ODT) — generalized anxiety disorder. MindMed and Definium Therapeutics are the same company; the rebrand was effective January 2026 (Nasdaq: DFTX).¹⁴²
• Resilient Pharmaceuticals (formerly Lykos) MDMA-AT — PTSD (designation active despite 2024 CRL).²⁷

GH Research GH001 (inhaled mebufotenin/5-MeO-DMT): Phase 2b positive (MADRS -15.5, 57.5% Day 8 remission); FDA clinical hold lifted Jan. 2026; Phase 3 planned 2026; 11-min duration. Note: GH001 does NOT have a BTD as of May 2026.¹³⁶

• AtaiBeckley BPL-003 (intranasal mebufotenin/5-MeO-DMT benzoate nasal spray) — treatment-resistant depression. BTD October 16, 2025; Phase 2b: MADRS -11.1 vs -5.8 comparator (p=0.0038); Phase 3 (ReConnection 1 [~350 participants] and ReConnection 2 [~300 participants]): parallel pivotal TRD trials; MADRS at Week 4 primary endpoint; first patient dosing targeted Q2 2026; topline expected early 2029.¹³⁷

B.5 Population Epidemiology as Evidence of Scale

Rockhill et al. (2025, Annals of Internal Medicine; RAND/Colorado School of Public Health multisource study) documented that 31.3 million U.S. adults have used psilocybin — more than have used cocaine, LSD, methamphetamine, or illegal opioids.¹⁰⁸ Past-year use increased 188% among adults over 30 between 2019 and 2023. Use is concentrated among people with mental health conditions and chronic pain. The question is not whether use is happening — it is whether it happens with or without safety infrastructure.

The National Network of Depression Centers (NNDC) Task Group — 21 academic medical centers — published a consensus statement in eClinicalMedicine (September 2025) simultaneously recognizing psilocybin's "therapeutic potential" and calling for evidence-based integration planning.¹¹⁶ This is mainstream academic psychiatry engaging psilocybin as a legitimate pharmaceutical development category — cite it with clinical and policy audiences who want to know where the academic medical establishment stands.

C. FDA July 2026 Final Guidance Document

FDA finalized its psychedelic-drug clinical-investigations guidance in July 2026 (Docket No. FDA-2023-D-1987). The final guidance gives sponsors current recommendations for trial design, including safety monitoring, dose-response assessment, and psychotherapy considerations. Use the final guidance—not the superseded 2023 draft—when communicating with regulators, clinical administrators, and research teams.⁶⁵

XII. Communication Architecture by Audience

A. Skeptical Clinicians and Researchers

Opening frame: "I want to show you the Phase 3 data — including the null trials — and ask what finding would change your assessment."

Strongest arguments:

Pre-empt these objections:

NDA Review Window: Practitioner Guidance. Once Compass files its NDA (targeted year-end 2026), COMP360 will be under active FDA review — but it will still be Schedule I, not approved, and not available through RTT unless Compass consents. Licensed psilocybin service providers in Oregon and Colorado can continue operating under state law. For licensed healthcare professionals who want to provide psilocybin therapy during this window: dual-licensure under Oregon HB 2387 allows licensed providers to deliver psilocybin services under state law without FDA approval; federal Schedule I status creates ongoing prosecution exposure (politically improbable but legally available); professional licensing boards may treat state-compliant Schedule I conduct as grounds for discipline. The gap between NDA filing and FDA approval is the highest-risk legal window for practitioners: the substance has not been approved, RTT access is manufacturer-consent-dependent, and no intermediate pathway exists outside state-legal frameworks.

Facilitator Training and Implementation Infrastructure. For clinicians and practitioners who want to move from awareness to implementation: the primary training programs as of May 2026 are (a) MAPS MDMA-AT training program (therapist and facilitator certification; MAPS is a 501(c)(3) nonprofit separate from Lykos/Resilient Pharmaceuticals; MAPS continues training therapists globally despite the 2024 CRL, including completing a DOD-affiliated training program December 2025 and entering a Columbia University research partnership February 2026); (b) Fluence (interdisciplinary training in psychedelic-assisted therapy; most established for licensed mental health professionals); (c) the Integrative Psychiatry Institute (IPI) Certificate in Psychedelic-Assisted Therapies and Research; (d) the California Institute of Integral Studies (CIIS) Certificate Program; and (e) Synthesis Institute (Netherlands; psilocybin therapy training with legal practicum in Dutch jurisdiction). Key session protocol elements across programs: preparation sessions (2-4 prior to dosing), session-day monitoring (vital signs, psychological support, safe environment), integration sessions (minimum 2-3 post-dosing). Contraindication screening: personal or family history of psychotic-spectrum disorders; uncontrolled cardiac conditions; active mania; pregnancy; current MAOI use; lithium co-administration.

Billing codes: AMA CPT 0820T/0821T/0822T (effective January 1, 2024). The AMA created three Category III CPT codes for "Continuous In-Person Monitoring and Intervention During Psychedelic Medication Therapy" (0820T, 0821T, 0822T; June 30, 2023; effective Jan. 1, 2024).¹³⁸ Critical limitations: (1) Category III tracking codes — NOT reimbursable under Medicare, Medicaid, or private insurance as of May 2026; (2) cover the dosing/monitoring session only — preparation and integration sessions are not covered; (3) designed to collect utilization data and lay groundwork for Category I codes upon FDA approval. Current implication for practitioners: dosing sessions can be reported with these codes alongside applicable E&M codes, but payment is payer-dependent and most commonly cash-pay. Integration and preparation sessions are billed under standard psychotherapy codes (90837, 90834, etc.) when delivered by a licensed psychotherapist; when delivered by a facilitator without a psychotherapy license, there is currently no billing infrastructure. For context: FDA-approved esketamine (Spravato) uses permanent Category I codes with full Medicare/Medicaid coverage because it is FDA-approved and REMS-managed — the Category III codes are the infrastructure being built ahead of that approval for psilocybin.

Oregon's licensed service center model requires training specifically approved by OHA under Oregon Administrative Rule 333-333; not all external programs qualify — verify OHA approval before enrolling with intent to practice in Oregon.

B. Policymakers and Legislators

Opening frame: "Texas put $50 million of state money into this. Oregon has served over 10,000 clients without a single hospitalization. Germany, Australia, and the Czech Republic have medical frameworks. What is the cost of continued inaction when bipartisan precedents exist?"

C. Conservative and Religious Audiences

Political Support Durability. Current advocacy rests on personality-dependent support and a rescindable EO. Trigger laws, funded appropriations, and published Phase 3 data survive administration changes. Strategic priority: statutory lock-in now.

Opening frame: "These medicines are saving veterans like Marcus Luttrell. Rick Perry, Trump's Energy Secretary, calls ibogaine advocacy his life's mission. Joe Rogan stood beside President Trump when he signed the executive order⁷² — and Luttrell told the president: 'It absolutely changed my life for the better.' This is a pro-life, pro-veteran, pro-family issue."

• Use: "Restoring lives," "veteran care," "supervised by physicians," "FDA pathway," "Right to Try," "bipartisan."
• Avoid in initial contact: "Psychedelic culture," "consciousness expansion," "ceremony" (lead with the clinical evidence first).

Strategic Risk: The Kennedy-Pollan Tension. Michael Pollan has publicly warned that psychedelic medicine risks being damaged if it becomes associated with Robert F. Kennedy Jr.'s anti-vaccine, anti-fluoride agenda: entanglement with those positions "could do long-term damage to psychedelics" by converting what is now a bipartisan scientific issue into a culture-war proxy. This is a live strategic risk, not a theoretical one. Advocates should: (a) present psychedelic science alongside other evidence-based treatments, not as an alternative-medicine category; (b) avoid rhetorical alignment with anti-establishment health claims; (c) maintain explicit connections to peer-reviewed evidence in high-impact journals (NEJM, Lancet, Nature Medicine, JAMA); and (d) when speaking to conservative audiences, foreground the Trump EO and the bipartisan legislative record rather than any individual political figure's personal advocacy. The conservative case for psychedelics is strongest when it is grounded in veteran welfare, fiscal conservatism, and religious liberty — not in generalized skepticism of mainstream medicine.

D. Legal Professionals

Critical note for legal professionals: The current DEA rescheduling petition targets Schedule II — which carries prescribing requirements structurally incompatible with the session model (DEA Form 222, no refills, in-person prescriber visit per refill). The correct advocacy target is Schedule III, not Schedule II. See the Schedule II vs. Schedule III analysis in Section V.A.

Opening frame: "The federal regulatory landscape changed at least three significant times in twelve months. Here is the current map of what has changed and what has not."

E. General Public

Opening frame: "In Phase 3 trials of one or two supervised psilocybin sessions in people who had failed multiple prior antidepressants, 39% achieved clinically meaningful improvement. For the population with cancer-related existential distress, psilocybin produced sustained clinical responses in 60—80% of participants. If a treatment with that kind of record were available for someone you love, would you want them to have access to it?"

Note on population specificity: The 60-80% figures above (cancer-related existential distress) are from Ross 2016 — a screened population with life-threatening cancer, 90% white.⁶ The 78%/83% figures are from Griffiths 2016 — also cancer-specific, 94% white. Neither generalizes to general-population MDD or TRD. Use the COMP005/COMP006 Phase 3 data when the audience concerns TRD specifically.⁵

F. Media and Journalists

Key recent evidence for media coverage: Phase 2 psilocybin PTSD signal (McGowan et al. 2025; open-label; n=22; CAPS-5 -29.9 at Week 4; note 118) and first double-blind RCT positive OCD signal (Ching et al. 2025, Yale; note 119). Frame both correctly: open-label Phase 2 (PTSD) and preliminary RCT positive signal with quantitative results pending (OCD) — not Phase 3 efficacy data.

• Always name the phase of any clinical trial when citing results. "Phase 3 RCT" vs "Phase 2" vs "open-label pilot" are not interchangeable.
• COMP005⁹ and COMP006¹⁰ are the highest-evidence findings in the field; lead with them when covering psilocybin for TRD. Cite each separately.
• Cite null results alongside positive results. Mueller 2025 (LSD microdosing ADHD, null)¹⁸ and Rieser 2025 (psilocybin AUD relapse prevention, null)¹⁷ are as important to cite as any positive finding.
• The 78% and 83% figures from Griffiths 2016 are for cancer-related existential distress specifically — in a 94% white, highly educated, pre-screened population — at 6-month crossover follow-up with n=51.⁵ This does not generalize to general-population depression.
• Distinguish FDA approval (esketamine only), FDA Breakthrough Therapy designation (expedited review, not approval), and priority review vouchers (cuts review time; does not guarantee approval).
• "22 veterans per day" is an outdated figure from a 2012 study. The current VA figure is 17.5 per day (2023 data).⁷¹

XIII. Indigenous Communities and Harm Reduction Audiences

A. Indigenous and Tribal Communities

• Explicit acknowledgment of the historical relationship between ethnobotanical appropriation and indigenous community harm.
• Clear differentiation between clinical/pharmaceutical psilocybin (synthetic COMP360) and traditional plant medicine ceremonies.
• Recognition that NAC peyote protections exist because of indigenous advocacy against active federal suppression — not as a concession.³³
• The conservation imperative for peyote is an indigenous sovereignty issue, not merely an ecological one. Use San Pedro; do not harvest peyote without indigenous guidance.
• Intellectual property and ceremonial knowledge ownership: pharmaceutical companies developing ibogaine derivatives without Bwiti community involvement raise unresolved bioprospecting concerns.

Legal Architecture for Indigenous Rights. The relevant frameworks: (1) American Indian Religious Freedom Act Amendments (42 U.S.C. § 1996a): protects NAC peyote use by enrolled tribal members; does not extend to non-Native practitioners.³³ (2) RFRA: applies to any person with sincere religious belief; not tribe-specific.³⁴ (3) UNDRIP (Article 31): protects indigenous communities' rights to traditional knowledge; not self-executing U.S. law; relevant in international bioprospecting contexts. (4) Nagoya Protocol (Convention on Biological Diversity): U.S. not a party; relevant when plant materials are sourced from indigenous territories internationally. Practical obligations: non-Native practitioners have no right to administer peyote under federal or state law absent a RFRA claim; operators using ayahuasca or iboga sourced from indigenous territories should obtain prior informed consent from affected communities; no U.S. court has adjudicated an indigenous IP claim over a psychedelic preparation — open legal questions remain.

B. Harm Reduction Audience

• Lead with accurate risk stratification: classic psychedelics are low-toxicity and low-addiction-risk but carry psychiatric risks for predisposed individuals; MDMA and ketamine carry distinct and different risk profiles.
• Drug checking services: fentanyl adulteration is a documented hazard for MDMA in unregulated markets (see Section IV.F). For psilocybin, NBOMe compound adulteration is the primary documented risk (see below). Support reagent testing, spectrometry services, and harm reduction education for both.

Psilocybin-specific adulteration: NBOMe compounds. The primary documented adulterant risk for materials sold as psilocybin is NBOMe compounds (25I-NBOMe, 25C-NBOMe, 25B-NBOMe) — synthetic 5-HT2A agonists active at microgram doses, significantly more toxic than psilocybin, with documented fatalities. Indistinguishable by appearance alone.¹⁴¹ Ehrlich reagent turns purple with indoles (psilocybin) and is NEGATIVE for NBOMes — this single test identifies the most dangerous known adulterant. Add Hofmann reagent for pressed pills. EcstasyData.org and DanceSafe mass spectrometry events provide highest confidence. Note: fentanyl co-seizures with psilocybin exist in law enforcement data, but fentanyl as a direct adulterant intentionally added to psilocybin products does not have the same documented evidence base as NBOMe adulteration.

• Do not advocate supervised clinical access as the only legitimate model. The evidence base should inform (not gatekeep) experiences outside clinical settings.

Harm Reduction Infrastructure 2026. Key organizations: DanceSafe (drug checking, reagent kits, fentanyl test strips); Zendo Project (MAPS-associated psychedelic crisis support); Kosmicare (Boom Festival model, peer-reviewed efficacy); Bunk Police (reagent kit manufacturer and education); EcstasyData.org (public lab testing database).

Safety kit minimum: Ehrlich reagent (indole detection), Mecke reagent, fentanyl test strips; water and sugar; blood pressure cuff; quiet grounded space; sober designated sitter.

Emergency protocol: Acute psychological crisis: low-stimulation environment, grounding, do not leave person alone, avoid police contact except for medical emergency. Ibogaine cardiac emergency: continuous monitoring + IV magnesium + immediate EMS. MDMA + MAOI serotonin syndrome: life-threatening; immediate EMS.

C. Recovery Community

• Acknowledge that psilocybin and other classic psychedelics can be triggering for individuals in recovery, particularly those with poly-drug histories.
• The Bogenschutz 2022 AUD trial was conducted in controlled, supervised settings.¹⁶ The Rieser 2025 AUD trial was also controlled.¹⁷ Neither licenses unsupervised use in active addiction.
• Frame as an additional tool for individuals who have not achieved stable recovery through available pathways — not as a replacement for 12-step programs.

D. Autonomous Adult Use

Adults who use psychedelic substances outside clinical or ceremonial settings constitute the largest actual user population and are among the people most directly affected by stigma. Destigmatizing their use is not ancillary to the broader project — it is a significant portion of the project. A destigmatization framework that implicitly requires medicalization as its entry condition reproduces a different form of the same gatekeeping it purports to oppose.

Cognitive liberty as a foundational principle. The right to alter one's own consciousness is a foundational principle of bodily and cognitive autonomy, increasingly articulated in legal scholarship.⁸⁶ Bublitz and Merkel extended the principle to a human right against crimes against minds.⁸⁷ Ienca and Andorno proposed cognitive liberty as foundational to four new neurotechnology-era human rights.⁸⁸ Manríquez Roa and colleagues applied this framework directly to psychedelic policy.⁸⁹ Nita Farahany's The Battle for Your Brain (2023) developed its implementation through existing international human rights frameworks.⁴⁷ The U.S. Supreme Court's recognition in Sell v. United States (2003) of a fundamental liberty interest against forced mental alteration is the closest current constitutional anchor.⁹⁰ This right does not depend on a clinical diagnosis, a licensed setting, or institutional approval. It applies to the person in a research hospital and the person in a living room with equivalent force.

Risk reduction over abstinence framing. Accurate, non-judgmental information about dosage, set and setting, drug interactions, contraindications, and adulteration risks saves lives and reduces harm. Drug-checking kit use nearly doubled at New York City EDM events between 2017 and 2022, and during the same period suspected adulteration among those who tested their supply fell 69%.⁸² On-site drug checking at UK festivals led approximately 1 in 5 users to dispose of their supply upon learning the contents.⁸³ Structured harm reduction support at festivals significantly reduces psychiatric hospitalization.⁸⁵ The primary safety hazard in unregulated psychedelic markets is adulteration, not the substance itself at known doses. Abstinence-only framing does not address adulteration. Harm reduction does.

Quality of engagement, not institutional setting. Even in the worst psilocybin experiences people report outside clinical settings — specifically selected as their single most difficult experience — 84% endorsed benefit, and adverse outcomes were associated with absence of preparation, comfort, and social support rather than the absence of clinical infrastructure per se.⁷⁷ A ceremonial context, a clinical protocol, and a thoughtful autonomous experience can each be conducted with care or without it. Set, setting, preparation, and integration are the operative variables, regardless of institutional wrapper. Healy et al. (2025) documented significant therapeutic outcomes in both organized ceremonies and raves/electronic dance music events.⁷⁹

The field's own foundation. The concept of "set and setting" that structures every clinical trial was formalized through autonomous practice by Leary, Metzner, and Alpert (1964), codified by Norman Zinberg through systematic naturalistic observation (1984), and then adopted by clinical researchers without this genealogy being consistently acknowledged.⁹¹ Zinberg's (1984) canonical codification of these principles in naturalistic drug research is the bridge between that community knowledge and the clinical protocols of today.⁹² The 1970—1992 research freeze did not erase the knowledge base; underground therapeutic communities, harm reduction practitioners, and autonomous users preserved it. The clinical renaissance of the 1990s through today depended on that preservation. That history is not a liability to manage or distance from. It is the intellectual foundation of the field.

Practical communication guidance.

• Do not require clinical framing as a precondition for taking someone's experience seriously.
• Do not describe non-clinical use as "uncontrolled" as though clinical use were the control condition for validity. "Unsupervised" is a more accurate and less loaded descriptor when context matters.
• Acknowledge that many people who use these substances autonomously have done so safely and purposefully for years. The population-level literature documents consistent associations between classic psychedelic use and reduced psychological distress and suicidality: Hendricks et al. 2015 (n>190,000),¹⁹ Johansen & Krebs 2015 (n=135,095),⁷⁵ Sexton et al. 2020 (weighted N=261M).⁷⁶
• Support drug checking services and reagent testing access — these directly address the primary hazard (adulteration) in unregulated markets without requiring recipients to first commit to a clinical or ceremonial framework. Drug-checking-kit use doubled at NYC EDM events while suspected adulteration fell 69%,⁸² on-site checking led 1 in 5 festival users to dispose of substances,⁸³ and structured crisis support significantly reduces hospitalization.⁸⁵
• When discussing risks, specify the actual risk vectors: adulteration, drug interactions, contraindicated personal histories (psychosis-spectrum, uncontrolled hypertension, lithium co-administration), inadequate preparation. Treat "recreational" or "autonomous" use as a context descriptor, not a risk factor.⁷⁷

E. Therapist Misconduct: Acknowledge It, Frame It Correctly

The most credibility-damaging error an advocate can make is being unprepared for the therapist misconduct question. Prepare for it.

What happened. The Meaghan Buisson case (King's College London / MAPS Phase 2 Vancouver trial) involved documented sexual and emotional boundary violations by two therapists during MDMA-assisted therapy sessions. The case resulted in academic publication retractions and contributed to FDA's 2024 Complete Response Letter for the MDMA NDA, which cited trial-site data integrity failures. The September 2025 scoping review in Psychological Medicine confirmed the broader pattern: altered states produced by psychedelic-assisted therapy create structural conditions — elevated suggestibility, transference, dissolution of normal relational boundaries — that increase patient vulnerability to manipulation. This is not unique to psychedelics; it appears in high-dose ketamine therapy and other consciousness-altering contexts.

Correct framing for advocacy contexts. (1) Acknowledge it directly and without minimization: "The misconduct that occurred in the MDMA trials was real, serious, and correctly identified by FDA as a regulatory problem." (2) Distinguish the substance from the practitioner: the misconduct was not caused by MDMA — it was caused by practitioners who violated protocol and ethical norms. Structural safeguards address this. (3) Enumerate the structural safeguards: dual-therapist protocols (one male, one female whenever possible); mandatory session video recording (Oregon OAR 333-333-4060 requires recording for licensed service centers); independent ethics reporting pathways; mandatory trauma-informed training for all facilitators; screening of facilitators for boundary-violation history. (4) Note that medicalization increases protection: a licensed, regulated context with mandatory recording and dual-therapist requirements is structurally safer than unregulated access. This is a genuine argument for the regulatory model, not a weakness of it.

What not to say. Do not say "a few bad actors." The Psychological Medicine 2025 scoping review identified the structural vulnerability as systemic, not individual. Do not dismiss the FDA CRL as scientifically unfounded — FDA's concerns were partly pharmacological (functional unblinding) and partly site-integrity concerns that were real and documented. Engage the full critique honestly.^{127 128}

XIV. Language Guide

Core Terminology by Audience

Clinical/Medical Audiences

• Instead of "trip": "dosing session," "administration session."
• Instead of "hallucinations": "altered states of consciousness," "subjective perceptual changes."
• For clinical audiences, name the molecule ("psilocybin," "COMP360 synthetic psilocybin") rather than "plant medicine." This is audience-specific translation, not a general preference or a judgment that "plant medicine" is imprecise. "Plant medicine" is accurate and appropriate in ceremonial, indigenous, and autonomous-use contexts — see Spiritual/Ceremonial Audiences below.
• Instead of "healing": "clinically meaningful remission," "symptom reduction," "therapeutic response."

Policy/Legislative Audiences

• "Novel psychiatric treatment modality" (before the substance name in initial framing).
• "Supervised FDA-reviewed clinical protocol" (not "ceremony").
• "Evidence-based reform" (not "legalization" for medical access measures).

Conservative/Religious Audiences

• "Veteran mental health treatment" (lead with the population before the substance).
• "Right-to-Try treatment" (invokes Trump-signed federal law).³⁵
• "Medical protocol supervised by psychiatrists" (anchors in medical legitimacy before substance identity).

Spiritual/Ceremonial Audiences

• "Plant medicine" and "entheogen"⁵¹ are accurate and appropriate.
• "Psychedelic" (coined 1956—1957⁵⁰) is the most accepted scientific term across all audiences.

The Functional Unblinding Caveat

With any sophisticated audience, proactively state: "Participants in psychedelic trials typically know whether they received an active dose, which introduces expectancy effects. Modern trials address this with active comparators and objective clinician-rated measures. This does not explain away the results, but it is a genuine methodological limitation worth acknowledging."

XV. Claims to Never Make

Scientific Claims

Legal and Policy Claims

Factual Errors Documented in Advocacy Materials

XVI. Beyond Medicine: The Entheogenic Argument

The medical framing of psychedelics, while tactically essential for regulatory progress, is also limiting. It confines the conversation to pathology: these substances are legitimate insofar as they treat DSM diagnoses. The fuller argument — grounded in the evidence and in philosophy — extends well beyond that frame.

Human Beings Have Always Sought to Expand Consciousness

The ritualized use of mind-altering plants is one of the most consistent cross-cultural behaviors in documented human history. Peyote use has been biochemically confirmed for 5,700 years (El-Seedi et al. 2005)¹⁰¹ and independently confirmed by Bruhn et al. (2002).¹⁰² Ayahuasca ceremony has documented history for at least 1,000 years in the Amazon. Cannabis was listed in the United States Pharmacopeia from 1850 through 1942 — mainstream pharmacology for nearly a century before its political removal. We fast, meditate, chant, and pray — all to move beyond ordinary mental states. Psychedelics and cannabis, used with intention, are among the oldest and most reliable tools for this. The medical framing keeps these substances in the "sick people using clinical tools" box. The entheogenic framing opens the question of what healthy people might gain — and whether "health" means something richer than the absence of diagnosed pathology.

The Evidence Base Is Not Only About Illness

When psilocybin produces an experience that 94% of healthy volunteers at 14-month follow-up still rate as having increased their well-being or life satisfaction, and 83% rate among the five most spiritually significant experiences of their lives⁹⁷ — that is not a side effect. That is the intended function. When 71—100% of cancer patients at 4.5-year follow-up still attribute positive life changes to a single psilocybin session⁹⁶ — that is durable transformation.

William James argued in 1902 that chemically induced altered states can produce genuine mystical experiences indistinguishable in character from the most profound spontaneous religious experiences, and considered these data among the most significant for understanding consciousness.¹⁰⁵ This argument predates any legal prohibition by 68 years. The cognitive liberty doctrine — the right to alter one's own consciousness — is the contemporary legal expression of the same principle — grounded in Sententia's foundational doctrine⁸⁶ and developed in Farahany's contemporary framework.⁴⁷

The Language of "Legitimate Use" Needs Examination

When clinical protocols require supervised settings as a condition of legitimacy, they re-produce in pharmacological form the same gatekeeping structure drug prohibition created in legal form. Both define who gets to be an acceptable relationship with these substances. Both locate the problem in the substance rather than in the context.

The evidence does not support the position that clinical supervision is always required for benefit or safety. The population-level literature documents associations between naturalistic classic psychedelic use and better mental health outcomes across datasets ranging from 130,000 to 261 million individuals (Hendricks 2015,¹⁹ Johansen & Krebs 2015,⁷⁵ Sexton 2020).⁷⁶ The prospective cohort evidence documents therapeutic outcomes at both organized ceremonies and raves.⁷⁹ Even in worst-experience surveys, 84% of naturalistic users endorsed benefit from the most challenging experience they had ever had.⁷⁷

None of this means that preparation, support, integration, and risk awareness are not valuable — they clearly are, and the evidence supports their value. It means that the value of those practices is separable from the value of institutional credentialing, and that responsible use outside clinical infrastructure is both possible and documented.

What the Field Owes Autonomous Practitioners

The "set and setting" concept that structures every clinical psychedelic trial was formalized through autonomous practice,⁹¹ preserved during the 1970—1992 prohibition by underground therapeutic communities and autonomous users, and codified for clinical adoption from that community knowledge base.⁹² Scientists whose personal autonomous experience with these substances preceded their institutional careers built much of the field. The research base used to justify clinical investment was substantially generated by people who first encountered these substances outside any clinical framework.

A destigmatization framework adequate to this history does not treat autonomous users as a risk category to be managed. It acknowledges them as the people who maintained the knowledge, ran the risk, and made the field possible — and it extends to them the same epistemic respect it extends to Phase 3 trial participants.

Forthcoming empirical test of the mystical-experience mechanism. COMP005 and COMP006 both collected Mystical Experience Questionnaire data from participants. The Phase 3 MEQ analyses — correlating mystical experience depth with MADRS response — will be the largest and most rigorous test of the MEQ-as-mechanism hypothesis in the field's history. If the MEQ-response correlation holds in Phase 3 data (consistent with Griffiths 2011 and cancer-distress trials), the entheogenic argument gains its strongest empirical anchor yet. If it does not — if the Ellis VA finding (5D-ASC non-correlation) extends to Phase 3 MEQ data — the claim that mystical experience quality is the active therapeutic ingredient faces a significant empirical challenge, and the argument in this section rests on a weaker foundation. The entheogenic argument should be presented as persuasively supported but not yet confirmed at the Phase 3 level. Those Phase 3 MEQ analyses are the single most important forthcoming data point for the foundational theory of this field.

XVII. Functional Unblinding: The Field's Central Methodological Challenge

Functional unblinding is the single most credible methodological objection to psychedelic clinical trial results, and it requires a consolidated response rather than distributed mentions across audience sections. Every sophisticated clinical, regulatory, or media audience will raise it; every advocate needs to be able to answer it fully.

What it is. Participants in psychedelic trials can typically tell whether they received an active dose. In Mueller et al. 2025 (Note 18), 80% of participants correctly identified their allocation even at the 20 μg microdose level. If participants know they received the active drug, their expectations and therapeutic engagement may inflate subjective outcomes independent of any pharmacological effect. This is a genuine concern that cannot be dismissed.

How the field is responding. Four methodological strategies are in active use:

(1) Active comparators. The psilocybin vs. escitalopram trial (Carhart-Harris 2021, Note 7) used an active SSRI as the comparator, not placebo. COMP006 used 1 mg psilocybin as the control, not placebo — creating a condition where both arms experienced some drug effect. MindMed's GAD program is testing a 50 μg LSD arm specifically designed to examine dose-response below the perceptual threshold.

(2) Clinician-rated primary outcomes. COMP005 and COMP006 use clinician-administered MADRS as the primary endpoint — a structured interview scored by a blinded rater who is not the participant. Clinician-rated measures are harder to inflate through expectancy than self-report. This does not eliminate unblinding concerns but substantially reduces them.

(3) Dose-response confirmation. COMP006 specifically compared 25 mg (two doses) against 1 mg (two doses). If expectancy alone drove outcomes, no dose-response signal should appear between arms where both participants believe they received psilocybin. The significant between-arm difference (MADRS -3.8) is difficult to explain purely by expectancy.¹⁰

(4) Non-hallucinogenic neuroplastogens as a benchmark. Aarrestad et al. 2025 (Note 111) demonstrated that TBG — a non-hallucinogenic ibogaine analogue — produces the same structural neuroplasticity as hallucinogenic compounds. When dendritic spines grown after TBG were experimentally ablated, the antidepressant behavioral effect disappeared — directly proving that the mechanism is pharmacological and not contingent on subjective experience. This is the most powerful scientific response to the "it's all placebo" critique: the mechanism works without any subjective drug effect. The COMP360 Breakthrough Therapy designation is based on the Compass drug-only regulatory strategy, which treats the supervised session as a safety requirement rather than the active therapeutic ingredient.¹¹¹

What to acknowledge. Functional unblinding does inflate subjective self-report measures. Set, setting, and therapeutic support genuinely contribute to outcomes — whether those contributions are "placebo" or "pharmacologically potentiated learning" is a conceptual question that BDNF/TrkB biology has partially answered. The correct position is not to deny the unblinding problem but to explain the mechanistic evidence that transcends it and the design strategies that mitigate it.

For media and clinical audiences: always name whether a study used active comparator, dose-ranging design, or clinician-rated primary outcomes before describing results. These design features determine how much weight to give a finding.

GH001: the no-psychotherapy precedent. GH001 Phase 2b used a single-day dosing paradigm with NO structured psychotherapy — and produced 57.5% remission at Day 8 and 73% remission at 6 months.¹³⁶ If Phase 3 confirms this, it is the strongest evidence that structured psychotherapy is not pharmacologically necessary for at least some psychedelic compounds — directly restructuring the integration session debate, payer coverage logic, and regulatory specifications. GH001 and TSND-201 together constitute a two-compound challenge to the "experience plus therapy" model. The key empirical question they pose: if the experience is not necessary (TSND-201: no subjective effect) AND the therapy is not necessary (GH001: no structured psychotherapy), what exactly is the active ingredient?

TSND-201 and the drug-only regulatory precedent. If TSND-201 (methylone) receives FDA approval for PTSD before any hallucinogenic compound — and before Compass's COMP360 or Usona's psilocybin — it would establish the regulatory precedent that the monoamine-transport mechanism without hallucinogenic effect is approvable in this therapeutic space. That precedent has two implications for the functional unblinding debate: (1) it confirms that the drug-only regulatory strategy is viable — a compound can be approved for psychiatry without requiring a subjective psychedelic experience; (2) it undermines the claim that the psychedelic experience is necessary for therapeutic effect. Conversely, if Compass's COMP360 is approved first — with the psychedelic experience intact and the session treated as a safety requirement — it leaves the question of experiential necessity open. The sequence of FDA approvals will be read, rightly or wrongly, as a regulatory verdict on whether the experience is the treatment or merely the delivery mechanism.

Convergent industry bet on ultra-short-duration psychedelic formats. GH001 (~11-min psychoactive window, inhaled via proprietary device), BPL-003 (~100 min to discharge readiness, intranasal nasal spray), and bretisilocin (~90-min psychoactive duration, oral) represent three independent development programs — Phase 3-stage inhaled 5-MeO-DMT, Phase 3-ready intranasal 5-MeO-DMT, and Phase 2a psilocybin-analog — converging on the same hypothesis: the full-day session model is the primary commercialization barrier, and reducing psychoactive duration is the key to fitting psychedelic therapy into standard outpatient appointments. AbbVie ($1.2B acquisition), AtaiBeckley (merged entity + BTD), and GH Research (Phase 3 planning) pursuing this thesis simultaneously is the market pricing the operational problem. The clinical model built around psilocybin 4-6 hour window and the short-duration model are not competitors for the same patients; they may address different care settings and payer preferences. Short-duration compounds, if approved, are far more compatible with standard insurance outpatient reimbursement logic than full-day infrastructure models. GAD approval implications: if DT120 ODT Voyage (topline expected early Q3 2026) is positive, it would constitute the first Phase 3 confirmation of any psychedelic compound for an anxiety disorder — opening a new regulatory and insurance coverage category. GAD is first-line treatable (no treatment-resistance filter required), affecting ~31 million Americans. Federal mental health parity law (MHPAEA) already requires parity for anxiety disorder coverage; an FDA-approved psychedelic for GAD would have a more direct path to insurance reimbursement mandates than a TRD indication that requires prior-failure documentation. For policymakers: a GAD approval substantially expands the legislative ask from "access for the most treatment-resistant patients" to "access for anyone diagnosed with an anxiety disorder who hasn't responded to first-line treatment."

XVIII. Corporate, Transactional, and IP Landscape

A. Patent Landscape Overview (2025—2026)

The psychedelic pharmaceutical IP landscape has undergone rapid expansion. Psychedelic Alpha's Q1 2026 tracker documented 271 new U.S. patent applications and 156 PCT (international) applications added in 2025, with 122 U.S. patents issued to companies operating in the space during the same period.¹⁴⁵ The most active 2025 filers were CaaMTech, GH Research, Gilgamesh Pharmaceuticals, AtaiBeckley, and Compass Pathways, each with more than a dozen new filings.¹⁴⁵

Three dominant IP categories. First, formulation patents: ODT (Definium's Zydis exclusive, USPN 12,036,220), inhaled delivery (GH Research's inhaled mebufotenin device), and intranasal formulations (AtaiBeckley BPL-003 nasal spray). Second, process patents: synthesis routes, purification methods, and GMP manufacturing processes. Third, composition of matter claims on novel analogs and non-hallucinogenic derivatives: tabernanthalog (TBG), bretisilocin (GM-2505), and Transcend's methylone analogs. The prior art challenge: many psychedelic compounds appeared in 1960s psychiatric literature; composition-of-matter patents on the core molecules are generally unavailable. Patentable novelty lies in formulation, method of treatment, dosing regimen, and structural derivatives.¹⁴⁵

Data exclusivity vs. patent protection. FDA grants 5 years of new chemical entity (NCE) data exclusivity upon approval; 7 years for orphan drug designation. Psilocybin's TRD indication may qualify for orphan designation (affecting fewer than 200,000 U.S. patients annually). Data exclusivity provides market protection independent of patent coverage, which is critical given the prior art exposure on molecule-level claims.

B. Key M&A Transactions 2024—2026

Three landmark transactions signal pharmaceutical-scale validation of the psychedelic therapeutic category:

AbbVie / Gilgamesh Pharmaceuticals (bretisilocin, GM-2505). May 2024: $65 million upfront collaboration and option-to-license. August 2025: AbbVie exercised option, acquiring bretisilocin for up to $1.2 billion.⁷⁴ Bretisilocin is a 5-HT2A agonist and serotonin releaser with ~90-minute psychoactive duration vs. 4—6 hours for psilocybin. AbbVie's acquisition price is the market's valuation of the operational difference: a psychedelic-type therapy that fits inside a standard outpatient psychiatric appointment.

Otsuka / Transcend Therapeutics (TSND-201 methylone, PTSD). March 2026: acquisition for up to $1.225 billion.¹⁴⁴ TSND-201 is methylone — a non-hallucinogenic MDMA structural analog with monoamine transporter mechanism and no 5-HT2A activity. BTD July 2025; National Priority Voucher April 27, 2026. The acquisition signals that a non-hallucinogenic psychedelic-adjacent mechanism for PTSD has reached pharmaceutical-scale acquirer value. Practical implication: the psychedelic therapeutics M&A market is operating at blockbuster-drug valuations even before first approval.

AtaiBeckley merger (June 2025) and DMT IP licensing (early 2025). atai Life Sciences and Beckley Psytech merged in June 2025, creating AtaiBeckley Inc. In early 2025, Psy Therapeutics licensed all rights to its DMT intellectual property to AtaiBeckley. These transactions consolidate the 5-MeO-DMT and DMT IP landscape into fewer entities, with AtaiBeckley now holding both BPL-003 (intranasal 5-MeO-DMT, BTD October 2025) and acquired DMT IP.

MindMed → Definium Therapeutics rebrand (January 2026). Corporate rebrand only; no asset transfer. Definium holds all MindMed IP as legal successor, including the Catalent Zydis ODT exclusive (USPN 12,036,220). Ticker change: MNMD → DFTX, effective January 13, 2026.¹⁴³

C. Investor Due Diligence Framework

For investors, acquirers, and counsel performing due diligence on psychedelic pharmaceutical companies, seven domains require heightened scrutiny:

(1) IP chain of title. Distinguish: (a) owned patents vs. exclusive license vs. non-exclusive license vs. right to use; (b) field-of-use restrictions (e.g., Definium's Zydis rights are limited to lysergide forms — a competitor using Zydis ODT for psilocybin would not infringe); (c) sublicensing rights; (d) milestone and royalty obligations; (e) termination triggers in exclusive license agreements.

(2) Regulatory pathway and clinical hold risk. FDA clinical holds have material value implications. GH001 was under clinical hold (lifted January 5, 2026); holds create timeline uncertainty and development cost exposure. BTD status: review, not approval. The MDMA NDA decline (August 2024) established that even Phase 3 data + BTD does not guarantee approval.²⁷

(3) DEA Schedule I manufacturing constraints. The DEA Aggregate Production Quota (APQ) governs total domestic Schedule I manufacturing. In 2026, DEA set the psilocybin APQ at 50,000g — a 67% increase from 30,000g in 2025 (psilocin APQ separately 80,000g). Companies require DEA Schedule I researcher registration and quota allocation. Supply chain disruption from APQ limits is a material operating risk for clinical-stage companies.

(4) State licensing exposure for service center companies. Oregon/Colorado licensed operators carry ongoing federal Schedule I exposure. Banking restrictions: no FDIC-insured bank is obligated to serve Schedule I businesses; account closure without notice is legally possible at any time. Insurance: constrained availability; standard commercial liability may exclude coverage for federally illegal conduct.

(5) Clinical trial diversity and generalizability. The Hopkins cancer trial (Griffiths 2016) was 94% White; NYU (Ross 2016) 90% White.⁵ (Griffiths 2016).⁶ FDA's 2022 diversity action plan requires diversity action plans for Phase 3 trials; failure to include diverse populations creates label generalizability constraints and post-approval comparative effectiveness risk.

(6) Functional unblinding exposure. The FDA's MDMA NDA decline explicitly cited functional unblinding and data integrity. Trials that rely on self-report primary endpoints without active comparators carry the greatest exposure. COMP005/COMP006's use of clinician-rated MADRS and 1mg active comparator represents the field's current best practice.

(7) Therapist misconduct liability. The Buisson case (MAPS Phase 2 Vancouver) demonstrates that therapist misconduct in psychedelic sessions creates retractions, regulatory consequences, and trial integrity liability. Acquirers of clinical-stage psychedelic companies should audit facilitator training records, session recording compliance, and dual-therapist protocol documentation.

D. Corporate Structure Considerations for Operators and Developers

Service center operators (Oregon, Colorado). Oregon requires that each psilocybin service center licensee hold a state license; licensed facilitators must hold individual facilitator licenses. Healthcare professionals delivering services under dual-licensure (Oregon HB 2387) face both state administrative licensing risk and federal DEA registration risk.³⁹ LLCs are the most common operating structure; professional corporations are required in some states when licensed health professionals are the primary operators. Banking: maintain multiple payment processor relationships; document financial arrangements in writing.

Drug development companies. C-corporation structure (Delaware) is standard for venture-backed pharmaceutical development. Public benefit corporation (PBC) designation is available for companies wishing to signal mission alignment (e.g., Usona's nonprofit model; some service centers have used PBC). IP holding company structures — a Delaware HoldCo holding IP, licensing to operating subsidiaries — are common in pharma and appropriate for psychedelic IP portfolios with multi-jurisdiction coverage.

Federal tax. Schedule I drug researchers and developers are NOT subject to 26 U.S.C. § 280E — which prohibits business expense deductions for businesses engaged in the trafficking of Schedule I/II controlled substances. The Internal Revenue Service's application of 280E to state-licensed cannabis operators hinged on the "trafficking" element; clinical research and pharmaceutical development of Schedule I compounds has not been held to constitute trafficking. Consult a tax attorney before assuming 280E applies or does not apply to any specific psychedelic business structure. Note: Oregon and Colorado psilocybin service centers may face 280E exposure depending on their operating structure; the cannabis Schedule III rescheduling (April 28, 2026) removes 280E for state-licensed medical cannabis operators but does NOT extend to psilocybin service centers.

XIX. Equity, Access, and Demographic Gaps

A. The Research Whiteness Problem

The psychedelic clinical trial literature has a severe and documented racial and ethnic diversity gap that must be acknowledged whenever citing its findings. Doss et al. (2024, systematic review) documented substantial underrepresentation of non-White participants across the published psychedelic trial literature. Specific trial demographics: Hopkins cancer-distress (Griffiths 2016): 94% White, n=51.⁵ NYU cancer-distress (Ross 2016): 90% White, n=29.⁶ Bogenschutz 2022 AUD (n=93): 78.9% non-Hispanic White.¹⁶ MAPP2 was a meaningful exception with a more diverse sample (26.9% Hispanic/Latino, 33.7% non-White), but MAPP2's NDA was declined.²⁶

The generalizability problem is not merely academic. Jones and Nock (2022) found that race and ethnicity significantly moderate the protective associations between classic psychedelic use and mental health outcomes: associations robust for White participants are substantially attenuated for racial and ethnic minorities. This means the data most frequently cited in destigmatization work may not describe the experience of the populations that carry the highest mental health burden. Any argument that "psychedelics reduce suicidality" must be qualified with this moderating data.

The historical context. Racial and ethnic minorities were also the primary targets of the War on Drugs' enforcement, creating both historical trauma around drug use and persistent disparities in the criminal justice consequences of that use.¹⁸¹ A destigmatization framework that does not explicitly address these disparities is not a complete destigmatization framework — it destigmatizes for some people while ignoring the harms visited on others.

B. Cost and Access Barriers

The access paradox: the populations with the highest burden of treatment-resistant mental illness — lower income, rural, uninsured, people of color — are precisely the populations least able to access current psychedelic services. Oregon's licensed psilocybin services cost $1,000—$3,500 per session, cash-pay only; no insurance coverage exists as of May 2026.¹⁸³ Australia has 12—13 authorized prescribers for the entire country.

The transportation and time burden is not captured in session cost: a 6—8 hour dosing session requires vehicle access, childcare, and work flexibility that many low-income patients do not have. The integration sessions (minimum 2—3 post-session) compound this burden. The populations most likely to be among Rockhill et al.'s 31.3 million naturalistic psilocybin users — those with mental health conditions and chronic pain — are using psychedelics outside any access infrastructure precisely because they cannot afford or access the regulated framework.¹⁰⁸

The Usona exception. Usona Institute's nonprofit model would distribute psilocybin at cost without commercial licensing if approved.¹³⁵ This could materially lower the price floor for psilocybin therapy compared to a commercial Compass model — potentially changing the access equity calculus. Whether Usona's nonprofit distribution model survives FDA approval and Schedule III rescheduling at scale is an open structural question.

C. Community-Centered and Culturally Responsive Models

Effective equity-oriented psychedelic access requires more than price reduction. Cultural responsiveness — facilitators who share the participant's cultural background, language, and lived experience; ceremonial traditions that belong to the communities using them; harm reduction materials in languages other than English — is a structural prerequisite for access that actually works. Oregon's OAR 333-333 includes equity provisions; BIPOC-centered service center licensing and workforce development programs are active in Oregon. MAPS community partnership programs are developing culturally specific MDMA-AT protocols.

The spectrum of appropriation: at one end, fully commercialized extraction of indigenous plant medicine practices without benefit to the originating communities; at the other, community-owned and community-operated programs grounded in traditional knowledge with benefit-sharing. Practitioners and advocates should apply UNDRIP Article 31 (protecting indigenous communities' rights to traditional knowledge) and the Nagoya Protocol (prior informed consent for biological resources from indigenous territories) as frameworks, not aspirational statements. No U.S. court has adjudicated an indigenous IP claim over a psychedelic preparation; the legal questions remain open.

D. Policy Remedies Available Under Existing Authority

(1) Section 1115 Medicaid waiver authority: state demonstration projects can cover approved psychedelic therapy before federal coverage is established. Oregon and Colorado are positioned to use this authority immediately upon FDA approval of any psilocybin or DT120 indication. No legislative change required at the federal level.

(2) Clinical trial diversity mandates: FDA's 2022 diversity action plan guidance requires Phase 3 sponsors to submit diversity action plans. Psychedelic trial sponsors that have not complied face label constraint risk. Advocacy directed at FDA to enforce this requirement in pending psychedelic NDAs is available under existing authority.¹⁸⁴

(3) SAMHSA harm reduction grants: SAMHSA programs currently funding opioid harm reduction (fentanyl test strips, naloxone distribution) can be expanded to psychedelic harm reduction under existing statutory authority. No new appropriation required — administrative reinterpretation of existing grant program scope.¹⁰⁸

(4) Insurance coverage mandates: Oregon and Colorado can require insurers to cover FDA-approved psychedelic therapy as a mental health benefit under state parity laws, independent of federal action. State mental health parity statutes model this approach. For advocates: the legislative ask is not just regulatory approval — it is explicit insurance mandate language in state omnibus health bills.¹⁴⁶

XX. Insurance, Reimbursement, and Coverage Mechanics

A. Mental Health Parity and the Legal Pathway

The Mental Health Parity and Addiction Equity Act (MHPAEA, 29 U.S.C. § 1185a) requires group health plans and health insurance issuers that cover mental health and substance use disorder (MH/SUD) benefits to ensure those benefits are not subject to more restrictive financial requirements or treatment limitations than those applied to medical/surgical benefits.¹⁴⁶ For plans that cover FDA-approved treatments for MDD, PTSD, or GAD: once psilocybin or DT120 ODT is FDA-approved, MHPAEA creates a legal argument that it must be covered on par with analogous physical health treatments — insurers cannot categorically exclude an approved MH/SUD treatment without the same exclusion applying to comparable medical/surgical treatments.

Non-quantitative treatment limitation (NQTL) analysis. MHPAEA's most powerful application is the NQTL prohibition. Plans that cover Spravato (esketamine) for TRD but categorically exclude psilocybin for TRD after approval — or that impose prior authorization requirements for psychedelic therapy that are not imposed on analogous medical procedures — may face NQTL parity challenges. The MHPAEA Enforcement Final Rule (September 9, 2024, 89 Fed. Reg. 72,990) strengthened NQTL comparative analysis requirements and created affirmative documentation obligations for plans.¹⁴⁶

GAD vs. TRD indication implications. GAD (generalized anxiety disorder) is a first-line treatable condition; MHPAEA coverage arguments do not require documentation of prior treatment failure. If DT120 ODT is approved for GAD (Definium's lead indication), MHPAEA creates a broader path to coverage mandates than a TRD-only psilocybin approval, which requires demonstrating treatment resistance and failed prior antidepressants. A GAD approval substantially expands both the eligible population and the insurance access argument. Federal mental health parity law already requires coverage parity for anxiety disorders; an FDA-approved psychedelic for GAD would have a more direct MHPAEA path than any treatment-resistant indication.

B. Current State: What Exists (May 2026)

CPT codes 0820T/0821T/0822T (effective January 1, 2024): three Category III tracking codes for "Continuous In-Person Monitoring and Intervention During Psychedelic Medication Therapy." Critical limitations: (1) Category III codes are NOT reimbursable under Medicare, Medicaid, or private insurance as of May 2026; (2) cover the dosing/monitoring session only — preparation and integration sessions are not covered; (3) designed to collect utilization data and establish infrastructure ahead of Category I codes upon FDA approval.¹³⁸

Integration and preparation sessions: billed under standard psychotherapy CPT codes (90837, 90834, etc.) when delivered by a licensed psychotherapist; when delivered by a facilitator without a psychotherapy license, there is currently no billing infrastructure. Oregon/Colorado service centers operate outside insurance billing entirely. Cash-pay pricing: $1,000—$3,500 per dosing session in Oregon.

C. The Spravato Model: What Comes Next

Spravato (esketamine) is the only psychedelic-adjacent compound that has traversed the full coverage pathway, providing the operational template for what psilocybin and DT120 ODT will face. Upon FDA approval (March 2019), Spravato received: permanent Category I CPT codes with J-codes; REMS program certification requirement; full Medicare Part B and Medicaid coverage (as a REMS-managed drug administered in a certified healthcare setting); private insurer coverage following CMS coverage determination.³⁰ Annual worldwide sales reached approximately $1.7 billion in 2025. The pathway from FDA approval to routine reimbursement took approximately 3—4 years. Psilocybin and DT120 ODT will follow a similar arc.

Payer timeline for psilocybin (COMP360). Commercial health plans will almost certainly require durability data from both COMP005 and COMP006 before making coverage decisions. COMP006 Part B durability data expected Q3 2026; following NDA filing (targeted year-end 2026) and FDA priority review (~1—2 months), the earliest plausible commercial insurance coverage date for COMP360 is 2028. Medicaid coverage follows commercial and is structurally slower; likely 2029—2030. During this gap, the only access options are Oregon/Colorado cash-pay services ($1,000—$3,500/session) or clinical trial enrollment.¹²⁹

DT120 ODT for GAD: the faster coverage path. A GAD indication is not TRD-limited. If Definium's DT120 ODT Voyage trial (topline expected early Q3 2026) is positive and NDA filing follows within 12—18 months, the GAD coverage pathway is faster than TRD because: (a) no treatment-resistance documentation requirement for prior authorization; (b) MHPAEA's existing anxiety disorder parity mandate; (c) broader eligible population (31 million U.S. adults with GAD vs. the subset with TRD). A GAD approval could be the most commercially significant near-term psychedelic coverage event.¹⁴²

D. Practitioner and Client Guidance

Prepare cost documentation now: Oregon/Colorado service centers should maintain detailed records of session costs, preparation and integration fees, and any out-of-pocket payments. This documentation will be necessary for future insurance reimbursement claims once coverage is established.

State mandate advocacy: practitioners and operators in Oregon and Colorado should engage state legislative advocacy for explicit insurance mandate language in omnibus health bills, analogous to state mental health parity statutes. The legislative window between NDA filing and FDA approval is the optimal advocacy period — mandate language can be drafted and passed before coverage is required.

REMS preparation: service centers and clinical providers should anticipate REMS program requirements analogous to Spravato's REMS (certified healthcare settings, mandatory monitoring, provider certification). Build the operational infrastructure now: session recording, dual-facilitator protocols, vital signs monitoring, and documentation systems. REMS compliance will be the gate to Category I billing codes.

XXI. Criminal Defense and Federal Schedule I Exposure

A. The Federal Statutory Framework

Practitioners advising operators, facilitators, attorneys, and individual clients must understand the specific federal statutes that create criminal exposure regardless of state authorization:

21 U.S.C. § 841(a)(1). Prohibits the knowing or intentional manufacture, distribution, dispensing, or possession with intent to distribute any controlled substance. Applies to service center operators, facilitators, and anyone who provides a psychedelic substance to another person, even in a licensed, state-authorized, therapeutic context. Penalties under § 841(b): below threshold weights (1g LSD; 100g psilocybin), no mandatory minimum applies; base offense level governed by USSG § 2D1.1. Most facilitator-context distributions are below threshold weights.¹⁴⁷

21 U.S.C. § 856 (the "crackhouse statute"). Prohibits knowingly opening, maintaining, or managing any building or location for the purpose of manufacturing, distributing, or using any controlled substance. Directly applicable to Oregon and Colorado licensed service centers; the "knowingly" element is easily satisfied by licensed operation. State authorization does not constitute a federal defense to § 856. Federal prosecution of licensed service centers is currently legally available but politically improbable under the Trump administration given Executive Order No. 14,401; that calculus changes with every administration; federal enforcement policy may change with each administration.¹⁴⁷ The April 2026 EO has reduced enforcement probability without eliminating the exposure.³⁷

The Cole Memo gap. DOJ's Cole Memo (August 29, 2013) established a non-prosecution policy for state-compliant cannabis operators meeting eight federal priorities. No equivalent formal policy governs psychedelics. The Trump EO directed FDA and DEA toward psychedelic access pathways, creating an informal non-prosecution signal, but that signal is neither statutory nor binding. Practitioners must advise clients that federal prosecution exposure is real and ongoing, even if enforcement is currently improbable.³⁷

B. Who Carries Federal Exposure

Service center operators and facilitators. Oregon Measure 109 licensees and Colorado Prop 122 healing center operators carry ongoing § 841 (distribution) and § 856 (maintaining premises) exposure. Licensed healthcare professionals who deliver services under Oregon HB 2387 dual-licensure face additional DEA registration risk: DEA registration (required for controlled substance prescribing) could theoretically be suspended or revoked for conduct involving Schedule I substances, even if state-compliant.³⁹

Attorneys advising clients. ABA Model Rule 1.2(d) bars lawyers from counseling a client to engage in criminal conduct or assisting a client in conduct the lawyer knows is criminal. However, ABA Formal Opinion 2023-504 (November 8, 2023) clarifies that a lawyer may advise a client regarding conduct that is lawful under applicable state law — even if that conduct constitutes a federal crime — provided the lawyer also advises the client about the related federal law and the possibility of federal law enforcement action.¹⁴⁹ This opinion, developed for cannabis law, applies by direct analogy to psychedelic law practice. Counsel may advise on state-legal psychedelic operations, draft compliance documents for licensed service centers, and assist clients in understanding state regulatory requirements, while simultaneously informing clients of their ongoing federal Schedule I exposure.

Religious ceremony operators. RFRA is the strongest existing defense for religious ceremony operators, but it does not provide blanket immunity. The defense must be raised, documented, and litigated case-by-case. Documentation before any enforcement contact is essential: written declarations of sincerity, ceremony histories, community participation records, scholarly expert declarations.³¹

C. RFRA as Criminal Defense

Post-O Centro, the RFRA burden-shifting framework requires: (1) a sincere religious belief; (2) a substantial burden on that belief; (3) government failure to demonstrate a compelling interest applied through the least restrictive means as applied to this specific claimant. The unanimous Supreme Court held in O Centro that Schedule I classification alone does not automatically satisfy the compelling interest test.³¹

Defense practice: documentation protocol. Document sincerity before any enforcement contact. Sincerity evidence: (a) written declarations of the claimant's religious beliefs and practice history; (b) ceremony records showing consistent practice over time; (c) community participation records — who else participates, how often, in what capacity; (d) clergy, elder, or community endorsements; (e) written descriptions of the specific sacramental function of the substance within the tradition. The most defensible RFRA claims are narrow, specific, and documented — limited to the specific ceremony, congregation, and preparation at issue, not broad decriminalization advocacy.

Circuit considerations. Ninth Circuit: extended O Centro to Santo Daime's Church of the Holy Light of the Queen. Tenth Circuit: O Centro's home circuit. RFRA claims are less developed in other circuits. File in favorable circuits where possible. Government's strongest counter-arguments: compelling interest in Schedule I enforcement as applied to this claimant; evidence of commercial motive; child exposure risk; fraud (non-sincere beliefs). Avoid: commercial sales elements, broad decriminalization arguments in pleadings, mixed secular and religious purpose.

What RFRA does not protect. Commercial distribution without sincere religious motive; conduct by practitioners with no documented sincerity in the relevant tradition; anything that looks like a business operation with a religious label. The government can still win RFRA cases with the right evidence. Practitioners should treat O Centro as a viable litigation strategy, not a blanket authorization.

D. Sentencing and USSG § 2D1.1

Federal drug sentences for psychedelic-related offenses begin with the Drug Equivalency Tables under USSG § 2D1.1. Psychedelic equivalencies: LSD = 100 grams marijuana per gram of LSD (adjusted weight method: carrier medium weight multiplied by 500); psilocybin = 500 grams marijuana per gram; MDMA = 500 grams marijuana per gram.¹⁴⁸ Most facilitator-context offenses, where the quantity is measured in individual doses rather than kilograms, produce offense levels well below the crack-cocaine-era Guidelines extremes.

Safety valve (18 U.S.C. § 3553(f); USSG § 5C1.2). Available to first-offense, non-violent drug defendants who meet five criteria: (1) no more than 1 criminal history point; (2) did not use violence or a firearm; (3) no death or serious bodily injury; (4) not an organizer, leader, manager, or supervisor; (5) truthfully provided all information about the offense. Safety valve eliminates mandatory minimums and permits below-Guidelines sentences. Most psychedelic facilitator defendants are likely to qualify.¹⁴⁸

Mitigating factors in psychedelic sentencing. Mitigating arguments available to psychedelic defendants that are uncommon in conventional drug cases: (a) therapeutic intent and victim consent (the "client" sought the service; no coercion); (b) religious or ceremonial purpose (§ 3553(a)(1) nature and circumstances of the offense); (c) harm reduction orientation (no adulteration, accurate dosing, trained facilitator); (d) low recidivism risk; (e) first offense. Courts retain § 3553(a) discretion to vary below Guidelines; document these factors in PSR objections and sentencing memoranda.

E. Practitioner Guidance: Advising Operators and Clients

What attorneys can do under ABA Rule 1.2(d) and Formal Opinion 2023-504: advise clients on the requirements of Oregon Measure 109 and Colorado Prop 122; draft compliance documents for state-licensed service centers; assist in understanding OHA licensing requirements and OAR 333-333 operational rules; counsel clients on RFRA defense strategy and documentation; advise on the federal prosecution risk landscape. What attorneys cannot do: assist a client in conduct the lawyer knows is criminal without simultaneously advising the client of the federal criminal exposure. The critical practice note: every engagement involving state-legal psychedelic conduct should include an explicit written federal-law disclosure to the client documenting that (a) the conduct is federally prohibited under the CSA; (b) state authorization does not immunize against federal prosecution; (c) federal enforcement policy may change with each administration.¹⁴⁹

Emergency protocol: federal search warrant. If a client's service center receives a federal search warrant: (1) do not obstruct — allow the search to proceed; (2) document everything seized with contemporaneous records; (3) assert attorney-client privilege over all communications with counsel; (4) do not make statements to agents without counsel present; (5) contact counsel immediately; (6) preserve all records not subject to seizure. Federal search warrants for state-legal psychedelic operators are rare but possible; preparation is the difference between a manageable event and an operational catastrophe.

XXII. Counter-Narrative Playbook

The five adversarial narratives below appear repeatedly in legislative testimony, media coverage, and public debate. Each has a factual anatomy that is different from how it's usually argued. This section provides the complete attack-response framework for each.

Narrative 1: "People Die from Psychedelics"

The claim. Psychedelics are dangerous — people die. This is typically deployed without substance-specificity, conflating ibogaine cardiac mortality, MDMA heat stroke deaths at raves, adulteration fatalities, and classic psychedelic overdose events into a single "psychedelics kill people" frame.

The facts. No deaths were recorded in 3,504 screened participants across 114 studies with analyzable adverse-event data in the Hinkle et al. 2024 meta-analysis.¹¹ National poison control data (Leonard et al. 2018, n=5,883 psilocybin mushroom exposures over 16 years): psilocybin mushrooms associated with lower emergency medical treatment rates than most other substances.⁶² Ibogaine is categorically different: documented cardiac mortality risk, QTc prolongation, hERG binding. The deaths that do occur in psychedelic contexts involve: ibogaine cardiac events in unmonitored settings; MDMA hyperthermia in overcrowded settings without hydration and cooling; adulteration (NBOMe compounds, fentanyl in MDMA markets). The substance being blamed in each case is different.

The response. "Which substance? Under what conditions? With what screening? The mortality evidence is substance-specific, setting-specific, and screening-specific. Conflating ibogaine cardiac deaths in unmonitored settings with psilocybin clinical trial safety data is not a statement about psychedelics — it is a category error. In medically supervised settings with properly screened participants using classic serotonergic psychedelics, zero deaths have been documented in the modern research era. For ibogaine specifically, cardiac monitoring and magnesium protocol are the binding constraint; the deaths that have occurred are failures of monitoring, not failures of the pharmacology.

What to never say. "No one has ever died from psychedelics." False. Ibogaine deaths are documented. Do not make this claim.

Narrative 2: "This Is a Profit Scheme by Pharmaceutical Companies"

The claim. Big Pharma is commodifying plant medicines, patenting nature, and using the psychedelic renaissance to create new billion-dollar markets while indigenous communities and autonomous practitioners are criminalized. This narrative has legitimate dimensions — acknowledge them.

The legitimate concern. AbbVie acquiring bretisilocin for $1.2 billion⁷⁴ and Otsuka acquiring Transcend for $1.225 billion¹⁴⁴ confirms that pharmaceutical-scale investment is real. Patenting of traditional knowledge without benefit to originating communities is a genuine bioprospecting harm. Pricing that excludes those most in need is a real access equity problem.

The full response. (a) Usona Institute is a 501(c)(3) nonprofit that would distribute psilocybin at cost without commercial licensing — the field is not monolithic.¹³⁵ (b) Oregon and Colorado licensed service centers are mostly small businesses, not pharmaceutical corporations; the $1,000—$3,500 session costs reflect facilitator time, overhead, and insurance — not pharmaceutical profit extraction. (c) The alternative to regulated commercial access is unregulated black market access, not free access. (d) The profit-scheme argument, if taken to its logical conclusion, would prevent the clinical infrastructure from existing at all, leaving only the unregulated market that the argument purports to oppose. (e) The correct response to corporate capture is equity-centered regulation (diversity mandates, indigenous benefit-sharing requirements, insurance coverage mandates, Medicaid inclusion) — not opposition to medical access itself.

Narrative 3: "FDA Was Right to Reject MDMA — These Are Dangerous Therapies"

The claim. The FDA's 2024 rejection of the MDMA NDA — combined with the advisory committee's 9-2 and 10-1 votes against effectiveness and benefit-risk — proves that psychedelic therapy doesn't work and that FDA was right to be skeptical. This narrative frames the CRL as a categorical verdict on the field.

What FDA actually said. FDA declined the NDA for methodological reasons: functional unblinding, data integrity concerns at specific trial sites, and limited evidence generalizability.²⁷ FDA did not find that MDMA-AT lacks efficacy. The Phase 3 data showed 67% (MAPP1) and 71% (MAPP2) of MDMA recipients no longer met PTSD diagnostic criteria, vs. 32% and 48% placebo — striking results that FDA's methodological concerns cannot erase. The BTD remains active. FDA's concerns are about how the evidence was collected, not whether the therapy works.

The field's response. (a) The functional unblinding problem has specific design solutions already deployed in next-generation trials: active comparators, clinician-rated primary outcomes, dose-response confirmation (COMP006's 25mg vs 1mg). COMP005 and COMP006 both met their primary endpoints using these designs. (b) The Trump April 2026 EO directed FDA toward accelerated re-review of MDMA-AT for veterans.³⁷ (c) TSND-201 (methylone, non-hallucinogenic MDMA analog) received a National Priority Voucher April 27, 2026 — FDA is not categorically rejecting the monoamine-transport mechanism; it is demanding better methodology.¹⁴⁴

What to never say. "FDA was wrong." This is strategically counterproductive. FDA identified real problems. Say: "FDA identified real methodological problems that the next generation of trials is specifically designed to address.

Narrative 4: "Therapists Abuse Patients in Psychedelic Sessions"

The claim. The MDMA trial therapist misconduct scandal proves psychedelic-assisted therapy creates structural conditions for abuse, and these treatments cannot be safely delivered.

The facts. The Meaghan Buisson case (King's College London / MAPS Phase 2 Vancouver trial) involved documented sexual and emotional boundary violations by two therapists during MDMA-assisted therapy sessions. The case resulted in academic publication retractions and contributed to FDA's 2024 CRL. The September 2025 scoping review in Psychological Medicine confirmed the broader pattern: altered states produced by psychedelic-assisted therapy create structural conditions — elevated suggestibility, transference, dissolution of normal relational boundaries — that increase patient vulnerability to manipulation. This is a real problem. Do not minimize it.¹²⁸

The structural response. (a) The misconduct is not caused by the substance; it is caused by practitioners who violated protocol and ethical norms. (b) The structural safeguards specifically designed to prevent this are: dual-therapist protocols (one male, one female whenever possible); mandatory session video recording (Oregon OAR 333-333-4060 requires recording for licensed service centers); independent ethics reporting pathways; mandatory trauma-informed training; facilitator screening for boundary-violation history. (c) Medicalization increases protection, not decreases it: a licensed, regulated context with mandatory recording and dual-therapist requirements is structurally safer than unregulated access. This is a genuine argument for the regulatory model.

What to never say. "A few bad actors." The Psychological Medicine scoping review identified the structural vulnerability as systemic. Do not dismiss the FDA CRL as scientifically unfounded — FDA's site-integrity concerns were real and documented. Engage the full critique honestly.

Narrative 5: "This Will Become the Next Opioid Crisis"

The claim. Pharmaceutical companies will aggressively market psychedelic drugs, doctors will over-prescribe, and we will see a wave of addiction and societal harm analogous to opioid overprescribing. This is the most common legislative objection and the most pharmacologically baseless for classic serotonergic psychedelics.

The pharmacological response. Classic psychedelics (psilocybin, LSD, DMT, mescaline) do not activate the dopamine reward pathway in the manner associated with addiction. They are not mu-opioid receptor agonists. Tolerance develops rapidly, making daily use pharmacologically self-limiting — the mechanism is directly opposite to the opioid crisis's dose escalation dynamic. Johansen and Krebs (2015, n=135,095 NSDUH adults, 19,299 psychedelic users) found no significant associations between lifetime classic psychedelic use and any mental health problem or suicidal behavior. The Hinkle 2024 meta-analysis documented zero cases of addiction in 3,504 research participants.¹¹

The policy response. The opioid crisis resulted from three specific conditions that are not present in the psychedelic therapy model: (1) pharmaceutical industry false marketing of opioids as non-addictive (factually wrong for their pharmacology); (2) inadequate prescriber education about addiction liability; (3) pill mills — no screening, no monitoring, on-demand home dosing. The psychedelic therapy model is structurally opposite: screened participants with contraindication exclusion; supervised sessions with trained facilitators; integration support; no refills or on-demand dosing; session-based rather than daily pharmacotherapy.

The honest caveat. Ketamine and MDMA carry documented abuse liability — they require a different answer. The opioid-comparison objection is most damaging when advocates conflate substance classes in their response. The correct answer is substance-specific: "For classic psychedelics like psilocybin and LSD — no addiction mechanism exists. For ketamine and MDMA — different risk profiles that the regulatory model already recognizes differently, including REMS requirements and scheduling distinctions. Conflating them is the error, not the concern."

What to never say. "Psychedelics are not addictive." This is true for classic psychedelics but false for ketamine and cannabis, which are frequently discussed in the same political context. Speak substance-specifically or not at all.

XXIII. Practitioner Compliance Infrastructure

Every state-licensed psychedelic service center operates under a foundational tension: the substances it lawfully provides under state law remain Schedule I controlled substances under the federal CSA. A robust compliance infrastructure does not resolve this tension, but it demonstrates to state regulators, clients, and the public that the operator takes its obligations seriously within the framework the state has created. In an emerging industry operating under legal uncertainty, compliance infrastructure is the operator's primary evidence of legitimacy.¹⁵⁰

A. The Compliance Stack: Three-Tier Hierarchy

Compliance operates through a three-tier hierarchy. A service center's obligations ultimately derive from statute. In Oregon, ORS Chapter 475A establishes the entire regulated psilocybin ecosystem: eligibility screening, client protections, OHA rulemaking authority, civil enforcement authority, and employee retaliation protection.¹⁵⁰ Administrative rules convert statutory goals into operational requirements. Oregon Administrative Rules Chapter 333, Division 333, specifies client-process controls, informed consent requirements, mandatory reporting timelines, session recording requirements, inspection authority, and enforcement categorization.¹⁵¹ And compliance is ultimately proven through documented procedures, training records, and contemporaneous records showing each required step occurred. Compliance is not what you intend — it is what you can prove.

Oregon's enforcement toolkit is not advisory. The Oregon Health Authority may: (1) inspect licensed books and records with 72 hours' notice; (2) inspect licensed premises at any time without advance notice; (3) investigate and discipline licensees even after license lapse, suspension, or revocation; and (4) impose civil penalties of up to $5,000 per violation. The most expensive compliance failure is always the one discovered by the inspector rather than by the operator.¹⁵⁰

B. The Seven Pillars of Service Center Compliance

Pillar 1: Governance and Accountability. A credible compliance system assigns explicit responsibility for interpreting regulatory requirements, maintaining standard operating procedures, monitoring adherence, managing incidents and reporting, and preparing for inspections. Four functional roles (which may overlap in smaller operations but must remain identifiable): (a) Compliance Lead — policy owner, regulatory liaison, reporting owner; (b) Clinical/Safety Lead — session safety systems, incident escalation, training oversight; (c) Records and Reporting Owner — data compilation, retention, submission controls, quarterly reporting accuracy; (d) Facility/Operations Lead — premises compliance, access controls, inspection readiness. Monthly or quarterly governance cadence: review incidents and complaints, verify reporting completeness, audit client-process requirements, update SOPs to reflect rule changes.¹⁵¹

Pillar 2: Client-Process Controls. Oregon defines psilocybin services as including preparation, administration, and integration sessions and ties client protection requirements directly to that tripartite model. Three compliance gates:

Informed consent (OAR 333-333-5040): Informed consent is a mandatory compliance gate — a required checkpoint that produces a signed, retained document — without which services cannot lawfully continue. If a regulator can point to a missing or deficient informed consent record, enforcement exposure exists regardless of whether the session was clinically competent. The consent document is both a client protection and a compliance artifact.¹⁵¹

Client information form (OAR 333-333-5050): Distinct from the informed consent document; must be completed and received by the facilitator before every administration session. This is the primary statutory eligibility screening mechanism under ORS 475A.350, covering exclusionary conditions including lithium use within 30 days, active psychosis, and ideation of harm to self or others. Treat it as a separate compliance gate from informed consent, with its own documentation, retention, and audit protocols.¹⁵⁰ per ORS 475A.350 exclusionary criteria.¹⁵¹

Facilitator continuity (OAR 333-333-5000): Written consent is required if facilitators change across session types for the same client. Operationalize through staffing workflows, scheduling documentation, and client-facing acknowledgment records.¹⁵¹

Pillar 3: Policies, SOPs, and Training. SOPs convert rule text into consistent, repeatable practice. Their absence is itself an enforcement finding. Maintain SOPs in five functional families:

(1) Client journey and documentation: intake and eligibility screening, informed consent delivery and retention, preparation/administration/integration session protocols, emergency escalation logic. (2) Incident and safety reporting: adverse reaction definitions, escalation pathways, emergency services contact procedures, incident record preservation. (3) Misconduct and mandatory reporting: "reportable event" definitions, decision trees for mandatory reporting triggers, 24-hour reporting workflows for harm or endangerment misconduct (OAR 333-333-5140), retaliation-safe internal escalation lanes. (4) Records, reporting, and data quality: quarterly reporting data compilation and validation, retention schedule management, audit trails documenting changes to records. (5) Regulator interface: inspection response protocols (who speaks, what is produced, how records are provided), investigation response protocols, corrective action plan processes.¹⁵¹

Mandatory employee training must cover informed consent requirements, incident escalation protocols, mandatory misconduct reporting timelines, recordkeeping and reporting duties, and inspection response procedures. Training documentation is especially critical: OAR 333-333-5140 creates independent reporting duties for individual staff members and treats failure to report as a separate violation. Employee retaliation protection: ORS 475A.489 makes it an unlawful employment practice to discharge, demote, suspend, or otherwise discriminate against an employee who reports misconduct. Communicate this protection to staff as part of misconduct training.¹⁵⁰

Pillar 4: Reporting Duties and Data Infrastructure. Oregon mandates quarterly reporting under ORS 475A.372 and ORS 475A.374. Required quarterly calculations and reporting elements must be computed and submitted for the prior quarter. Compliance infrastructure must include: (a) a data dictionary defining each required field; (b) collection workflows ensuring data is captured contemporaneously; (c) validation checks confirming accuracy before submission. OHA publishes program-level data via a public interactive dashboard — a compliance infrastructure should treat public reporting risk as a governance concern: accuracy and consistency determine how the service center appears in publicly accessible datasets.

Pillar 5: Incident Response and Mandatory Reporting. Oregon's mandatory reporting requirements operate on independent 24-hour timelines. OAR 333-333-5140 requires reporting of harm or endangerment misconduct within 24 hours; failure to report is a separate violation. Incident response infrastructure must include: (a) clear adverse reaction definitions; (b) documented escalation pathways; (c) emergency services contact procedures; (d) immediate internal notification timelines; (e) record preservation protocols. Note: individual staff members have independent mandatory reporting duties — not just the Compliance Lead. A session facilitator who witnesses misconduct has a 24-hour reporting obligation regardless of what the Compliance Lead decides.¹⁵¹

Pillar 6: Complaint Systems. Oregon's rules require complaint-processing infrastructure. A compliant system includes: an accessible intake mechanism for client, employee, and third-party complaints; documented review and response workflows; escalation criteria linking complaints to mandatory reporting triggers; and records of all complaints and dispositions. Complaint documentation protects the service center: it demonstrates responsiveness to the regulator and creates evidence of good-faith compliance management.

Pillar 7: Inspection Readiness. OHA may inspect licensed premises at any time. An inspection-ready service center maintains: (a) a designated inspection response team with clear role assignments; (b) an organized, retrievable records system with current indexed files; (c) a clean premises that matches the licensed floor plan; (d) trained staff who know what to produce, who speaks with inspectors, and how to handle unexpected requests. Conduct internal "mock inspection" drills annually. The inspection response protocol document should be physically present at the service center at all times.¹⁵⁰

C. Five-Level Compliance Maturity Scale

Most service centers in Oregon's early years are at Level 1 or 2 on a five-level maturity scale. Level 1: Ad hoc — no formal SOPs; compliance depends on individual facilitator knowledge; no documented training records; incident response informal. Level 2: Developing — some written SOPs; inconsistent implementation; training documented for some but not all staff; quarterly reporting manual and error-prone. Level 3: Defined — complete SOP set; consistent implementation; documented training for all staff; quarterly reporting automated with validation checks; internal audit capacity. Level 4: Managed — compliance metrics tracked; regular internal audits; corrective action plans documented and closed; proactive regulatory engagement. Level 5: Optimizing — continuous improvement culture; benchmark against peer programs; external compliance audit; integration of compliance signals into clinical protocol refinement. Regulators generally expect Level 3 by the time of first inspection for established operators. The gap between Level 1 and Level 3 is primarily documentation — it is achievable without large capital expenditure.

D. Oregon vs. Colorado: Key Structural Differences

Service centers operating in both states or comparing frameworks should note: (1) Oregon's framework is facilitator-centric — all services must occur through a licensed service center with a licensed facilitator; no personal possession rights outside that framework. Colorado's Proposition 122 (2022) added personal possession and home cultivation rights for adults 21+, making Colorado more permissive in the non-commercial track. (2) Colorado's licensed healing center model covers psilocybin, psilocin, DMT, ibogaine, and mescaline (excluding peyote); Oregon's covers only psilocybin/psilocin. (3) Colorado's state licensing authority is the Natural Medicine Division of the Department of Revenue (the same agency that oversees cannabis); Oregon's is OHA. Compliance obligations and enforcement culture differ. (4) Session recording requirements: Oregon OAR 333-333-4060 mandates video recording of all administration sessions; Colorado's rules differ — verify current Colorado recording requirements before assuming equivalence.¹⁵¹

Legal risk aggregation for dual-state operators. Service centers operating in both Oregon and Colorado carry: ongoing federal Schedule I exposure in both states (two jurisdictions of state-authorized conduct, each independently exposing the operator to § 841/§ 856 federal liability); two separate state licensing regimes with distinct reporting timelines, enforcement authorities, and inspection rights; and professional licensing risks for healthcare professionals that may span both state licensing boards plus the federal DEA. Document compliance with each state's framework independently; do not assume that Oregon compliance satisfies Colorado requirements or vice versa.

XXIV. Psychedelic Business Formation and Licensing

This section is a practical reference for attorneys advising psychedelic service center operators, drug developers, and investors. It covers entity structure decisions, Oregon and Colorado licensing requirements, federal complications for Schedule I businesses, and capitalization considerations.

A. Oregon Service Center Licensing (OHA/OPS)

Oregon Psilocybin Services (OPS), within the Oregon Health Authority, has accepted applications for four license types since January 2, 2023, via the TLC (Training Program, Licensing, and Compliance) online portal.¹⁵⁷

(1) Facilitator License (ORS 475A.325). Requirements: 21 years or older; high school diploma or equivalent; completion of OHA-approved training program; passage of OHA examination. Oregon residency requirement expired January 1, 2025 — out-of-state facilitators may now apply. Annual continuing education: 4 hours required per year effective January 1, 2026. License is individual (not entity-held). A facilitator may work at multiple service centers. Important: facilitator licensees must be identified in service center license applications; a service center cannot operate without at least one licensed facilitator.¹⁵⁷

(2) Service Center License. The licensed premises at which clients 21 and older access psilocybin services. A client must complete a preparation session with a licensed facilitator before any administration session. A service center must maintain a physical location; mobile or home-delivery models are not authorized. Required licensed individuals: at least one licensed facilitator. Must comply with ORS Chapter 475A and OAR Chapter 333, Division 333. Session recording required under OAR 333-333-4060. Application fees non-refundable; renewal window opens 120 days before expiration; incomplete renewals due 60 days before expiration.¹⁵⁰ See also Oregon Psilocybin Services licensing information.¹⁵⁷

(3) Manufacturer License. Covers cultivation, processing, and packaging of psilocybin products for sale to service centers. Manufacturers may not sell directly to clients. Requires separate licensed premises from the service center. Manufacturer licensees must comply with product tracking and testing requirements under ORS 475A and OAR 333-333.¹⁵⁷

(4) Laboratory License. Psilocybin product testing. Third-party testing of all psilocybin products before sale to service centers is required under OPS rules. Lab licensees are distinct from manufacturers and service centers.¹⁵⁷

OHA enforcement authority. OHA may inspect licensed premises at any time; investigate and discipline licensees even after license lapse; and impose civil penalties of up to $5,000 per violation. Persons operating outside the licensed system may be subject to criminal penalties under Oregon law.¹⁵⁰

B. Colorado Natural Medicine Division Licensing

Colorado's Proposition 122 (2022) and the subsequent Natural Medicine Health Act created a licensing framework administered by the Colorado Department of Revenue's Natural Medicine Division. The framework mirrors Oregon's in broad structure but differs in several material ways:

(1) Broader substance scope: the Colorado framework covers psilocybin, psilocin, DMT, ibogaine, and mescaline (expressly excluding peyote); Oregon's framework covers only psilocybin/psilocin. (2) Personal possession track: Colorado Prop 122 includes personal possession and home cultivation rights for adults 21+, independent of the licensed healing center framework. Oregon provides no personal possession rights outside the licensed service center. (3) Licensing authority: the Natural Medicine Division of the Department of Revenue (the same agency that oversees cannabis in Colorado); enforcement culture and rule structure differ from Oregon's OHA model. (4) License types: healing center, facilitator, manufacturer, testing facility. (5) Age minimum: 21+, same as Oregon.

Compliance note for dual-state operators: Oregon compliance does not satisfy Colorado requirements or vice versa. Maintain independent compliance systems for each state. Each state's licensing authority has independent inspection rights, enforcement tools, and reporting requirements.¹⁵¹

C. Entity Structure Decision Tree

Oregon service centers: LLC vs. professional corporation vs. sole proprietor. LLCs are the most common operating structure for Oregon psilocybin service centers. The facilitator license is individual — the entity holds the service center license; the individual facilitator holds their facilitator license and must be associated with the licensed service center. Important for health professionals: Oregon does not require a professional corporation for psilocybin service center operations (unlike, e.g., medical practice law in many states). Healthcare professionals who are also OHA-licensed facilitators operate under dual-licensure (Oregon HB 2387) without a mandatory PC structure. However, healthcare professionals operating through a medical practice entity (PC or PLLC) should confirm their professional licensing board's position on operating a psilocybin service center through a non-professional entity before forming an LLC.³⁹

Drug development companies: C-corp vs. PBC vs. nonprofit. Delaware C-corporation is standard for companies seeking VC investment or eventual public markets. Nonprofit 501(c)(3) structures (like Usona Institute) are available for mission-driven organizations that intend to distribute at cost without commercial licensing — the access equity implications are material. Public benefit corporation (PBC) is available for for-profit entities that want to signal mission alignment in their charter (fiduciary duty includes public benefit alongside profit) without the operating constraints of a nonprofit. IP holding company structures (HoldCo owning IP, licensing to operating subsidiaries) are common in pharma and appropriate for multi-jurisdiction psychedelic IP portfolios. For cannabis-model operators who have built analogous structures: the psychedelic entity is not per se subject to §280E the way a cannabis trafficking business is — but the analysis is fact-specific and requires tax counsel.

Professional corporation requirements for licensed healthcare providers. Healthcare professionals (physicians, NPs, PAs, psychologists, LCSWs) in Oregon who deliver psilocybin services under dual-licensure face both state administrative licensing risk (professional board) and federal DEA registration risk. Check: (a) professional licensing board position on participation in Schedule I activities even under state licensure; (b) DEA registration implications (DEA registration could theoretically be suspended for Schedule I conduct even if state-compliant); (c) malpractice insurance — standard professional liability policies may not cover psychedelic services; verify coverage and obtain riders or separate coverage where available.³⁹

D. Federal Complications for Schedule I Operators

Banking. No FDIC-insured bank is legally obligated to serve Schedule I businesses. Oregon service centers typically operate through credit unions and payment processors that accept state-licensed cannabis clients — this is at-will and legally precarious. Maintain written records of all financial arrangements. Understand that account closure without notice is possible at any time. Payment processors may apply higher transaction fees and reserve requirements to Schedule I businesses. The SAFE Banking Act, which would have provided federal protection for cannabis-related banking, has not passed as of May 2026.

DEA Schedule I researcher registration. Drug development companies conducting Schedule I research require DEA Schedule I researcher registration (21 C.F.R. § 1301.18). Registration is facility-specific. Annual Aggregate Production Quota (APQ) allocation limits total domestic Schedule I manufacturing. In 2026, DEA set the psilocybin APQ at 50,000g — a more than 67% increase from 30,000g in 2025 (psilocin APQ separately set at 80,000g for 2026). APQ constraints are a material operating risk for early-stage companies that must plan supply for Phase 3 trials.

Insurance. Standard commercial general liability policies may exclude coverage for federally illegal conduct. Service centers should obtain policies specifically covering state-legal psychedelic services (a small but growing specialty insurance market). Review policy language for exclusions referencing controlled substances, criminal activity, or federally illegal operations. Directors and officers (D&O) insurance for psychedelic companies: disclose Schedule I activities to underwriters; misrepresentation of the business's regulatory status may void coverage. Professional liability for healthcare providers: as noted above, verify that existing malpractice coverage extends to psychedelic services.

E. Capitalization Models

Venture capital: available for for-profit C-corps; preferred stock with liquidation preferences and anti-dilution protections is standard. Notable: psychedelic companies have faced valuation compression since 2021-2022 hype cycle; institutional capital now requires clear regulatory pathway (BTD + Phase 3 enrollment) rather than preclinical story. Strategic acquisition model: AbbVie ($1.2B bretisilocin) and Otsuka ($1.225B Transcend) demonstrate that big pharma will acquire late-stage assets at blockbuster valuations.⁷⁴ Otsuka's $1.225B Transcend acquisition confirms big pharma will acquire late-stage psychedelic assets at blockbuster valuations.¹⁴⁴

Grant funding: particularly relevant for nonprofit models (Usona), academic research programs, and SAMHSA harm reduction grants. The Trump EO directed $50M ARPA-H matching funds for state-level psychedelic research programs (Texas IMPACT has received this commitment). State research program grants through Texas IMPACT, Kentucky's opioid abatement trust fund allocation, and Mississippi's medical ibogaine research program represent emerging public funding channels.³⁷

Revenue model for service centers: cash-pay only in current environment. Oregon service centers charge $1,000-$3,500 per session. No insurance coverage as of May 2026. Financial sustainability requires volume and session pricing that covers facilitator time, overhead, insurance, and OHA compliance costs. Note: integration and preparation sessions (minimum 2-3) represent additional revenue but also additional labor cost. The economics improve significantly when insurance coverage begins post-FDA approval — model the cash-pay phase as a bridge to a coverage-based model.

XXV. International Psychedelic Tourism and Treatment Abroad

A growing number of U.S. clients travel abroad for psychedelic therapy, particularly for psilocybin (Jamaica, Netherlands), ayahuasca (Brazil, Peru, Costa Rica), and ibogaine (Mexico). U.S. practitioners advising these clients, and U.S. facilitators operating abroad, face specific legal questions that this section addresses.

A. CSA Extraterritorial Scope and Residual U.S. Liability

The baseline rule: CSA generally does not apply abroad. Several federal courts have upheld an 11th Circuit line of decisions establishing that, when there is no intent to import controlled substances into the United States, the Controlled Substances Act does not apply to activities conducted outside the U.S. This means U.S. facilitators organizing psychedelic retreats abroad, and U.S. clients attending those retreats, would generally not face CSA liability for the retreat activities themselves.¹⁵⁸

Residual U.S. liability survives in four specific scenarios. (1) Recruitment from within the U.S.: if a U.S.-based facilitator or retreat company recruits U.S. clients from within the U.S., that U.S.-based recruitment activity may expose the facilitator to U.S. law regardless of where the retreat occurs. (2) Import: any controlled substance brought back to the U.S. — including in the body of a client who consumes it abroad and then returns — is subject to import prohibition. The risk is primarily analytical rather than practical for classic psychedelics (which are not detected in routine customs screening and metabolize rapidly), but it is legally present. (3) Conspiracy: if the foreign retreat operation constitutes an ongoing drug trafficking conspiracy that is directed, coordinated, or funded from within the U.S., U.S. conspiracy liability (21 U.S.C. § 846) may apply. (4) Money laundering: U.S.-based processing of proceeds from a foreign operation that would constitute a Schedule I drug offense in the U.S. may constitute money laundering under 18 U.S.C. § 1956.¹⁵⁸

Liability mitigation for operators. Comprehensive participant agreements covering: clear description of the substance to be administered, the legal status in the host country, the client's voluntary consent to participate, disclaimer of U.S. legal liability, and acknowledgment that the client understands the substance's status under U.S. federal law. Co-facilitator agreements with similar liability allocation. These documents do not eliminate exposure but substantially mitigate civil liability and document good-faith disclosure.¹⁵⁸

B. Jurisdiction-by-Jurisdiction Guide

Jamaica: the most permissive jurisdiction. Psilocybin mushrooms have never been scheduled under Jamaica's Dangerous Drugs Act. Psilocybin mushrooms are legal for possession, use, sale, and cultivation. The Jamaican government actively encourages the development of the psilocybin retreat industry. However: Jamaica is a signatory to the 1971 UN Convention on Psychotropic Substances, which creates a treaty gray area (psilocybin is a Convention Schedule I substance, but Jamaica has not domestically scheduled it). Enforcement is subjective. The practical reality: numerous retreat centers operate legally and openly; enforcement of international treaty obligations is not a current Jamaican law enforcement priority. Not a formal medical program — no national therapy protocols, no licensed facilitator requirements, no mandatory safety standards. For practitioners advising clients: Jamaica is the lowest-regulatory-barrier destination, but operator quality varies enormously. Recommend specific quality markers: trained facilitators, documented screening, emergency protocols, medical professional on-call.

Mexico: ayahuasca, peyote, and ibogaine. Ayahuasca and peyote ceremonies operate in a legal gray area in Mexico. Peyote has significant indigenous ceremonial protection under Mexican law; non-indigenous ceremonial use exists in a less clearly protected space. Ibogaine is not scheduled under Mexican federal law, making Mexico the primary destination for U.S. ibogaine clients (see Section IV.H on ibogaine for clinic quality considerations). LSD and MDMA are scheduled and prohibited in Mexico. Enforcement of psychedelic laws in ceremonial and retreat contexts is generally low priority, but is not zero — legal counsel with Mexican jurisdiction knowledge is required for operators.

Netherlands: psilocybin truffles, not mushrooms. Dried psilocybin mushrooms are scheduled and prohibited in the Netherlands. Psilocybin truffles (sclerotia of Psilocybe species) were not scheduled in the 1995 amendment to Dutch drug law that scheduled dried mushrooms, creating a legal loophole that has been tolerated rather than closed. Truffle-based retreat centers operate commercially. The Dutch government's general position is that possession, sale, and production of drugs are illegal under law — the truffle industry operates under tolerated exception, similar to cannabis coffeeshops. Not equivalent to a national medical psilocybin program. Client guidance: truffle-based retreats are legally tolerated; the product's psilocybin content is real but dose-standardization is less precise than pharmaceutical formulations.

Costa Rica, Brazil, and Peru: ayahuasca. Costa Rica has no specific statute prohibiting ayahuasca; retreat centers operate legally and openly. Brazil has legally protected ayahuasca for religious use since 1987. Peru has cultural heritage protection for ayahuasca and active retreat industries. For U.S. clients: all three are viable lower-risk destinations for ayahuasca ceremonies. Practitioner guidance: research the specific retreat center; verify facilitator training; confirm emergency medical protocols; assess the DMT import issue (the ayahuasca metabolizes fully within hours and is not detectable on return).

Australia, Czech Republic, Germany: medical access, not tourism. These jurisdictions offer legal psychedelic access but as medical treatment within a healthcare framework, not as retreat or wellness tourism. Australia requires an authorized prescriber relationship and Schedule 8 prescription — a tourist cannot walk in to a retreat; they must establish a clinical relationship with a licensed prescriber who determines medical necessity. Czech Republic (effective January 1, 2026) requires therapeutic access through specialized healthcare facilities. Germany (July 2025) operates a compassionate-use program for patients meeting specific treatment-resistance criteria. For U.S. clients: possible in theory; logistically complex; requires pre-visit clinical vetting, not ad-hoc booking. For practitioners advising clients: verify whether the client qualifies medically and whether the specific clinic they're considering is actually enrolled in the relevant compassionate-use or authorized-prescriber program.

C. Client Guidance: What Practitioners Can and Cannot Do

What practitioners can advise. Under ABA Model Rule 1.2(d) and Formal Opinion 2023-504: practitioners may advise clients on the legal status of substances in the relevant foreign jurisdiction; the applicable U.S. law (including residual CSA liability analysis); risk mitigation steps (participant agreements, facilitator vetting, medical screening); and what clients should and should not bring back to the U.S. Practitioners may also advise retreat operators on the legal framework applicable to their foreign operations, including the CSA extraterritorial analysis.¹⁴⁹

Employment and professional licensing implications for returning clients. (1) Drug testing: classic psychedelics (psilocybin, LSD, DMT, mescaline) are not included in standard 5-panel or 10-panel employment drug tests. Psilocin (the active metabolite of psilocybin) is detectable for approximately 1-3 days in urine using specialized testing. Standard workplace drug panels do not test for psilocybin or psilocin. (2) Professional licensing: clients who are licensed healthcare professionals or attorneys should understand that participating in foreign psychedelic therapy may create professional licensing questions if their conduct comes to the attention of their licensing board — even if the foreign conduct was legal in the host country. There is no established precedent, but the risk is not zero for regulated professionals. (3) Security clearance holders: participation in foreign psychedelic therapy could, in theory, be disclosed in security clearance investigations or renewals as a foreign activity involving illegal substances under U.S. law. Advise clearance holders accordingly.

Facilitator liability exposure operating abroad. U.S.-licensed healthcare professionals who facilitate psychedelic sessions abroad may face: professional licensing consequences in their home state if their conduct becomes known to their licensing board; DEA registration review if their DEA registration is implicated (Schedule I conduct, even abroad, may be grounds for DEA scrutiny); civil liability under U.S. law if harm occurs and the client brings a U.S. civil action. For non-licensed facilitators (no professional license at stake): primary exposure is the residual CSA liability analysis above. For all operators: maintain comprehensive participant agreements, document informed consent, and retain records of safety protocols.¹⁵⁸

XXVI. Pediatric and Adolescent Considerations

The psychedelic therapy field is adult-focused: all existing state regulated programs (Oregon, Colorado) require 21+, all current BTD holders's clinical programs enrolled adults, and the applicable state age restrictions are binding. This section addresses the emerging evidence for pediatric applications, the regulatory pathway for any future pediatric access, the risks specific to adolescent populations, and the clinical and policy framing relevant to advocates.

A. Eating Disorders: The Primary Evidence Case

Anorexia nervosa has the highest mortality rate of any psychiatric condition — estimated at approximately 5-10% per decade of illness and up to 10% lifetime mortality — and is notable for the complete absence of FDA-approved pharmacotherapy. No medication has ever received FDA approval to treat anorexia nervosa. This is the single strongest argument for psychedelic research in the context of pediatric and young adult populations: a condition with the highest lethality among psychiatric illnesses and zero approved pharmacotherapy has failed on standard treatment approaches, and psychedelic mechanisms (neuroplasticity, disruption of rigid cognitive patterns, therapeutic window for body image processing) align with the hypothesized pathology of eating disorders.²⁰⁵

Peck et al. 2023 (Nature Medicine): Phase 1 safety data for psilocybin in anorexia nervosa. Peck et al. (UC San Diego Eating Disorder Treatment & Research Center; Phase 1 open-label feasibility study; n=10 adult females meeting DSM-5 criteria for AN or partial remission; single 25-mg synthetic psilocybin with psychological support; NCT04661514): no clinically significant changes in ECG, vital signs, or suicidality; two participants developed asymptomatic hypoglycemia at post-treatment, resolved within 24 hours; all adverse events mild and transient. Participants' qualitative reports suggest the treatment was acceptable for most participants. Authors conclude: psilocybin therapy is safe, tolerable, and acceptable for females with AN.¹⁵⁶ This is the first Phase 1 safety data for psilocybin in anorexia nervosa. Note: the study enrolled adult females (mean BMI 19.7 — most were weight-restored or in partial remission), not severely malnourished adolescents at lowest weight. The safety data does not extend to the most vulnerable AN patients.

Hirsch et al. 2025 (CNS Drugs): the pharmacological development landscape. Hirsch et al. (2025, Cedars-Sinai; systematic review of pharmacological interventions for eating disorders 2010-2025; 43 eligible clinical trials, 24 distinct compounds) identified psilocybin as one of only a small number of emerging agents showing promise for anorexia nervosa — a striking assessment given that the review covered 15 years of pharmacological development and found only one FDA approval (lisdexamfetamine, for binge eating disorder, not AN) and very few positive late-stage results. The review concludes that psilocybin is among the few compounds with plausible mechanistic rationale and early feasibility evidence for AN. OCD in eating disorder presentations: psilocybin's documented signal for OCD (Ching et al. 2025 Yale, first double-blind RCT for treatment-refractory OCD) is relevant because eating disorder presentations frequently involve OCD-spectrum features — the same rigid, intrusive cognitive patterns that psilocybin appears to disrupt in OCD may be implicated in AN pathology.

B. Age Restrictions in Existing Programs

All existing state regulated psychedelic programs set a minimum age of 21: Oregon (ORS 475A), Colorado (Prop 122), and New Mexico (SB 219, still building toward December 2027 operational deadline). No regulated psychedelic program in the U.S. or internationally provides for pediatric access (under 18) as of May 2026. Australia's authorized prescriber model is available to adults — pediatric prescriptions would require extraordinary clinical justification and are not contemplated in standard practice. The Czech Republic's framework specifically covers patients in specialized healthcare facilities — no pediatric access pathway exists. Practitioners, advocates, and service center operators: there is no legal pathway for providing regulated psychedelic services to anyone under 21 in any U.S. state program. Any marketing, communication, or treatment practice that could be construed as targeting or accommodating minors carries severe legal, regulatory, and reputational risk.¹⁵⁰

C. Pharmacological Considerations for Adolescent Populations

Adolescent brain development and 5-HT2A receptor sensitivity. The adolescent brain is not simply a smaller adult brain. Synaptic pruning and neuroplasticity in the prefrontal cortex continue through approximately age 25. The 5-HT2A receptor — the primary target of classic serotonergic psychedelics — is expressed at higher density in adolescent cortical neurons than in adult neurons, and the prefrontal-limbic connectivity that governs emotional regulation is still developing. This creates two considerations: (a) psychedelic effects may be quantitatively different (more intense, longer-lasting) in adolescents than the adult evidence base captures; and (b) the neuroplasticity window that makes psychedelics therapeutically promising in adults may carry a different risk-benefit profile in a brain that is already in active neuroplastic reorganization. The adult evidence base does not generalize to adolescent populations. Any future pediatric trial would require independent safety and dosing data.^{211 212 213 214 215}

Cannabis-specific adolescent risk: a mandatory disclosure in any destigmatization context. Cannabis has documented risks in adolescent populations that classic psychedelics do not have in the same form. Heavy adolescent cannabis use is associated with increased psychosis-spectrum disorder risk in predisposed individuals. Meier et al. (2012, PNAS, Dunedin birth cohort, n=1,037, followed to age 38): persistent cannabis use beginning in adolescence was associated with an approximately 8-point IQ decline not seen in those who began in adulthood. Cannabis use disorder (DSM-5 criteria) affects approximately 17% of those who begin in adolescence vs. 9% of lifetime users generally. Destigmatization of cannabis for adult use is appropriate; destigmatization must be paired with clear communication of the adolescent-specific risk profile. Conflating adult and adolescent cannabis risk in advocacy contexts is both scientifically inaccurate and strategically counterproductive.

D. FDA PREA and the Pediatric Trial Pathway

The Pediatric Research Equity Act (PREA) requires sponsors of drugs for new indications to conduct pediatric studies of those drugs, unless FDA grants a waiver. For psilocybin or DT120 ODT: upon NDA approval for an adult indication (TRD, MDD, or GAD), the sponsor would receive a pediatric study request from FDA requiring studies in the pediatric population if the indication is reasonably likely to be used in children. Eating disorders in adolescents and pediatric OCD are the two most likely initial pediatric study targets. Pediatric studies require: separate IND, pediatric-specific dosing and safety data, age-specific consent and assent frameworks, parental/guardian consent procedures, and specialized ethics review. The timeline from adult approval to pediatric label expansion is typically 5-10 years given the development requirements.

What advocates should and should not say about pediatric use. DO say: anorexia nervosa has the highest mortality of any psychiatric condition and zero FDA-approved pharmacotherapy; early Phase 1 safety data for psilocybin in adult AN patients is promising; pediatric clinical research is urgently needed but requires separate investigation. DO say: the 21+ age restriction in existing state programs is appropriate given the current state of evidence. DO NOT say: psilocybin is safe for adolescents. DO NOT say: psychedelic therapy should be available to minors now. DO NOT cite the adult evidence base as establishing safety or efficacy in minors. The eating disorder case for pediatric research is the most compelling available, and it is compelling based on the medical need and mechanistic rationale — not on a safety evidence base that does not yet exist for minors.

XXVII. Commissioner's National Priority Vouchers and the Post-EO Regulatory Landscape

On April 18, 2026, President Trump signed Executive Order No. 14,401, Accelerating Medical Treatments for Serious Mental Illness (91 Fed. Reg. 21,709). This section covers the EO's four operative provisions and their practical implications for practitioners, sponsors, and advocates.³⁷

A. Commissioner's National Priority Vouchers (CNPVs)

Mechanism. The EO directed FDA to develop a CNPV program to accelerate FDA review of Breakthrough-designated psychedelic drugs. FDA Commissioner Marty Makary announced on April 24, 2026 that FDA would prioritize review of qualifying psychedelic BTD programs, collapsing standard review windows from 6—12 months to potentially weeks for qualifying products.³⁸ Three specific products received priority vouchers on April 24, 2026: Compass Pathways COMP360 (psilocybin, TRD), Usona Institute psilocybin (MDD), and Transcend Therapeutics TSND-201 (methylone, PTSD). Definium Therapeutics (DT120 ODT, GAD) and AtaiBeckley (BPL-003, TRD) and GH Research (GH001, TRD) hold BTD status but did not receive CNPVs as of May 2026 — CNPVs require a product near NDA readiness. Note: The DemeRx NB noribogaine Phase 1 IND was separately cleared by FDA on April 24, 2026 as the first U.S. clinical study authorization for an ibogaine derivative (alcohol use disorder, inpatient monitored setting) — this IND clearance is distinct from the CNPV designations and described in Section VII.B.³⁸

Competitive dynamics. CNPV review is sequential: the first sponsor to file a complete NDA under a CNPV designation will receive the first expedited review. This creates a competitive incentive to file first. Current race: Compass's rolling NDA is targeted for Q4 2026 completion (Part B durability data due early Q3 2026); GH001 is in Phase 3 initiation (H2 2026) and is years away from NDA; BPL-003 Phase 3 data is not expected until early 2029. Compass has the clearest near-term NDA path.¹⁶¹ COMP005 (n=258, MADRS -3.6) and COMP006 (n=568, MADRS -3.8) are the two Phase 3 datasets.⁹ Both met primary endpoints with p<0.001.¹⁰

What CNPVs do not do. CNPVs are an administrative review-acceleration tool. They do not: (1) waive FDA's statutory review obligations; (2) lower the evidentiary standard for approval; (3) reschedule any substance; (4) change the CSA; (5) authorize patient access. FDA can still decline an NDA under a CNPV if the data package does not meet approval standards. A psychedelic program with modest effect sizes (COMP360's -3.6 to -3.8 MADRS deltas) remains subject to scrutiny regardless of priority designation. No patient access today.³⁷

Product-specific rescheduling mechanics. The applicable precedent is Epidiolex (cannabidiol): upon FDA approval, DEA scheduled Epidiolex specifically as Schedule V while leaving psilocybin-containing mushrooms at Schedule I. The same model will apply to COMP360 psilocybin: FDA approval triggers a DEA scheduling proceeding for COMP360 specifically, not for psilocybin as a substance class or for unformulated psilocybin. Practitioners: a COMP360 Schedule V or III designation would not authorize Oregon or Colorado service centers to operate under a different federal framework; those programs dispense natural psilocybin, not pharmaceutical COMP360. Two separate legal tracks coexist: (1) product-specific rescheduling for COMP360; (2) substance-level rescheduling for psilocybin under the Aggarwal petition (still pending HHS).¹⁷⁰

B. Right-to-Try + Ibogaine: The Drafting Tension

The April 2026 EO directed FDA and DEA to establish a pathway for eligible patients to access investigational psychedelics — including ibogaine compounds — that have met "basic safety requirements" under the federal Right to Try Act (RTT; 21 U.S.C. § 360bbb-0a).³⁷ The RTT requires that a drug have completed Phase 1 safety trials as a prerequisite. Harvard Law's Mason Marks has publicly flagged that ibogaine arguably has not met the RTT Phase 1 threshold in the statutory sense — a drafting tension between the EO's aspiration and the statute's requirements. The EO's RTT expansion aspirations may require congressional action or narrow FDA administrative interpretations to be operative for ibogaine specifically. Practitioners advising ibogaine access clients: do not represent the April 2026 EO as authorizing ibogaine access under RTT as of May 2026; the pathway is aspirational, not operative.

C. DEA Early-Rescheduling Review at Phase 3 Completion

The EO directed the Attorney General to begin scheduling reviews upon Phase 3 completion, not only upon FDA approval. This potentially shortens the post-approval rescheduling window by approximately three months per Psychedelic Alpha analysis. Practical meaning: DEA would begin preparing the scheduling analysis while FDA is still conducting its review, such that the scheduling order could issue promptly upon approval rather than on a separate 90-day DEA track. This acceleration does not change the substance-level vs. product-specific distinction described above.³⁷

D. HHS/ARPA-H State Match and VA Data Sharing

The EO committed approximately $50 million in federal matching support through HHS/ARPA-H for state government psychedelic research investments — expressly responsive to Texas's $100M IMPACT commitment. The EO also directed HHS, FDA, and the VA to establish data-sharing memoranda to accelerate clinical-evidence generation for Breakthrough-designated psychedelics.³⁷ The EO's ARPA-H state-match mechanism leverages those investments.⁴² VA participation in multiple active psychedelic trials (New York, California, Oregon, per NPR April 2026) reflects this alignment. VA participation in psychedelic trials is the first since the 1960s. For advocates and researchers: the ARPA-H matching mechanism creates a new federal grant pathway for state-level psychedelic research programs; the governance model for accessing this funding is still being developed and is distinct from the NIH/NIAAA grant system.

XXVIII. State Research Funding and the Federal-State Matching Model

A new ecosystem of state-funded psychedelic research has emerged since 2024, creating grant and collaboration opportunities for pharmaceutical companies, academic medical centers, and advocacy organizations. This section covers the major state programs and the new federal-state matching model.

A. Texas IMPACT Ibogaine Consortium ($100M)

Texas SB 2308 (signed by Governor Abbott, June 11, 2025) allocated $50 million in state funding for the IMPACT (Institutions for Mental health research with Psychedelic-Assisted therapies for Combating Trauma) ibogaine research consortium. Following the failure to identify a qualifying private partner under the statute's match requirement, Texas committed the full $100M (combining state funds and the April 2026 EO's $50M federal match commitment) to a program led by UTHealth Houston and UTMB Galveston.⁴² The April 2026 EO committed $50M in federal matching support.³⁷

Scope: two-year multi-center program covering opioid use disorder, PTSD, TBI, treatment-resistant depression, and Parkinson's disease; quarterly progress reports required beginning December 1, 2025. Former Texas Governor and U.S. Energy Secretary Rick Perry is a leading ibogaine advocate, having undergone ibogaine treatment personally. The program is among the largest government-funded psychedelic research commitments globally. Note: all research under SB 2308 occurs within DEA Schedule I researcher registration and FDA IND frameworks; state authorization does not provide federal research authorization.⁴²

B. Other State Research Programs

Arizona HB 2871 (signed June 2025). Committed $5—10 million to ADHS (Arizona Department of Health Services) for Phase 1 ibogaine trials in neurological disease and TBI; RFP released October 2025. Arizona's program is narrower in scope than Texas but is among the first state health department-issued RFPs for ibogaine research.

Kentucky SB 77 (enacted April 2026). $21 million from the opioid abatement trust fund for ibogaine research, following veto override. Kentucky's opioid crisis framing positions the ibogaine research program as opioid abatement spending — a model other states may replicate given the scale of opioid settlement funds available for abatement purposes.¹⁰⁶

Mississippi HB 314 (signed March 26, 2026). $5M from opioid settlement funds for medical ibogaine research, effective July 1, 2026. Mississippi's program is the smallest among the current wave but notable for Governor Reeves's signature in a traditionally conservative state.¹²³

Indiana, Missouri, Louisiana, Ohio. Indiana HB 1001 (effective July 1, 2025) expanded the state therapeutic psilocybin research fund to include ibogaine. Missouri's Veterans Mental Health Innovation Act (pending) covers FDA ibogaine trials for OUD/TBI. Louisiana Veterans Task Force recommendations were due February 2026. Ohio established a study committee on ibogaine research in the FY26-27 state operating budget.

C. The Federal-State Matching Model: Governance and Access

The April 2026 EO's $50M ARPA-H state-match commitment creates a new funding architecture: states that commit research dollars trigger federal matching, with combined funds flowing to university-hospital-pharma consortia for Schedule I clinical investigation. Several governance questions remain unresolved:

(1) DEA Aggregate Production Quota (APQ) interaction: state-funded trials require DEA Schedule I researcher registrations and APQ allocations; the current APQ system is not designed for state-level clinical programs at scale. Texas's program will require DEA to allocate significant ibogaine APQ. (2) FDA IND management: each participating institution requires its own IND or umbrella IND; multi-site investigator-initiated IBogaine INDs are complex and require a sponsor. (3) IP capture: if state-funded research develops patentable data, ownership allocation between the state, university, and pharma partners requires contractual clarity at program inception. (4) Schedule II rescheduling implications: if HHS responds affirmatively to the Aggarwal psilocybin petition (or if a separate ibogaine rescheduling petition is filed), research protocols designed around Schedule I constraints may need to be modified. (5) Federal preemption: state program design cannot override FDA trial design standards; COMP-style methodological rigor (active comparators, blinded rater assessments, pre-registered endpoints) is required for data creditable by FDA.³⁷ State programs must align with federal FDA trial design standards.⁴²

For practitioners: clients seeking to participate in state-funded research programs — as sponsors, academic investigators, contract research organizations, or pharmaceutical partners — should engage counsel early on the federal authorization questions (DEA registration, APQ, IND) rather than treating state program award as sufficient legal authorization.

XXIX. Religious-Use Practice After Church of Gaia: The DEA Petition Path Without Litigation

The Church of Gaia's May 2025 exemption establishes for the first time that the DEA's 2009 administrative petition process — which had produced zero approvals in 24 petitions through January 2024 — can work. This section provides a practitioner's guide to the Terrapin Legal strategy and how it contrasts with the litigation paths that previously dominated this space.¹⁶⁴ The GAO 2024 report documents the prior failure rate of the petition pathway.¹⁶⁵

A. The Landscape Before Church of Gaia

Prior to May 2025, every recognized ayahuasca and psychedelic church in the U.S. had obtained its RFRA exemption through litigation or lawsuit settlement: Union do Vegetal (SCOTUS, 2006); Santo Daime/Church of the Holy Light of the Queen (9th Circuit, 2009 and subsequent proceedings); Church of the Eagle and the Condor (D. Ariz. settlement, April 2024); Church of the Celestial Heart (California settlement, May 5, 2025). The GAO documented zero administrative-pathway approvals through January 2024, with six psilocybin-specific petitions producing three withdrawals and three still-pending determinations.¹⁶⁵ O Centro (2006) and the Ninth Circuit's Santo Daime ruling are the two foundational RFRA cases.³¹ (O Centro established binding SCOTUS precedent; Santo Daime extended that precedent in the Ninth Circuit.)¹⁶⁷ The implicit message to psychedelic churches: to get an exemption, sue the DEA. Church of Gaia changed that.

B. The Terrapin Legal Strategy: Key Elements

Counsel Pat Donahue and Taylor Loyden of Terrapin Legal (Spokane) developed a strategy built on cooperation rather than confrontation. The five structural elements practitioners should understand:

(1) Voluntary abstinence during pendency. Church of Gaia suspended all ayahuasca use while the petition was pending — for years. This eliminated the government's strongest procedural argument (ongoing Schedule I violations) and demonstrated good faith. Most churches that have tried the petition process while continuing to serve their sacrament faced DEA rejection or prosecution. The abstinence commitment is the most operationally significant element of the Terrapin approach. Not all churches will be willing or able to make this commitment, particularly larger congregations with active ceremonial calendars.¹⁶⁴

(2) Security and tracking protocols. The DEA required detailed documentation of how ayahuasca would be stored, tracked, and accounted for. The church accepted these requirements, working with DEA to develop a protocol that DEA found satisfactory. The church declined to agree to destruction of unused sacrament (which DEA initially requested), negotiating instead for storage protocols. This negotiated middle ground — accepting DEA's legitimate security interests while protecting the church's theological objections to destruction of sacred material — is a model for future negotiations.¹⁶⁴

(3) DEA education on spiritual components. DEA agents are trained in law enforcement, not theology or anthropology. Terrapin Legal invested in educating the DEA investigators about the spiritual significance of ayahuasca within the church's tradition, the community structure, and the distinction between sacramental use and drug trafficking. Loyden describes the DEA investigators as having conducted the site visit respectfully and with genuine curiosity. Expert declarations from religious scholars, ethno-botanists, and indigenous elders are standard documentation; presenting them proactively during the petition process rather than in adversarial litigation changes the dynamic.

(4) Memorandum of Agreement, not court order. The outcome is a privately negotiated MOA between the church and DEA, not a public court opinion. This means: (a) no public precedent that other churches can cite directly; (b) the specific terms are confidential; (c) the exemption is vulnerable to changes in DEA leadership and political priorities in ways that a court order would not be; (d) no appeal rights if DEA later revokes the exemption. Harris Sliwoski's legal commentary notes this vulnerability specifically: without litigation, future exemptions "remain vulnerable to changes in DEA leadership." For practitioners: advise clients that the non-litigated path is faster and cheaper, but less durable than a court-ordered exemption.¹⁶⁴

(5) Timeline and resource commitment. The process took years from initial petition submission to MOA signing. Churches should plan for a multi-year administrative engagement with DEA, not a months-long application process. Budget for ongoing legal counsel throughout the pendency period.

C. Contrast with Litigation Paths

The litigation pathway produces durable court precedents but requires years of adversarial proceedings, substantial legal fees, and ongoing risk of adverse rulings. The Singularism v. Provo preliminary injunction (February 2025) illustrates that litigation can produce rapid interim relief (a TRO ordering police to return seized psilocybin) but does not guarantee a final favorable judgment. Singularism faces sincerity and commercial-motive challenges that will be litigated on the merits.¹⁶⁶

For practitioners counseling a church on which path to pursue: the petition pathway is appropriate for established congregations with (a) documented multi-year history of sincere religious practice; (b) willingness to suspend sacramental use during pendency; (c) resources for ongoing administrative engagement; and (d) community structure and governance that can comply with DEA security/tracking requirements. The litigation pathway is more appropriate for churches that: (a) cannot suspend practice; (b) have already had sacrament seized and need immediate relief; or (c) have access to litigation funding and a strong sincerity record.

All sources below were read in full at the hyperlinked URL, or — where the primary source is paywalled — verified against the most authoritative accessible secondary source, which is explicitly identified in the note. PMIDs and DOIs verified against PubMed metadata as of May 2026. Citation format: Bluebook (law review form for journal articles; federal register form for regulatory documents; U.S. Reports for cases).

Destigmatization Toolkit • Revised Edition v45 • Current as of June 2026 • Recommended re-verification cycle: every 90 days, pending FDA NDA reviews, the DEA cannabis hearing opening June 29, 2026, COMP005/COMP006 Part B durability data expected Q3 2026, and any new MDMA NDA submission by Resilient Pharmaceuticals.

About the Author

RN Collins (she/they) is a legal researcher, writer, and advocate working at the intersection of psychedelic law, cannabis policy, health equity, and cognitive liberty. She holds an M.S. and is pursuing a J.D., and currently serves as a legal intern at Antithesis Law PC in Venice, California — a boutique firm specializing in psychedelic and cannabis law.

RN's work spans primary source verification, legal research, policy analysis, science communication, and public education. She approaches this field from the conviction that accurate information is itself a form of access — and that the populations most harmed by psychoactive plant medicine stigma are precisely those most disconnected from the clinical, legal, and institutional infrastructure that shapes policy.

She is particularly focused on equity gaps in psychedelic research and access, Indigenous sovereignty and bioprospecting concerns, LGBTQ+ inclusion in clinical frameworks, and the intersection of cognitive liberty with federal drug scheduling.

About This Toolkit

The Destigmatization Toolkit for Psychoactive Plant Medicine was produced by RN Collins in collaboration with Antithesis Law PC. It represents nineteen audit cycles, 222 primary-source citations verified against original papers, and a multi-audience design built on the conviction that the same facts need to be communicated differently to land for a policymaker, a clinician, a concerned parent, and a harm reduction worker.